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ABSTRACT
Kate Bronstein
Antibiotic Occurrence and Associated Environmental Hazard: A Case Study of a Drinking
Water Reservoir Impacted by Wastewater Discharge
(Under the direction of Howard S. Weinberg, Marc Serre, and Douglas Crawford-Brown)
The fate and transport of 26 common human and veterinary antibiotics were
investigated in a small, semi-urban watershed that is impacted by wastewater discharges.
The watershed ultimately links an impacted reservoir, in which twelve of the twenty-six
antibiotics were detected at concentrations up to 2 g/L, to a downstream drinking water
source. A Bayesian Maximum Entropy framework with modern spatiotemporal geostatistics
was used to process information about one antibiotic, sulfamethoxazole, in this watershed
and this study demonstrates the practical benefit of using field measurements and model
predictions to establish a more complete map of contaminant transport. Generated maps
show that the areas of greatest accumulation are within the streams where antibiotics appear
to follow a pseudo-first order rate of removal from the aqueous phase. An environmental
hazard assessment was then performed, and among the antibiotics studied, sulfamethoxazole,
ciprofloxacin, and erythromycin were found to present the greatest environmental hazard.
iv
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1. BACKGROUND AND LITERATURE REVIEW
1.1 Background on Pharmaceutically Active Compounds
The continued exponential growth in the human population has created an increasing
demand for natural resources, specifically placing a strain on the limited supply of
freshwater. Thus, protecting the integrity of drinking water sources is one of the most
important issues of the 21st century. Recently, emerging contaminants, such as
pharmaceuticals, biogenic hormones, and personal care products have been detected in
wastewater effluents and surface waters (Karthikeyan and Meyer, 2006; Kim et al., 2007b;
Yang and Carlson, 2003; Vanderford et al., 2003). Research has shown that many
pharmaceutically active compounds (PhACs), such as antibiotics, can enter the environment,
disperse, and persist to a greater extent than first anticipated (McArdell et al., 2003;
Vanderford et al., 2003; Barber et al., 2006; Batt et al., 2006).
Pharmaceuticals are medicinal drugs that are developed with the aim to cure or
prevent disease and a subset of these, antibiotics or antibacterials, are used to treat bacterial
infections. There are two types of antibiotics; those that kill bacteria (bactericidal) and those
that only inhibit growth of certain bacteria that will continue to grow if the drug dosage
decreases (bacteriostatic). Most natural antibiotic groups, or those not obtained exclusively
from chemical synthesis, were discovered by the mid-1950’s, which means that antibiotics
developed since then are just chemical variations of the older structures. Almost every new
2generation of an antibiotic is developed to overcome a resistance to a former generation.
New generations of antibiotics include a functional group on the basic nucleus structure so
that the resistance mechanism developed with the original antibiotic can be overcome
(Aymes, 2001).
The environmental occurrence of PhACs has been investigated in recent years (Golet
et al., 2003; Kolpin et al., 2002; Batt et al., 2006; Donn et al., 2008) because of their
ubiquitous usage throughout the developed world, their ability to dissolve in water, their
ability to be excreted partially or fully unmetabolized, and their resistance to biodegradation
in natural waters. These characteristics along with incomplete removal during wastewater
treatment processes (Yang and Carlson, 2003; Gobel et al., 2004) have allowed
pharmaceutical compounds to enter the aquatic environment. It has also been postulated that
at environmental concentrations (low µg/L or ng/L) toxic effects may be induced in certain
non-target aquatic species. Therefore, the environmental and public health risk that these
compounds potentially pose should be thoroughly investigated in order to understand long-
term effects and to also determine whether or not the risk is substantial enough to necessitate
a change in conventional or onsite wastewater treatment, disposal practices, and the
frequency with which these medications are dispensed.
1.2 Pathways into the Environment
PhACs can enter the environment through human and animal excretion and the
improper disposal of unused or expired drugs (Figure 1.1). Veterinary pharmaceuticals are
given to pets and used in both aquaculture and confined animal feeding operations (CAFOs).
Antibiotics are given prophylactically to prevent illness and to promote growth in animals on
CAFOs, which generate millions of gallons of feces and urine that contain residual levels of
3these compounds (Saptoka et al., 2007). This waste is stored in lagoons and sometimes
sprayed on nearby fields as fertilizer. Occasionally, the untreated wastewater can end up in
nearby creeks or rivers because the lagoons may leach through the soil or breach the banks
(Sapotka et al., 2007). Antibiotics are also employed in aquaculture farms where they are
used as feed additives or directly added to the water to prevent disease (Lalumera et al.,
2004).
Figure 1.1: Pathways into the environment (Heberer, 2002)
PhACs administered to humans are excreted to varying degrees, or flushed down the
toilet if the drugs are no longer needed or have expired. About 15 – 90% of an antibiotic or
pharmaceutical can pass through the body unmetabolized (see Table 1.1). In addition to
excretion from the body, effluent from pharmaceutical plants and hospitals also makes its
way into surface waters. These compounds then enter the environment through point
4sources, such as wastewater treatment plants (WWTPs) or non-point sources such as on-site
wastewater treatment systems. Most WWTPs or domestic septic systems are designed to
treat conventional pollutants such as fecal coliform, suspended solids, biochemical oxygen
demanding materials, etc. and not a wide variety of modern anthropogenic chemicals, many
of which are biodegradable and environmentally persistent. A large portion of antibiotics are
not completely removed during WWTP processes, and therefore remain in the wastewater
effluent, which is then discharged to receiving waters, or leached through the soil in the case
of domestic septic system discharges. In many instances, the receiving waters flow into
downstream drinking water reservoirs.
Table 1.1: Human excretion rates of commonly prescribed antibiotics
Analyte % Excreted Reference
Tetracycline
Tetracycline 80 - 90
Doxycycline > 70
Oxytetracycline > 80
Chlortetracycline > 70
Minocycline ~ 60
Hirsch et al., 1999
Quinolone
Ciprofloxacin 65 - 85
Norfloxacin 56 - 62
Physician’s Desk Reference,
2005
Enrofloxacin 65 - 80 Plumb, 2005
Roxithromycin > 60 Hirsch et al., 1999
Levofloxacin < 10 Ellsworth et al., 2004
Sulfonamide
Sulfamethoxazole 60 McEvoy, 2004
Erythromycin > 60 Hirsch et al., 1999
Diaminopyrimidine
Trimethoprim 45 - 56 McEvoy, 2004
Note: Data is not readily available for all of the target analytes in this study and only values that were widely
available are presented here.
5Therapeutic classes of PhACs that have been investigated in the environment include
antibiotics, analgesics and anti-inflammatory drugs, anti-epileptic drugs, beta-blockers,
blood-lipid regulators, anti-depressants, contrast media, oral contraceptives, and cytostatic
drugs (Kolpin et al., 2002; Vanderford et al., 2003). It is important to note that many
pharmaceutical substances have not been investigated within each of these classes and long-
term environmental effects are largely unknown.
1.3 Causes for Concern
Antibiotics and other pharmaceuticals are powerful drugs used to treat many serious
and life-threatening infections and diseases. Despite their benefits and the fact that they
constitute merely one of a myriad of chemical classes discharged into the environment, the
evidence suggests that they are of special concern for several reasons. First, they are
ubiquitous and globally distributed; they are specifically designed or serendipitously
discovered to alter biological functions; they are associated with a wide range of side effects
in non-target organisms that include endocrine disruption, behavioral changes, and effects on
multiple levels of biological organization; they can cause chronic toxicity in aquatic species
at environmentally-relevant concentrations (low μg/L to ng/L); and finally, there is the
growing issue of antibiotic resistance (Halling-Sorensen et al., 1998; Kolpin et al., 2002;
Ferrari et al., 2003; Enick and Moore, 2007).
Bacteria, like all other organisms, evolve over time in response to environmental
situations. They are responsible for ear infections, some sinus infections, strep throat,
urinary tract infections, and many wound and skin infections. On the other hand, viruses are
responsible for causing influenza, colds, most sore throats, and most coughs. Antibiotics are
only able to treat bacterial infections; they are ineffective in treating viruses. However, they
6are commonly prescribed for viral infections and an unnecessary dose of the antibiotic is
given to the patient. Because of the large use and misuse of antibiotics in modern society,
many bacteria have developed resistance to antibiotics currently in use (Aymes, 2001). If
large numbers of bacteria are resistant to antibiotics, it will be more difficult and more
expensive to treat human bacterial infections. When antibiotics fail to work, consequences
include extra visits to the doctor, hospitalization or extended hospital stays, a need for more
expensive (and often more toxic) antibiotics to replace the older ineffective ones, lost
workdays, and sometimes death. The Center for Disease Control and Prevention (CDC)
published a report in 2007 stating that approximately 94,000 life-threatening infections and
19,000 deaths occurred in 2005 from drug-resistant staphylococcus bacteria in the U.S,
which resulted in more deaths than from AIDS alone (CDC, 2007). Other studies have
shown an increased resistance of levofloxacin and ciprofloxacin to Streptococcus
pneumoniae (Ho et al., 2004). Only when antibiotics are used solely for bacterial infections
and the whole prescribed dose is taken can the development of antibacterial resistance be
somewhat controlled.
Another potential impact that has not been studied in depth due to the complexity of
the issue is the potential implication to human health of consuming sub-therapeutic doses of
PhACs present in treated drinking water. PhACs have been detected in the low ng/L range in
treated drinking water, and it is difficult to quantify effects at such low levels because of the
myriad of factors that humans are exposed to in daily life.
The case study presented in this thesis investigates the presence and persistence of
PhACs in wastewater effluent on receiving surface waters and a downstream reservoir.
Environmental hazard to aquatic life associated with these chemicals is estimated using
7values and techniques from published literature. Case studies have been performed in the
past (Golet et al., 2002; Kolpin et al., 2002; Yang and Carlson, 2003; Barber et al., 2006;
Lissemore et al., 2006), but none have directly investigated the impact of PhACs in a
wastewater effluent discharged to a watershed involving a drinking water reservoir. This
case study is unique in that the three major water sources upstream from the reservoir each
contain a wastewater treatment plant that discharges anywhere from 4 to 16 million gallons
of effluent per day into the receiving stream. In times of extreme drought, as were the
conditions during the period of this study, the main water source flowing into the reservoir
was treated wastewater effluent. Sampling occurred upstream of the WWTP, at the point
where the effluent mixes with the stream water and at two downstream locations to determine
1) the presence of any targeted compounds upstream of the point of entry, 2) the
concentration of the targeted analytes in the effluent itself, 3) the persistence of PhACs
downstream of the WWTP, 4) if there are any non-point sources of the targeted compounds,
and 5) the concentration of the targeted compounds entering the reservoir. The benefits of
this study include determining the concentrations of targeted analytes in the watershed and
their persistence as they travel downstream to a drinking water source. Knowing the extent
that these compounds persist can help in watershed management issues in the future that
account for providing a pristine recreational area and drinking water source.
1.4 Target Analytes
Twenty-six commonly prescribed human and veterinary antibiotics have been
investigated in this case study (Table 1.2) because of their widespread use in this country and
around the world. Tylosin, enrofloxacin, and sarafloxacin are only used for veterinary
8purposes while ciprofloxacin, roxithromycin, minocycline, and norfloxacin are only used for
human purposes. Chemical structures of the targeted antibiotics are presented in Figure 1.2.
Figure 1.2: Chemical structures of target analytes (Reproduced from Ye, 2005)
9Figure 1.2 (Cont.): Chemical structures of target analytes (Reproduced from Ye, 2005)
Levofloxacin
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Table 1.2 presents chemical information relevant to the fate of antibiotics in the
environment including molecular weight, which is used in mass spectrometric analysis to
help identify the parent compound through a precursor ion. Log Kow is the octanol/water
partition coefficient. Values of Kow represent the tendency of a chemical to partition between
an organic phase and an aqueous phase. Chemicals with low Kow values can be considered
hydrophilic, meaning they have a higher tendency towards the aqueous phase, small
soil/sediment adsorption coefficients, and small bioaccumulation factors in aquatic life
(Reddy and Locke, 1994). Conversely, chemicals with high Kow values tend to be
hydrophobic and will be inclined to partition into the organic phase. The pKa determines the
acidic or basic properties of a substance, or rather at which pH values the analytes are
anionic, neutral, or cationic, which is also relevant for partitioning effects especially in the
environment but also during ingestion.
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Table 1.2: Physical properties of target analytes
Analyte Molecular Weight Log Kow pKa (20°C)
Sulfachlorpyridazine 284.7 0.31 1.4 a
Sulfadimethoxine 310.3 0.63 5.54 a
Sulfamerazine 264.3 0.14 1.58 / 6.98 b
Sulfamethazine 278.3 0.89 2.65 / 7.65 d
Sulfamethizole 270.3 0.54 d 5.45 e
Sulfamethoxazole 253.3 0.89 1.68 / 5.57 b
Sulfathiazole 255.3 0.05 2.30 / 7.20 b
Erythromycin-H2O 733.9 3.06 8.88 f
Roxithromycin 837.1 2.75 8.8 g
Tylosin 916.1 3.5 7.1 c
Lincomycin 406.5 0.56 7.6 e
Trimethoprim 290.3 0.91 1.32 / 7.45 f
Ciprofloxacin 331.3 0.28 6.43 / 8.49 f
Enrofloxacin 359.4 1.1 6.27 / 8.30 c
Flumequine 261.2 1.6 6.2 h
Levofloxacin 370.4 not available 5.7 / 7.9 i
Norfloxacin 319.3 -1.03 6.34 / 8.75 j
Sarafloxacin 385.4 1.07 6.00 / 8.60 c
Oxolinic acid 261.2 0.94 6.87 b
Pipemidic acid 303.3 -2.15 not available f
Chlortetracycline 478.9 -0.62 4.50 / 9.68 b
Demeclocycline 464.9 -1.14 not available f
Doxycycline 444.4 -0.02 not available f
Minocycline 457.5 0.05 not available f
Oxytetracycline 460.4 -1.22 3.27 / 7.32 / 9.11 c
Tetracycline 444.4 -1.3 3.30 / 7.68 / 9.69 c
a.Kim et al., 2007b; b. SciFinderScholar, American Chemical Society, 2006; c. Tolls, 2001; d. Diaz-Cruz et al.,
2006; e. Merck Index, 1996; f. Syracuse Research Corp., 2007; g. Huber et al., 2003; h. Delmas et al., 1997;
i. Hirano et al., 2006; j. Barbosa et al., 2001.
1.5 Occurrence in the Environment
Only recently have analytical methods been developed to detect and quantify PhACs
in different environmental matrices. These compounds have been investigated in wastewater
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effluents and surface waters since the 1990’s in the United States, Canada, Europe and more
recently in other countries. A comprehensive literature review of concentrations found in the
environment for the targeted analytes is presented in this section. These findings are rarely
reported in the open literature as noted by the Associated Press (AP), who recently published
a comprehensive nation-wide report suggesting an attempt to withhold information from the
public (AP, 2008). This report states that there are several reasons as to why findings are not
made publicly available. The main reason is that scientists and utilities do not want to falsely
alarm the public, who may take the results out of context. The effects of PhACs on humans
and the environment that are present in surface and drinking waters are not known at this
time, so one can not conclusively state that there are adverse health effects associated with
ingestion or exposure at the levels found in the environment. A third reason is due to
research funding and utility privacy, where utilities and researchers agree ahead of time to
keep the study results confidential. As more attention is focused to this issue and more
research is conducted, there will hopefully be more concrete data about the exposure effects
of PhACs in surface and drinking waters once valid occurrence data is obtained.
1.5.1 Wastewater Treatment Processes
Conventional wastewater treatment plants are not specifically designed to remove
PhACs and because these chemicals are highly water-soluble, they can persist in the
wastewater through different treatment stages (Kolpin et al., 2002). Several studies have
investigated the fate of PhACs in complex matrices including dairy effluent, hospital waste,
raw wastewater, and treated wastewater effluent, but as this case study focuses on the
presence of these compounds in treated wastewater effluent, only these values are presented
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in Table 1.3. Tables 1.3 attempts to compare and contrast levels of PhACs from many
different studies around the world, and is meant to be representative of the minimum and
maximum concentrations found in the literature. It is important to note that there are still
antibiotic and other pharmaceutical residuals present in surface waters at detectable levels,
making wastewater effluent a major source for these compounds in surface waters (Kolpin et
al., 2002). There are a limited number of published studies that have investigated the levels
of PhACs in the intermediate stages of wastewater treatment, hospital waste, or in effluent
from CAFOs.
Table 1.3: Occurrence of target analytes in wastewater treatment plant effluent
Analyte Conc. (µg/L) Reference
Sulfamethazine 0.018 Gobel et al., 2004
0.64 Yang and Carlson, 2003
Sulfamethoxazole 0.32 Yang and Carlson, 2003
0.31 Brown et al., 2006
1.34 Batt et al., 2006
Erythromycin-H2O 0.3 Karthikeyan and Meyer, 2006
0.199 McArdell et al., 2003
2.054 Xu et al., 2007
Trimethoprim 0.180 Brown et al., 2006
0.55 Karthikeyan and Meyer 2006
0.180 Xu et al., 2007
Norfloxacin 0.064 Golet et al., 2003
0.085 Xu et al., 2007
Ciprofloxacin 0.14 Karthikeyan and Meyer, 2006
0.97 Batt et al., 2006
Roxithromycin 0.021 Gobel et al., 2004
0.031 McArdell et al., 2003
Lincomycin 2.00 Brown et al., 2006
Enrofloxacin < 0.034 Nakata et al., 2005
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Table 1.3: Occurrence of target analytes in wastewater treatment plant effluent
(continued)
Analyte Conc. (µg/L) Reference
Sarafloxacin < 0.044 Nakata et al., 2005
Pipemedic Acid < 0.031 Nakata et al., 2005
Oxytetracycline 0.66 Yang and Carlson, 2003
Tetracycline 0.16 Yang and Carlson, 2003
0.85 Karthikeyan and Meyer, 2006
0.56 Batt et al., 2006
Demeclocycline 0.09 Yang and Carlson, 2003
Chlortetracycline < 0.05 Yang and Carlson, 2003
Error! Not a valid link.1.5.2 Surface Waters
The first major U.S. investigation of a wide-range of PhACs in surface waters was
conducted during 1999-2000 by the United States Geological Survey (Kolpin et al., 2002).
This study sampled 139 streams that were impacted by residential, industrial, or agricultural
areas. Eighty percent of the 95 targeted analytes were detected; 23 of these were antibiotics
and, although they were detected at lower concentrations than the other targeted analytes
(ng/L vs. µg/L), this study was important because it fueled the development of many
analytical techniques to more thoroughly detect this subset of pharmaceuticals at
environmentally relevant concentrations.
Very few studies have investigated the presence of PhACs in groundwater which, if
found, would suggest that these compounds are not adsorbing to the soil column after land
application such as from agricultural runoff, incompletely sealed landfills, or waste disposal
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from domestic septic systems. Results from a variety of occurrence studies in surface and
ground waters are presented in Table 1.4.
Table 1.4: Occurrence data of targeted analytes in surface and ground waters
Compound Conc. (µg/L) Matrix
Sulfachlorpyridazine 0.007a Surface Water
Sulfadimethoxine 0.056a - 0.24b Surface Water
0.046 - 0.068c Groundwater
Sulfamethazine 0.22b - 0.408a Surface Water
0.076 - 0.215c Groundwater
Sulfamethizole 0.13d Surface Water
Sulfamethoxazole 0.02e - 1.9d Surface Water
0.22b - 0.41f Groundwater
Sulfathiazole 0.016a - 0.08b Surface Water
Erythromycin - H2O 0.051a - 1.7d Surface Water
Roxithromycin 0.002a - 0.18d Surface Water
Tylosin 0.28d Surface Water
Su
lfo
na
m
id
es
Trimethoprim 0.015a - 0.71d Surface Water
Norfloxacin 0.03 - 0.12d Surface Water
Lincomycin 0.01 - 0.73d Surface Water
Ciprofloxacin < 0.019g - 0.03d Surface Water
Enrofloxacin 0.01d Surface Water
Sarafloxacin < 0.044g Surface WaterQ
ui
no
lo
ne
s,
m
ac
ro
lid
es
,
lin
co
sa
m
id
es
Pipemidic Acid < 0.031g Surface Water
Note: a. Lissemore et al., 2006; b. Lindsey et al., 2001; c. Batt et al., 2006; d. Kolpin et al., 2002;
e. Vanderford et al., 2003; f. Sacher et al., 2001; g. Nakata et al., 2005; h. Kolpin et al., 2004.
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Table 1.4: Occurrence data of targeted analytes in surface and ground waters
(continued)
Compound Conc. (µg/L) Matrix
Oxytetracycline 0.34d - 1.34b Surface Water
Tetracycline 0.11d - 0.3h Surface Water
Chlortetracycline 0.1h - 0.69d Surface Water
Te
tra
cy
cl
in
es
Doxycycline 0.02d - 0.073a Surface Water
Note: a. Lissemore et al., 2006; b. Lindsey et al., 2001; c. Batt et al., 2006; d. Kolpin et al., 2002;
e. Vanderford et al., 2003; f. Sacher et al., 2001; g. Nakata et al., 2005; h. Kolpin et al., 2004.
These occurrence studies (Table 1.3 and 1.4) suggest that many of the analytes are not
completely removed during wastewater treatment processes, and their presence in wastewater
effluent indicates that they are making their way into surface streams across the U.S. and
Europe. In general, the sulfonamides have been found at higher concentrations in surface
waters when compared to the quinolones and tetracyclines. Based on the lower Koc values
(Table 1.5 below), it is expected that the sulfonamides would more readily persist through
wastewater treatment processes and move into surface waters.
The ability of an analyte to adsorb to an organic surface can be predicted by its solid-
water distribution coefficient (Kd). Kd is the ratio of the concentration of the analyte in the
sorbent and in the water at equilibrium and defined as:
Kd = Koc * foc
This value can vary based on the fraction of organic carbon (foc) in the sorbent. The
normalized sorption coefficient (Koc) is a more accurate indicator of sorption and is,
therefore, recommended to predict the sorptive change of chemicals between water and solid
phase. To use Koc in this relationship, the compound must be nonionic because sorption of
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ionic contaminants is affected by soil pH, and the flow of the water must also be fairly calm
to ensure that sorption is occurring at equilibrium (Ahel and Giger, 1993). A compound with
a high Kow and high Koc values tends to partition into the organic phase, whereas a compound
with low Kow and low Koc will tend to remain in the aqueous phase. Table 1.5 presents
experimentally determined sorption coefficients of some antibiotics and pharmaceuticals.
Based on these Koc values, the sulfonamides would be expected to remain in the aqueous
phase, which favors their mobility through WWTPs and into surface waters. On the other
hand, the fluoroquinolones and tetracyclines will tend to strongly adsorb to soil minerals and
aquatic sediments due to their high Koc values.
The ability to adsorb to solid particles, both naturally occurring (e.g. clay, stream
sediment) and those added to the matrix during wastewater treatment (e.g. activated carbon,
coagulants) is a major factor in the removal of fluoroquinolones and tetracyclines during
treatment (Boxall, 2008). These interactions facilitate their removal by physical-chemical
(settling, flotation) and biological processes (biodegradation). Sorption of PhACs onto
sludge particles in WWTP processes is an imperative route describing their potential fate,
especially if the sludge will be used for land application.
18
Table 1.5: Sorption coefficients of antibiotics in soils, sediments, and slurry
Analyte Concentration(µg/g)a
Sample
(soil:texture/pH/%OC)
Kd
(L/kg)
Koc
(L/kg)
Sulfachlorpyridazine 0.05 - 20 clay loam/6.5/-- 1.8 --
0.05 - 20 sandy loam/6.8/-- 0.9 --
clay loam/6.2/3.1 4b 129
Sulfadimethoxine 1.0 - 10 silt loam/7.0/1.6 2.3 143
clay loam/6.2/3.1 10b 323
Sulfamethazine 0.2 - 25 sand/5.2/0.9 1.2 174
0.2 - 25 loamy sand/5.6/2.3 3.1 125
0.2 - 25 clay silt/6.9/1.1 1.0 82
0.2 - 25 sandy loam/6.3/1.2 2.0 208
Sulfathiazole -- clay loam/6.2/3.1 3c 97
Sulfamethoxazoled -- digested sludge/6.0/2.1 9.6-22.9
7.85-
32.1
Trimethoprim 500 µg/L sewage sludge/6.5/37d 76 205
Ciprofloxacin 250 µg/L sewage sludge/6.5/37d 417 1127
2- 200 loamy sand/5.3/0.70 427 61000
Enrofloxacin 2 -200 clay/4.9/1.63 3037 186340
2 -200 loam/5.2/0.73 5612 768740
Roxithromycind -- digested sludge/6.0/2.1
82.2-
83.3
8.09-
23.3
Tylosin 1.25 - 25 loamy sand/6.1/1.6 128 7990
1.25 - 25 sand/5.6/1.4 10.8 771
1.25 - 25 sandy loam/5.6/1.1 62.3 5660
1.25 - 25 sand/6.3/1.5 8.3 553
Oxytetracycline -- sewage sludge/6.5/37 3020 8160a
33 - 2000 mg/g pig manure 6h/24hd
83.2/77.
6 195
2.5 - 50 loamy sand/6.1/1.6 680 42500
2.5 - 50 sand/5.6/1.4 670 47880
2.5 - 50 sandy loam/5.6/1.1 1026 93320
2.5 - 50 sand/6.3/1.5 417 27790
285 organic marine sediment 2590 --
10.9 organic marine sediment 663 --
Tetracyclinee -- peat/4.55/-- 1620 --
Oxolinic acide -- marine sediment - mud 116 1190
marine sediment - sandy
mud 70 4510
marine sediment 0.3 17
Note: a if not indicated otherwise; b data derived from figures (Thiele-Bruhn, 2003); c Koc estimates for OC in
dry matter from Richards, 2007; d adsorption time; e data from Tolls, 2001; “—“ not available; if not indicated
otherwise, all data from Thiele-Bruhn, 2003.
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1.5.4 Degradation
PhACs in wastewater and surface waters can undergo several forms of natural
attenuation processes such as hydrolysis, biodegradation, and photolysis. Hydrolysis is a
process where organic compounds are broken down through interactions with water, and is
not considered a major factor of degradation because pharmaceuticals are designed for oral
ingestion and metabolism and, therefore, resistant to hydrolysis. Biodegradation is the
process by which microorganisms, for instance bacteria, break down a substance into more
elementary compounds. It is an important process when considering the persistence of
chemicals in soils due the presence of bacteria. Because neither hydrolysis nor
biodegradation are thought to readily occur in the water column, direct and indirect
photolysis are thought to be major players of degradation. Direct photolysis is the process by
which a substance undergoes a chemical change after absorbing light energy (i.e. sunlight),
whereas indirect photolysis involves natural photosensitizers such as humic acids and nitrates
(Andreozzi et al., 2003; Schmidtt-Kopplin et al., 1999). Water depth, turbidity, and humic
acids that absorb sunlight can inhibit photolysis, which indicates that PhACs may be less
persistent at the surface of a water body than at some depth below the surface (Andreozzi et
al., 2003). Another factor that influences photolysis is the intensity of solar irradiance at a
given latitude and season (Gao and Zepp, 1998). These mechanisms are not a particular
focus of this study, but a brief discussion is warranted as these processes may affect the fate
and transport of antibiotics and other pharmaceuticals in watersheds.
Andreozzi et al. (2003) found that the half-life of carbamazepine approached 100
days in winter at high latitutde (50°N), whereas the half-life for sulfamethoxazole,
diclofenac, ofloxacin, and propanolol approach 2.4, 5.0, 10.6, and 16.8 days respectively.
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This means that these compounds are remaining in the water column and may pose a
significant hazard to aquatic life until they are completely broken down. The presence of
nitrate ions reduced the half-life for all compounds except propanolol while humic acids
acted as inner filters for carbamazepine and diclofenac, and as photosensitizers for
sulfamethoxazole, clofibric acid, ofloxacin, and propanolol meaning that streams with a
higher concentration of humic acids would be expected to more quickly degrade these
compounds.
Verma et al. (2007) found that the half-life of tetracycline was 32, 2, and 3 days in
distilled, river, and wetland waters, respectively in the presence of direct sunlight. In the
same waters with no light exposure, the respective half-lives were 83, 18, and 13 days. This
indicates that direct photolysis will likely decrease the persistence of tetracycline in open
environmental waters and their degradation will be further enhanced due to the presence of
humic materials and nitrates acting as photosensitizers.
The two most common ways that fluoroquinolone can be reduced in surface waters
are via phototransformation and sorption to particles (Table 1.5, Koc values > 1000 for
ciprofloxacin, enrofloxacin, and tylosin); biodegradation is considered to be irrelevant (Golet
et al., 2003). More than 90% of enrofloxacin adsorbed to sediment (Table 1.5; Koc = 1127,
61000) (Nowara et al., 1997), and a half-life in summer months was just under 2 hours in
direct sunlight. In contrast to some of the compounds mentioned earlier, the presence of
humic substances has been found to decrease the rate of photodegradation of
fluoroquinolones into metabolites (Schmitt-Kopplin et al., 1999). Sorption is therefore
thought to be the major player due to their strong sorption properties (Table 1.5) (Nowara et
al., 1997; Tolls, 2001).
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1.5.5 Transport in Watersheds
Few published studies have investigated the occurrence, fate, and transport of PhACs
in watersheds, and none have included a drinking water source during a period of extreme
drought. Lissemore et al. (2006) conducted a watershed study with mainly agricultural
inputs in Ontario, Canada. Of the 28 human and veterinary pharmaceuticals targeted, 14
were detected in surface waters, 12 of which were veterinary pharmaceuticals that were not
detected in the wastewater effluent. This is evidence that agricultural areas can be a point of
entry for PhACs into surface waters via land application runoff and leaching through the soil.
Temporal fluctuations were also observed that correlated with manure or biosolids
application in the spring and fall months (May-November).
Barber et al. (2006) conducted a watershed study in the Boulder Creek, Colorado
watershed to determine if a range of chemicals including pharmaceuticals, pesticides,
herbicides, surfactant-degradation products, steroids, and hormones were present. Although
only two sampling events were conducted (during low-flow and spring runoff), several
compounds were present, including nonylphenol and sulfamethoxazole at various locations.
These were detected at higher concentrations during the low-flow event due to minimal
dilution and maximum concentrations were found downstream of the WWTP discharge in
the creek. Pharmaceuticals were only detected downstream of the WWTP discharge
indicating that this is the major source for these contaminants.
Another Colorado study looked at five tetracyclines (oxytetracycline,
chlortetracycline, demeclocycline, tetracycline, and doxycycline) and six sulfonamides
(sulfathiazole, sulfamerazine, sulfamethazine, sulfachlorpyridazine, sulfamethoxazole, and
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sulfadimethoxine) in the Cache la Poudre River, which is situated in a semi-arid region of the
United States (Yang and Carlson, 2003). None of the targeted antibiotics were detected at
the upstream pristine mountain site before anthropogenic input influences 43 miles
downstream, further indicating that urban areas are sources for these compounds.
Demeclocycline and tetracycline appeared in the river upstream of the influence from the
urban area and then increased slightly 20 miles downstream of this point due to the addition
of wastewater effluent to the river. The sulfonamides on the other hand were not detected in
the river water upstream of the urban area. Demeclocycline, tetracycline, chlortetracycline,
oxytetracycline, and doxycycline as well as two of the six sulfonamides (sulfamethoxazole
and sulfachlorpyridazine) were found in the river 8 miles downstream of the WWTP. As the
river transitioned from urban to agricultural influences 20 miles downstream of the WWTP,
oxytetracycline, chlortetracycline, tetracycline, and doxycycline were observed at their
highest concentration in the river. Tetracycline persisted unattenuated, while significant
degradation or adsorption of sulfamethoxazole and sulfachlorpyridazine appeared to have
occurred. Oxytetracycline, chlortetracycline, and sulfachlorpyridazine were not detected in
the wastewater effluent, which suggests the presence of these compounds can be mainly
attributed to agricultural sources, while the presence of sulfamethoxazole and doxycycline
were mainly of anthropogenic input. The sulfonamides were observed to undergo natural
attenuation processes such as photolysis and adsorption downstream of the WWTP, while the
tetracyclines were found at similar concentrations in both the WWTP discharge and at the
farthest downstream sampling location 20 miles from the WWTP.
Tetracycline sorption coefficients (Table 1.5) suggest that these compounds would be
prone to adsorption but the results of this study are unclear as to whether the tetracyclines
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actually persisted in the river water, or if additional non-point source pollution were
responsible for the concentrations detected. This study implies that antibiotics can enter the
watershed through point and nonpoint source pollution, and that inputs from agricultural
areas can increase the presence of veterinary antibiotics in a watershed.
Macrolide antibiotics were investigated in the Glatt River watershed in Switzerland
(McArdell et al., 2003). The river receives input from three WWTPs, is about 36 km long,
and has a water residence time of 15-20 hours. Roxithromycin, erythromycin-H2O, and
clarithromycin were detected in the treated wastewater effluent, but only clarithromycin was
present above detectable levels in the river. It is interesting to note that the antibiotics were
present in the effluent at levels two times greater in the winter than those found during the
summer months. This means that elimination during wastewater processes is lower in winter
months perhaps due to a lower biological activity, or that the influx of macrolides is higher
during these months. These seasonal differences must be considered when determining
environmental risk to aquatic life. Daily variations were observed for clarithromycin in the
effluent, but there was no pattern. This study showed that there is no significant removal of
clarithromycin (> 20%) in the Glatt River, but results from a previous study within the same
watershed showed substantial removal of ciprofloxacin (66%), and norfloxacin (48%) (Golet
et al., 2003). These results would be expected based on the high Koc values of both
ciprofloxacin and norfloxacin (both are fluoroquinolones).
None of these watershed studies have examined how the fate and transport of
antibiotics might impact downstream drinking water sources, which this case study intends to
do. Antibiotics, other pharmaceutically active compounds, and a variety of anthropogenics
are found in wastewater effluent discharged to surface waters, and many of these waters flow
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downstream into drinking water sources. It is therefore important to consider the persistence
and environmental hazard of these compounds when drinking water sources are nearby.
1.5.6 Drinking Water Treatment Plant Processes
There is concern that PhACs are persisting through drinking water treatment
processes and into municipal drinking water due to their presence in surface waters (Kolpin
et al., 2002; Gibs et al., 2007). Drinking water treatment processes include coagulation,
flocculation, sedimentation, and filtration of the source water. Disinfection occurs most
commonly in the U.S through the addition of chlorine or chloramines to the finished water
since these disinfectants maintain a residual in the distribution network. However, use of
ultraviolet light (UV) or ozonation at early stages of treatment, often for algae control or to
enhance coagulation, is expanding.
Removal of PhACs during drinking water treatment can occur by their partitioning
into the solid phase during coagulation or chemical transformation during reaction with
disinfectants. Sorption of organics onto solids during coagulation occurs mainly with
hydrophobic compounds (Snyder et al., 2003; Adams et al., 2002), but since most antibiotics
tend to be hydrophilic, coagulation and flocculation are not effective in their removal (Kim et
al., 2007b; Ternes et al., 2002).
Activated carbon filtration is another promising mechanism for removal, but contact
time, type of carbon, contaminant solubility, and competition for adsorption sites with larger
and more polar compounds such as natural organic matter may pose a problem (Kim et al.,
2007b; Matsui et al., 2002). Granular activated carbon adsorption is very effective in
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removing sulfamethoxazole and trimethoprim, as well as erythromycin, lincomycin, and
ciprofloxacin to some extent in drinking water (Ye, 2005).
Disinfection through chlorination, chloramination, or ozonation is effective in
transforming a host of micropollutants, but transformation rates depend on the compound
structure and oxidant dose (Kim et al., 2007b; Zweiner and Frimmel, 2000; Adams et al.,
2002; Huber et al., 2003; Ternes et al., 2002). Chlorination is practiced by dissolving
chlorine gas or hypochlorite in water. Free chlorine is a strong oxidant and can react with
many pollutants but it can produce disinfection by-products. Chloramines, formed by the
reaction of ammonia and free chlorine, are much weaker reactants and are slow to react with
pollutants. UV disinfection is a process where the most commonly used low-pressure
mercury lamps emit primarily monochromatic light at 254 nm. Disinfection occurs when
light photons are absorbed by the DNA nucleotides of microorganisms that absorb light
around 260 nm, consequently rendering the microorganism or pollutant ineffective (Pereira,
2005). This process is growing in popularity because it is effective against a wide range of
water-borne pathogens and does not produce any known disinfection by-products (DBP)
(Pereira, 2005). Ozonation occurs when water is infused with unstable ozone gas that is
toxic to many water-borne pathogens. Although ozonation, when used as a pre-oxidant, can
remove some of the common DBP precursors, it is known to produce bromate in the presence
of bromide. Zweiner and Frimmel (2000) found that ozonation is effective if the
concentration is equivalent to the organic matter content of the water, but the addition of
advanced oxidation processes (AOP) like ozone-hydrogen peroxide (O3/H2O2) proves more
effective in removing pharmaceuticals (> 90%) such as diclofenac, ibuprofen, and clofibric
acid.
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Ye (2005) conducted a comprehensive study of several water treatment processes and
results from a sampling event at a water treatment plant in North Carolina are shown in Table
1.6. The plant added sodium hypochlorite both prior to (1.5 mg/L) and after filtration (4.2
mg/L). Ammonia was then subsequently added (1.0 mg/L) to generate chloramines for
terminal disinfection. Results show that although several antibiotics were detected in
finished drinking water as well as tap water, most were at or below practical quantitation
limits.
Table 1.6: Occurrence of antibiotics in source, finished drinking water, and tap water
samples in a North Carolina drinking water treatment plant (Ye, 2005)
Mean Concentration (ng/L), (n=2)Antibiotic Source Finished Tap
Sulfamethoxazole 20 (4.5) <5.0
Tylosin <10 (4.5) <5.0
Erythromycin (4.2) (3.5) <5.0
Roxithromycin <10 (1.4) <5.0
Oxolinic acid (3.7) (1.0) (0.9)
Flumequine (3.6) (2.0) (1.9)
Note: “__” indicates that analyte detection was confirmed by the presence of two targeted tandem mass
spectrometry fragment ions and “( )” indicates that the analyte was detected and reported below the
practical quantitation limit.
The decrease in concentration between the source and finished water is likely due to
partitioning during coagulation or chemical transformation during disinfection. Any
antibiotics present in the water could have undergone microbial degradation, hydrolysis, or
adsorption onto the inner surfaces of the distribution pipes. Despite their detection below
practical quantitation limits, they are still present at sub-therapeutic levels after treatment and
may still pose a public health risk.
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1.6 Estrogens
Thousands of compounds could potentially cause endocrine disruption or be
endocrinally active in vertebrates such as fish, amphibians, reptiles, birds, and mammals.
Natural endocrine activity can be altered by mimicking a natural hormone, inhibiting the
binding of a natural hormone to the receptor, or changing the rate of removal of the hormone
from the endocrine system (Routledge and Sumpter, 1996).
Measurable levels of endocrine active substances (EASs) in lakes, rivers, streams, and
groundwater have been reported at environmentally relevant concentrations (Ternes, 1998;
Sacher et al., 2001; Kolpin et al., 2002). Steroid hormones have been found in surface waters
near agricultural runoff locations at concentrations up to 800 ng/L (Kolpin et al., 2002) and
in conventionally treated wastewater from 10 ng/L and up to 100 ng/L (Servos et al., 2005).
Several other studies have found similar low ng/L levels of estriol (E1), estradiol (E2), and
estrone (E3) in, or downstream of wastewater and septic effluents (Rodriguez-Mozaz et al.,
2004; D’Ascenzo et al., 2003; Wintgens and Gallenkemper, 2003). Higher levels of
hormones and other EASs in the surface waters and ground waters are more commonly found
closer to CAFOs than near WWTPs. Finlay-Moore et al. (2000) found concentrations of
estradiol in runoff from poultry litter-fertilized fields ranging from 20 to 2500 ng/L and soil
concentrations between 55 ng/kg and 675 ng/kg after land application. Kay et al. (2005)
identified overland flow of land applied manure slurries as a potential source for transport of
antibiotics to nearby aquatic environments.
Ethinylestradiol (EE2) has been shown to negatively impact fathead minnow
population growth and reproduction at concentrations as low as 4 ng/L (Grist et al., 2003).
E2 concentrations ranging from 5 to 25 ng/L can induce vitellogenin (a precursor to egg yolk
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production) in adult male zebrafish, whereas this is observed in juvenile male zebrafish at
concentrations up to 100 ng/L (Brion et al., 2004). Mixtures of nonylphenol and octylphenol
have shown antagonistic effects with E2 and EE2 in breast cancer cell assays (solvent or
aqueous based), indicating that such antagonism and/or synergism may play a significant role
in total observed estrogenicity (Rajapakse et al., 2004). There are many other studies
investigating the behavioral and developmental changes from exposure to EASs (Campbell et
al., 2006; Choi et al., 2004; Cooper and Kavlock, 1997; Huang et al., 2003). Estrogens in
treated wastewater effluent and surface waters are yet another indicator of the impact of
human generated waste on the environment.
1.7 Environmental Risk
In the United States, the National Environmental Policy Act of 1969 (NEPA) requires
all federal agencies to assess the environmental impact of their actions and ensure that the
interested and affected public is informed of environmental analyses (U.S. EPA, 2007b).
The Food and Drug Administration (FDA) is required, under NEPA, to consider the
environmental impacts (use and disposal) of a drug as an integral part of its regulatory
process when approving drug or feed additive applications. However, NEPA does not
require that the most environmentally beneficial course of action be taken.
In order to assess the environmental impact of antibiotics and pharmaceuticals in the
environment, an environmental assessment (EA) and environmental impact statement (EIS)
must be completed for new drugs (FDA, 1998; U.S. EPA, 2007b). Certain drugs that will not
significantly affect the quality of the human environment may be exempt from this process
(FDA, 1998). Examples of this instance include approval of a drug that will not increase its
use, drugs for use in nonfood animals, drugs for minor species (wildlife and endangered
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species), and therapeutics under veterinarian prescription. EAs focus on environmental fate
and ecotoxicology based on drug use patterns. An EIS is a statement that focuses on (i) the
environmental impact of the proposed action, (ii) any adverse environmental effects which
cannot be avoided, (iii) alternatives to the proposed action, (iv) the relationship between
short-term uses of the environment and maintenance and enhancement of long-term
productivity, and (v) any irreversible and irretrievable commitments of resources which
would be involved (FDA 1998, 2001).
EA for human drugs usually focus on the aquatic environment, whereas animal drugs
evaluate the fate and effects in the aquatic environment (fresh and saltwater), terrestrial
environments, dung pats and direct bird exposure. All EAs are available under the Freedom
of Information Act (FOIA).
1.7.1 Hazard Quotient Assessment Method
Many PhACs have been shown to induce adverse effects in microorganisms,
invertebrates, fish, and even birds despite going through a strict regulatory process. Some
antibacterial agents (flumequine, oxytetracycline), antidepressants and their metabolites
(fluoxetine, sertraline and norfluoxetine) have been observed to bioaccumulate in living
organisms such as fish and mussels (Delepee et al., 2004; Brooks et al., 2003). The anti-
inflammatory, diclofenac, has been reported to have harmful effects on rainbow trout as well
as vultures that have ingested deceased cows treated with this compound in India (Taggart et
al., 2007; Laville et al., 2004; Schwaiger et al., 2004). There have also been PhACs such as
gadobutrol, gadoxetic acid disodium, and gadofosvest trisodium that have not been found to
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cause an adverse effect in the aquatic environment using predictive risk techniques discussed
in this section (Farkas et al., 2008).
In order to determine the probability that an adverse effect will occur, representative
species are subjected to a chemical at a certain concentration for a certain period of time until
an effect or no effect is observed in a certain portion of the population. For example, an EC50
value or effective concentration value represents the concentration of a chemical that exerts a
non-lethal effect in 50% of the test population compared to the control population. An LC50
is similar, but it determines a lethal effect in 50% of the population, and a no effects
concentration (NOEC) is the highest observed concentration for which the effect does not
significantly differ from that of the control population.
The hazard quotient method is the most widespread method used for the semi-
quantitative characterization of the environmental hazard of PhACs (Emmanuel et al., 2005;
EMEA, 2006; Hernando et al., 2006; Lindberg et al., 2007; Farkas et al., 2008). This
involves calculating the ratio of the predicted environmental concentration (PEC) or
measured environmental concentration (MEC) divided by a predicted no effects
concentration (PNEC) (equation 1.1). MECs are used in the case study presented in this
thesis, but when MECs are not available, PECs must be used. PECs are calculated using
guidelines from the European Medicines Evaluation Agency (EMEA, 2006) using
information that estimates the production volume of a pharmaceutical per year, the
population size, amount of wastewater discharged per day, the removal rate during WWTP
processes, and dilution effects (equation 1.2).
Hazard Quotient = PEC or MEC / PNEC (eq. 1.1)
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PEC = A x (100 – R) / (365 x P x V x D x 100) (eq. 1.2)
where A = amount used per year (kg/year)
R = removal rate in %
P = the population size in the geographic area considered
V = volume of wastewater per day per capita (in m3)
D = dilution factor of wastewater by surface water flow
The PNEC is estimated by using published, peer-reviewed NOEC, EC50, or LC50 values
for a species multiplied by an assessment factor (AF) (equation 1.3). An assessment factor is
an expression of the degree of uncertainty when extrapolating from a limited number of test
species to that of the actual environment. It is also used to account for inter- and intraspecies
variability (EMEA, 2006; OECD, 1992). An AF is applied to the lowest NOEC if known, or
and LC50/EC50 value if a NOEC has not been determined. Table 1.7 suggests AF values for
available endpoints.
PNEC = NOEC (or EC50, LC50) / AF (eq. 1.3)
When the hazard quotient exceeds a value of 1, a hazard is suggested. In order to interpret
hazard quotients, the following breaks have been established: “low hazard” from 0.5 to 2,
“medium hazard” from 2 to 10, and “high hazard” at 10 +. Other studies have used the cutoff
point of 1, where a MEC/PNEC > 1 suggests an environmental hazard (EMEA, 2006;
Emmanuel et al., 2005; Hernando et al., 2006; Lindberg et al., 2007; Farkas et al., 2008), but
different values are used in this current research to distinguish between the comparative and
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absolute environmental hazard. PNEC is a regulatory concept meant to provide a margin of
safety in the face of uncertainty. It is a measure of comparative risk and should not be
interpreted as a measure of absolute risk. A value above 1 does not indicate a significant
value of risk; it just means that the margin of safety is being decreased (Crawford-Brown,
personal communication).
Table 1.7: Suggested assessment factors for various endpoints
Endpoint Number of Species Assessment Factor
NOEC 3 10
NOEC 2 50
NOEC 1 100
L(E)C50 3 1000
L(E)C50 2 1000
L(E)C50 1 1000
The hazard quotient method is a relatively simple and fast calculation used to
estimate potential environmental hazards. There are several weaknesses of this model as
there are with all models, and of toxicological studies in general. First, there is a general
absence of chronic toxicity data and there is debate about whether or not an AF can
accurately be used to extrapolate from test data to the real environment. Secondly, species in
toxicological experiments are exposed to high doses of pharmaceuticals for short periods of
time, which is not a realistic situation. In reality, pharmaceuticals are pseudo-persistent in
surface waters fed by wastewater effluent at much lower levels than used in toxicity studies.
Third, there are no strict guidelines as to which species to use in these toxicological studies
and comparability of LC50/EC50 between species is difficult. A range of LC50/EC50 values
for different species is used to estimate risks, but it would be much easier to compare the risk
of pollutants if one or two sensitive indicator species were used instead of the vast array
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found in the literature. Fourth, many studies use a predicted exposure concentration instead
of measured environmental concentrations, but there are many assumptions when predicting
concentrations and the standard formula may be not be truly accurate as to what is actually
occurring. Lastly, very few published toxicological studies have investigated the impact of
pharmaceutical mixtures at environmentally relevant concentrations. This is important
because wastewater effluent is a complex mixture of many chemicals, pharmaceuticals, etc.
and it is extremely difficult to determine the risk to aquatic life by only looking at the risk of
one chemical at a time. This issue is discussed in more detail in Section 1.7.2. Despite these
concerns, the hazard quotient method has been used in this case study as well as other
published studies (Emmanuel et al., 2005; Isidori et al., 2005; EMEA, 2006; Hernando et al.,
2006; Lindberg et al., 2007; Santos et al., 2007; and Kostich and Lazorchak, 2007).
1.7.2 Complexity of Assessing Risk of Chemical Mixtures
The goal of a risk assessment is to screen for hazards by considering worst-case
scenarios or to produce the best estimates of risk. Although methodologies currently exist
for estimating the environmental risk or hazard of industrial chemicals, there are valid
concerns about whether these environmental risk assessment tools may need to be revised or
replaced to appropriately evaluate the potential environmental impact of pharmaceuticals.
These concerns arise because pharmaceuticals are varied in structure, have diverse physical,
chemical, and ecotoxicological characteristics, and tend to have physical and chemical
properties that differ from general chemicals (Teuschler, 2007). In addition, the metabolism
rate and percentage of excretion of the parent compounds and/or its metabolites is not
considered in the risk assessment of general chemicals. WWTP removal efficiency must also
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be considered if it is assumed that all human pharmaceuticals enter the surface waters
through WWTP effluent.
Commonly, a risk assessment for chemical mixtures involves the additivity of effects
based on toxicological similarities or dissimilarities among components of a mixture that lack
supporting data (Teuschler, 2007). For instance, one could sum the hazard quotients of a
class of antibiotics because they work in a similar fashion, but this may not be truly
representative of the actual risk/hazard to an organism because very few published studies
have toxicologically investigated synergistic and antagonistic effects of mixtures. The more
simple additivity methods are useful in addressing potential health risks, but more research
into chemical mixtures needs to be completed. A mixtures assessment is chosen to estimate
the maximum potential risk and to therefore thoroughly protect the public, or to produce the
most accurate risk estimate for the exposure, resulting in estimates that protect the public on
average (Teuschler, 2007). Newer methods are emerging in response to the complexities of
chemical mixture exposure and effects and several key questions proposed by Teuschler
(2007) need to be addressed:
 When is it appropriate to use generalized approaches for chemical mixtures?
 What decision criteria can be used to determine that several chemicals share a
common toxic mode of action or have similarly shaped dose-response curves?
 What statistical, chemical, or toxicological evidence is needed to ascertain that
two complex chemical mixtures are sufficiently similar in nature such that
known toxicity data on one mixture is useful for estimating the toxicity of the
other?
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 Are there ways to incorporate information on toxicological interactions into a
risk assessment? At what exposure levels and mixing ratios do such data
show that a simple additivity model is inappropriate to apply?
 Are there methods to evaluate a complex mixture containing a large fraction
of unidentified chemicals?
Policy issues outside the realm of science play a role in whether or not it is worth
investigating the risk of chemical mixtures. The Safe Drinking Water Act Amendments of
1996 (U.S. Congress, 1996) call for the EPA to “[d]evelop new approaches to the study of
complex mixtures, such as mixtures found in drinking water, especially to determine the
prospects for synergistic or antagonistic interactions that may affect the shape of the dose-
response relationship of the individual chemicals and microbes, and to examine non-cancer
endpoints and infectious diseases, and susceptible individuals and subpopulations.” It is also
important to determine if the amount of human health protection will be increased after an
intensive look at chemical mixtures, especially when the chemicals themselves are below
their no-effects concentration (Teuschler, 2007).
Additivity concepts are often used as default procedures to estimate risk or hazard
from exposure to a simple mixture using data on a defined number of components under the
assumption that doses are in a region where toxicological interactions are not expected to
occur (Teuschler, 2007). When similar modes of action is the case, then a risk assessment
based on dose addition can be used where the doses of the chemical components are scaled
for relative toxicity and summed for use in estimating risk (e.g., the Hazard Index (HI)) (U.S.
EPA, 2000; Teuschler, 2007). However, these simple models based on dose additivity may
not hold for all toxic effects, and the relative toxic potency between chemicals may differ for
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different types of toxicity or toxicity by different routes (U.S. EPA, 2000). Another problem
based on dose addition is the assumption of similarly shaped dose-response curves for
mixture components. However, there is evidence that even with chemicals having dissimilar
modes of action, additive or near-additive interactions are common (U.S. EPA, 1998;
Konemann, 1981; Hermens et al., 1984).
Toxicological interactions are complex processes that are complicated by the dose
dependence of interactions, myriad chemical combinations and dose levels, and lack of data
beyond experiments on binary mixtures (Teuschler, 2007). Toxicity of chemical mixtures is
a concern, and more toxicological data on real world mixtures at environmentally relevant
concentrations (low µg/L or ng/L) needs to be further investigated. Because there are limited
published studies on chemical mixtures of antibiotics, the simple additivity approach is used
to estimate the combined potential environmental hazard of the targeted analytes in this case
study.
1.8 Estimating Concentrations of Antibiotics in Surface Waters with BME
A Bayesian Maximum Entropy (BME) framework with modern spatiotemporal
geostatistics can be used to process information about the space/time variability of pollutants
in their aquatic environment, the uncertainty and lack of monitoring data, and governing flow
and transport laws in order to obtain statistically estimated concentrations of pollutants at
locations within a watershed that were not sampled (Serre et al., 2004). BME consists of
techniques to conduct non-linear spatial predictions of data. Variability of antibiotic
concentrations in surface water over space and time is expected to be high due to daily and
seasonal fluctuations in usage and wastewater discharge flow. In this instance, the BME
framework is used to estimate concentrations of antibiotics in a watershed where a minimum
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number of samples have been taken due to budgetary and resource constraints as well as site
accessibility.
The models are useful in that they can predict analyte concentrations in areas and on
days when samples were not taken. This is useful for areas that are not accessible and for
budgetary constraints because less samples could be collected. However, some weaknesses
should be noted. First, the model predicts concentrations over a specified area and it does not
distinguish between land, air, or water so the reader must consider this when interpreting the
data. Second, there can be a large amount of variance associated with the expected
concentrations due to a lack of sampling points in the study area or a lack of sampling events,
etc. Third, weather events are not taken into account when predicting concentrations, so if
sampling data were all collected during a period of heavy rainfall, the estimations would
probably differ from estimations of a dry spell, etc. Fourth, the estimations are subject to
how the modeler manipulated the model to generate the estimations, and may differ from
person to person. Despite these limitations, it is a useful tool that shows general trends over
a whole study area during a specific time and can be useful in watershed management.
1.9 Policy and Regulatory Implications
The presence of pharmaceuticals in surface waters indicates problems with
contemporary healthcare and wastewater treatment processes. From the standpoint of
regulation, prescription drug disposal is one of the most important points of entry for
pharmaceuticals into the environment because it is somewhat controllable with behavior
modifications. The percentage of drugs that reach surface waters via disposal is somewhat
high in the U.S. (35.4% in U.S. vs. 11.4% in EU (Bound and Voulvoulis, 2004), and
regulating the disposal of pharmaceuticals is likely the simplest and least costly place to
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begin reducing the presence of pharmaceuticals in surface waters. Community education and
take-back programs are also relatively easy to implement at a low cost (Ph:ARM Team,
2007).
In the United States, regulation of pharmaceutical waste and disposal is managed at
different stages by various government agencies with distinctive agendas (FDA, 1998;
Erikson et al., 2005). Regulations by these agencies are often overlapping or poorly defined
and may not be enforced. Disposal by end-users is currently not regulated by any agency;
there are only suggestions for disposal that are not widely advertised. The FDA, EPA and
DEA are the three government agencies that have the most authority to regulate the disposal
of pharmaceuticals.
1.9.1 The FDA
The FDA regulates the safety of medicinal compounds for human use and, therefore,
has the potential to take the lead in addressing the issue of their presence in surface waters.
As mentioned earlier, NEPA specifies that before the FDA can approve any new drugs, an
EA of the drug must be completed. However, the FDA takes a more lenient approach than
would be assumed based on NEPA, as the agency categorically excludes the majority of
actions regarding drugs from the requirement of an EA (Erikson et al., 2005; Vincent, 1993).
A categorical exclusion is granted by the FDA for a “category of actions which do not
individually or cumulatively have a significant effect on the human environment and which
have been found to have no such effect” (CFR, 2006). Instead of strengthening its
requirements, the FDA has been making categorical exclusions easier to obtain.
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In the 1990s, the FDA established “additional categorical exclusions” and
“reevaluated and revised its environmental regulations to reduce the number of EAs required
to be submitted by industry” (DHHS, 1998). The FDA only requires that pharmaceutical
companies perform an environmental assessment of a new product if their stated anticipated
production of the drug is more than 40,000 kilograms per year, ignoring the possibility that
multiple companies might all be making the same drug (Thacker, 2005).
1.9.2 The EPA
There are no EPA programs that specifically regulate the presence of pharmaceuticals
in ground or surface waters, and it is unclear if there will be any in the near future due to the
complexity of accurately quantifying potential environmental and human health risks. The
presence and potential effects of pharmaceutical compounds may be addressed under EPA
programs such as the Safe Drinking Water Act (SDWA). This act requires EPA’s Office of
Water to set maximum contaminant levels in public drinking water based on the best
available peer-reviewed literature and the protection of the “at risk” portion of the
population. There are currently no existing regulations for pharmaceuticals (Conerly, 2005).
However, specific pharmaceuticals could be included in the Contaminant Candidate List
(CCL) under the SDWA, which identifies and lists contaminants unregulated by existing
regulations “known or anticipated to occur in public water systems” (U.S. EPA, 2007a). The
SDWA and other regulations may become important in situations of groundwater recharge or
the intentional reuse of wastewater. Though not intended to address the safety of wastewater
reuse, the SDWA and the National Primary Drinking Water Regulations (NPDWR) have
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served as starting points for developing water quality standards for reclaimed wastewater
(CDM, 2004).
Criteria for pharmaceuticals as toxins could be also developed under the Clean Water
Act (CWA) if adequate supporting data becomes available (Conerly, 2005). Other CWA
approaches that could help control the presence of pharmaceuticals in ambient waters include
the Effluent Guidelines program for the regulation of point sources (e.g., the pharmaceutical
manufacturing industry and the aquaculture industry), the Combined Animal feeding
Operations Rule, and the Fish Advisory Program (Conerly, 2005). The EPA requires more
research before any decision can be made as to which individual types of pharmaceuticals (if
any) might necessitate further attention in surface and drinking waters (Daughton, 2000).
The EPA also has the ability to regulate pharmaceutical compounds in the solid waste
stream. Pharmaceutical waste generated by end-users, households and certain small, non-
household generators are known as Conditionally Exempt Small Quantity Generators
(CESQGs), and are not regulated as hazardous waste (DTSC, 2003). Some pharmaceutical
waste is classified as hazardous waste under the Resource Conservation and Recovery Act
(RCRA) and the Code of Federal Regulations (CFR) (40 CFR Part 261) enforced by the EPA
and authorized states. Hazardous waste management involves specific management practices
including permits, special transportation manifests, and specific bans against land disposal
without treatment. Hospitals, nursing homes, pharmacies, and reverse distributors are
required to follow guidelines regarding the destruction of drugs that are considered hazardous
waste, but many of these institutions are either unaware of their RCRA obligations or choose
to ignore them (Oliver and Chapman, 2003). RCRA regulations have not been significantly
updated since 1976 and have not kept up with drug development (Smith, 2005). Compliance
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with RCRA regulations has proven difficult due to the difficulties of implementation and
enforcement within a health care setting, as well as a lack of interpretive guidance from the
EPA (Smith, 2005). Some wastes that are not regulated as hazardous under RCRA are
identified as hazardous in states with stricter regulations, such as California.
A pharmaceutical can be considered a hazardous waste if it is listed as a hazardous or
characteristic waste as per the CFR Title 40 Part 261 Subpart D. A characteristic waste
meets the characteristics of ignitability, corrosivity, reactivity, or toxicity. A number of
common drugs meet the definition of hazardous waste, including epinephrine, nitroglycerin,
nicotine, and many chemotherapy agents (Smith, 2002). Only 5% of pharmaceutical
products on the market would be regulated as RCRA hazardous waste if discarded by an
entity other than a CESQG (Smith, 2005).
Many consumers and businesses are not aware of the CFR regulations and have not
been informed of how to properly dispose of their unused or expired drugs. The Office of
National Drug Control and Policy currently suggests mixing unused or expired drugs with an
undesirable substance such as coffee grounds or cat litter, placing them in a sealable,
nondescript container and disposing of them in the garbage as opposed to flushing the drugs
down the drain. However, the FDA still suggests that several highly toxic compounds be
flushed due to their addictive properties (ONDCP, 2006) and these include;
 Actiq (fentanyl citrate)
 Daytrana Transdermal Patch (methylphenidate)
 Duragesic Transdermal System (fentanyl)
 OxyContin Tablets (oxycodone)
 Avinza Capsules (morphine sulfate)
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 Baraclude Tablets (entecavir)
 Reyataz Capsules (atazanavir sulfate)
 Tequin Tablets (gatifloxacin)
 Zerit for Oral Solution (stavudine)
 Meperidine HCl Tablets
 Percocet (Oxycodone and Acetaminophen)
 Xyrem (Sodium Oxybate)
 Fentora (fentanyl buccal tablet)
1.9.3 The DEA
The DEA limits its regulation of pharmaceuticals to those that are “controlled
substances” or their precursors. Controlled substances include legal and illegal drugs
meeting certain guidelines regarding potential for abuse, accepted medicinal use, and safety
(FDA, 2002). The DEA maintains a yearly registration program of individuals, known as
DEA registrants, within organizations or institutions that are legally able to handle controlled
substances in specific capacities (ODC, 2007b). DEA registrants include individuals that fall
into, or are employed in one of the DEA approved categories: pharmacy, hospital, clinic,
practitioner, teaching institution, mid-level practitioner, manufacturer, distributor, researcher,
analytical laboratory, importer, exporter, domestic chemicals, and narcotic treatment
programs (ODC, 2007b). Disposal of controlled substances by DEA registrants is carefully
regulated to ensure that the substance is rendered destroyed or unrecoverable (i.e.
incineration). The agency accepts several methods of disposal, including flushing them
down the drain, as viable means of destruction for controlled substances (RDWG, 2003;
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FDA, 2002). The DEA forbids the return of controlled substances from the end-user to any
DEA registrant, or transfer to anyone, except in certain cases (i.e. a law-enforcement agent)
(ODC, 2007a). The agency provides no guidance or recommendations regarding disposal at
the level of the end-user or patient (ODC, 2007a).
Other countries have also implemented take-back programs, such as Australia (Return
Unwanted Medicines www.returnmed.com.au project initiated in July 1998), British
Columbia, Canada (The Medications Return Program www.medicationsreturn.ca started in
November 1996) as well as Prince Edward Island and Ottawa, both in Canada, Sweden, and
11 European countries (Belgium, France, Luxembourg, Portugal, Spain, Denmark, Finland,
Germany, Italy, Sweden, and the U.K.). These programs range from a small-scale involving
only a few territories to countrywide pharmaceutical company involvement (Ph:ARM Team,
2007).
1.9.4 Previous Surveys and Findings
Institutional surveys
Several institutional surveys have been conducted across the U.S. and other countries
in order to determine the details of the pharmaceutical waste stream to help devise a solution
(Table 1.8). Kuspis & Krenzelok (1996) examined the disposal methods of 100 community-
based pharmacies around Pennsylvania. They found that pharmacies sent all non-distributed,
unopened, expired medications back to pharmaceutical companies for a return credit. Of the
remainder medications, 15% of pharmacists prefer on-site incineration, 17% preferred
disposal by a biohazard waste company, and 68% dispose of medications by placing them in
the garbage or flushing them down the sink or toilet.
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A pharmacy-based survey by Braybrook et al. (1999) in the United Kingdom
collected information from 529 people at 18 pharmacies over eight weeks in order to
characterize the reasons for medication return. Items were most commonly returned because
the medication was stopped or switched (42%), followed by an excess supply or just cleaning
out the closet (20%), patient death (16%), and medication stopped by the patient (14%). If
this survey were representative of the entire Health Authority in Britain, as much as £800,000
a year (or 1.5% of the annual prescribing budget) would be wasted (Braybrook et al., 1999).
A survey completed in King County, WA (which includes Seattle) gathered data on
the quantity and nature of pharmaceutical waste streams and drug waste management
practices from a variety of businesses including doctor’s offices, specialty and outpatient
facilities, veterinary offices, ambulatory/surgical centers, hospitals, pharmacies, and
nursing/boarding homes (Oliver and Chapman, 2003). The study found that a reverse
distributor is the most common disposal route (6,500 pills), while flushing pills down the
drain is the second most common (6,188 pills). Twenty-seven national reverse distributors
were contacted via telephone to identify types of services offered, acceptance policies, and
other general information about the industry (Chapman, 2003). Of the 23 reverse distributors
that provide services to King County, most only provide mail-in service and all accept
controlled substances and prescription drugs. Household drugs were typically accepted only
under certain conditions, such as the drug was returned through the pharmacy that dispensed
it; the drug was not a controlled substance; patient health information subject to privacy laws
was protected; and the reverse distributor held the contract as a “returns department” for the
manufacturer of the returned drug.
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Boivin (1997) conducted an 85-bed nursing home study in Ontario to calculate the
costs of medication waste for the period of October 17 to November 20, 1996. Nursing
homes are required to keep appropriate records of surplus prescribed drugs, and from this
Boivin calculated that 13.14% of dispensed medication was wasted. The study also divided
medication waste data into nine different categories. Topical agents were the most expensive
class of medications returned (27.17% of total cost of returned medication), followed by
respiratory (26.09%), and then neurologic and endocrinologic (17.65%) medications.
Table 1.8: Summary of institutional surveys
Survey Type of Survey Location Information Collected
Kuspis and
Krenzelok, 1996
100 community and
hospital pharmacies
Tri-state region
(PA, NY, NJ) Disposal methods.
Boivin, 1997 85-bed nursing home Ontario, Canada Cost of wastedmedications.
Braybrook et al.,
1999
Returns by 529 people
at 18 pharmacies United Kingdom Reasons for return.
Chapman, 2003 27 reverse distributors National
Identify services offered,
acceptance policies, and
other general information
about the industry.
Oliver and
Chapman, 2003 60 businesses
King County,
WA
Quantity and nature of
pharmaceutical waste
streams and drug waste
management practices.
Crisostomo et al.,
2006
Community-based
pharmacy study of 572
patients
Portugal Quantity and cost ofwasted medications.
Hauser, 2006 51 patients at onehospice Chicago, IL
Type, quantity, and cost of
wasted medications.
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Hauser (2006) examined the type, quantity, and value of wasted medications at one
hospice where 51 patients died during the study period, and found that a total of 4,762
milliliters (mL), 2,495.5 tablets, and 67 patches were disposed of, averaging to 9.7 drugs per
patient. The estimated cost of these medications was $5,558.75 if purchased as generics and
$10,535.85 if purchased as brand names, or an average of $109.00 or $206.59 per patient,
respectively. These studies have shown that large quantities of money are wasted along with
the actual unused or expired drugs.
Consumer Surveys
Only a limited number of end-user surveys on pharmaceutical disposal have been
completed, but collected information includes patient disposal practices and reasons for
disposal, beliefs, waste quantities and costs, number of medicine containers, and storage
times (Table 1.9). Kuspis and Krenzelok (1996), Morgan (2001), Seehusen and Edwards
(2006), and the BAPPG (2006) are surveys taken at several convenient locations, such as a
poison control center, retirement community, army medical center, and pharmaceutical
collection event, respectively. Bound and Voulvoulis (2005) and the Washington Citizens
for Resource Conservation (WCRC) (2006) are the most rigorous surveys to date; both are
randomly sampled phone surveys.
Four surveys show that trash is the most common disposal practice, and two surveys
found that the sink or toilet is the most common practice. It must be noted that the method of
data collection was not uniform in these studies (different disposal categories; some allow
more than one answer for disposal method while others do not; etc.). The WCRC survey also
compared the disposal practices for various demographic groups. Interestingly, younger
residents (aged 18 to 54 years) are more likely to dispose of unused or expired medicines in
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the trash, while residents aged 55 or older are more likely to use the sink or toilet. The
WCRC survey (2006) is the only random sample survey that was conducted in the United
States, and it is unclear whether its results apply uniformly to the rest of the nation.
Table 1.9: Summary of routes of disposal as determined by surveys in percent
Note: all units are in %; “- -“ means question was not investigated in survey.
Another method of disposal is not really what it implies. Drug recycling, or drug
donation is a new concept that is currently being tested in two states (California and
Oklahoma). Drug recycling entails collecting unused pharmaceuticals from nursing homes,
wholesalers, and manufacturers in order to redistribute them to medically indigent patients.
This type of program has the potential to minimize the amount of wasted drugs and also help
those that cannot afford their medications and would go without treatment due to the cost.
Drug recycling is not intended to take advantage of medically indigent patients in any way.
One issue related to drug recycling is expiration dates. Questions arise over whether
or not a drug that is past its expiration date can still be recycled. Expiration dates on
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pharmaceuticals were required by law in 1979 to determine a date where the manufacturer
guarantees the full potency and safety of the drug (Altschuler, 2002). An expiration date
does not mean how long or how safe the drugs actually are. In fact, many drugs still have the
same potency 10 to 15 years from their expiration date, and many medical authorities state
that it is generally safe to take them no matter how expired they are (Altschuler, 2002). In
some respects, an expiration date is purely a marketing ploy; if a bottle of aspirin lasted 10
years, a consumer would be less likely to buy more. A study commissioned by the U.S.
Army about 20 years ago confirms these results. The FDA analyzed over 100 prescription
and over-the-counter drugs and determined that 90% of the drugs had shelf lives of up to 15
years past the expiration date (Altschuler, 2002). Joel Davis, a former FDA expiration-date
compliance chief noted that there are a few exceptions to this rule, most notably:
nitroglycerin, insulin, and some liquid antibiotics. Storing drugs and antibiotics in a
refrigerator can drastically increase their shelf lives as well. Therefore, consuming recycled,
expired drugs will usually not lead to harmful health effects and may be more beneficial than
not taking needed medications at all.
Senator Joe Simitian of California sponsored Senate Bill 798 that allows for drug
recycling. Under the Bill’s stipulations, the medication cannot be a controlled substance and
cannot have been in the possession of a patient or any individual member of the public.
Patient confidentiality must be maintained, the drugs must be unexpired, unopened, and in
tamper-proof packaging; persons and entities accepting, disposing, and dispensing of
pharmaceuticals must also be protected against liability.
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Not surprisingly, there are a number of concerns surrounding drug recycling that need
to be addressed before it is implemented on a full-scale basis, but it is a viable option to
reduce the waste stream reaching surface waters, and to also help those in need.
There is no clear solution for the development of regulations or the proper disposal of
pharmaceuticals by end-users. Disposal guidelines, such as those recently released by the
White House Office of National Drug Control Policy (ONDCP) should be more widely
advertised within local communities in order to reduce the presence of pharmaceuticals in
surface waters. Policy options to address pharmaceutical disposal include permanent
collection at household hazardous waste facilities or other locations such as pharmacies; a
mail-back program; special collection events; or drug recycling. Controlled substance
regulations present a barrier to implementing any of these programs as only law enforcement
officials may accept controlled substances from end-users.
1.10 Research Objectives
The presence of antibiotics, other pharmaceuticals, and endocrine disrupting
compounds are increasingly detected in surface waters due to incomplete removal by
wastewater treatment plants and nonpoint sources. The scope of this research project is to:
 Determine the aqueous concentration and persistence of antibiotics in
wastewater and receiving waters in a watershed that includes a drinking water
source and recreational area.
Estimate the concentration of one antibiotics in the watershed at locations
where samples were not collected using the BMEGUI geostatistical software,
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and to also determine any spatial and/or temporal variations during the study
period.
 To complete an environmental hazard assessment of detected antibiotics.
 To investigate possible policy implications in order to reduce the presence of
pharmaceuticals in surface waters.
2. MATERIALS AND METHODS
2.1 Materials
Antibiotic standards purchased from Sigma-Aldrich (St. Louis, MO) include:
sulfathiazole, sulfamerazine, sulfamethazine, sulfamethizole, sulfachlorpyridazine,
sulfamethoxazole, sulfadimethoxine, erythromycin, tylosin, roxithromycin, trimethoprim,
lincomycin, norfloxacin, sarafloxain, flumequine, levofloxacin, pipemidic acid, oxolinic acid,
minocycline, oxytetracycline, tetracycline, demeclocycline, chlortetracycline, doxycycline;
all were 99% pure. Isotopically labeled standards (13C6-sulfamethoxazole, 13C3-ciprofloxacin,
and 13C2-erythromycin) were purchased from Cambridge Isotope Laboratories (Andover,
MA). The internal standard, simatone, was purchased from Accustandards (New Haven,
CT). Erythromycin-H2O was prepared at the University of North Carolina laboratory with
the erythromycin standard and the method described by McArdell et al. (2003) and Ye,
2005). Ciprofloxacin was purchased from ICN Biochemicals (Irvine, CA) and Enrofloxacin
was purchased from Fluka (Bachs, Switzerland).
HPLC-grade methanol, acetonitrile, and formic acid were purchased from Fisher
Scientific (Pittsburgh, PA). Disodium ethylenediamine tetraacetic acid (Na2EDTA) and
sodium azide were purchased from Aldrich (Milwaukee, WI). Laboratory grade water
(LGW) was prepared in the University of North Carolina laboratory using a water
purification system (Pure Water Solutions, Hillsborough, NC). The system filters
chloraminated tap water to 1 µm, removes residual disinfectants, reduces total organic carbon
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to less than 0.2 ppm with an activated carbon resin, and reduces conductivity to 18 Mohm
with mixed bed ion-exchange resins.
2.2 Cleaning Procedures
All non-volumetric glassware was detergent washed in a dishwasher, and then soaked
in a 10% nitric acid bath. The glassware was removed and rinsed three times with LGW and
then placed in a 110°C oven overnight or until thoroughly dry (about 4 hours). Volumetric
glassware (pipettes, volumetric flasks, and graduated cylinders) were manually detergent
washed with tap water, rinsed three times with LGW, then MeOH, and allowed to dry on a
clean Kimwipe placed in a clean plastic bucket that was placed in a safety hood. Caps and
septa were soaked in a clean beaker filled with a mixture of LGW and detergent for an hour
or more, rinsed with LGW, MeOH, and then dried on a clean Kimwipe.
Tubing used for solid phase extraction (SPE) was rinsed with LGW followed by
MeOH promptly after use. This was done by connecting the tubing to plastic cartridges
(containing no sorbent) to a vacuum manifold. With the vacuum on, LGW was aspirated
through each of the tubes for 30-60 seconds, followed by MeOH. The ends of the tubing
were then rinsed with LGW. The tubes were then allowed to vacuum dry before being
placed back in storage for later use.
2.3 Stock Solution Preparation
Stock solutions were prepared at 1 g/L concentrations following details listed in
Appendix A. Antibiotic, surrogate, and internal standard solutions were stored in a freezer at
approximately -15ºC and were typically held for no longer than three months (tetracyclines,
quinolones, macrolides, and lincomycin) or one year (sulfonamides and trimethoprim).
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Working mixtures of the 26 antibiotics were freshly prepared within two days of each
sampling event. Fresh working solutions were prepared prior to a sampling event.
2.4 Sample Collection
Grab samples were collected from wastewater treatment plant effluent at the point
where the effluent discharges from the WWTP and mixes with stream water, and at various
downstream locations during each sampling event. Local utilities were contacted for site
access permission when needed and to coordinate sampling events. It was agreed that local
utilities would remain anonymous for publication and communication outside of involved
researchers and collaborators. One upstream sampling point, the point of entry of wastewater
effluent, and two downstream sampling locations were identified on each stream. Various
locations throughout the receiving reservoir were sampled during the final sampling event,
while only one location in the reservoir was sampled more frequently. This sampling point is
located at an influent pipe for a drinking water treatment plant. The distance from the
influent pipe varied from 9 – 11 miles from the second downstream sampling point in each of
the streams. Sampling in the reservoir was conducted by a local utility due to the location of
the pipe. Criteria for identifying sampling locations were mainly based on the practicality
and accessibility of the location as all three streams flowed through a forested, intermittently
swampy, area downstream from the WWTP point of discharge. Upstream locations ranged
from 400 feet to 2 miles from the WWTPs; distance between the downstream sampling
points varied (Figure 2.1). Samples from each stream were collected on the same day, but it
was not possible to collect samples for all three streams in one day. However, samples from
all three streams and the reservoir were collected within 1-3 days of each other in the
direction of flow.
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Normal or worst-case (drought) conditions were desired for sampling events.
Weather conditions such as previous rainfall were considered when planning a sampling
event. Normal stream flow was determined by investigating stream flow and stream gage
data for each stream using the U.S. Geological Survey (USGS) real-time stream data. This
was possible because a USGS monitoring station was located at or near a downstream
location on each stream of the three streams involved in the study. The study was conducted
during times of extreme drought so dilution via rainfall was a negligible issue.
Between 2 and 4 liters were collected at each sampling location depending on the
type of analyses performed. Two liters were needed for the antibiotic analysis and one liter
for the yeast estrogen screen (YES) bioassay. These volumes ensured a sufficient amount of
sample in order to perform the analyses and determine analyte concentrations using the
method of standard addition. All water samples were either collected in pre-cleaned 1-L
amber bottles (Laboratory Supply Distributors, Mt. Laurel, NJ) and capped with screw caps
containing removable Teflon-lined septa, or pre-cleaned 4-L amber bottles that previously
contained HPLC MeOH (Fisher Scientific, Pittsburgh, PA). Sodium azide, a preservative
used to inhibit bacterial growth, was placed in the amber bottles at 100 µg/L. The sodium
azide solution was prepared by measuring out the appropriate mass and dissolving it in
LGW. The solution was stored in a refrigerator at 4°C for up to 6 months. After samples
were collected, they were placed inside a cooler stocked with frozen ice packs to keep them
stable during transport. Upon arrival at the University of North Carolina laboratory, samples
were immediately placed in a dark 4°C refrigerator until analysis. Aqueous samples were
processed within 24-36 hours.
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Figure 2.1: Sampling locations within watershed
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2.5 Sample Preparation
2.5.1 Sample Preparation for Antibiotic Analysis
Sample preparation for the antibiotic analysis was adopted from previous work in our
laboratory (Richards, 2007; Ye, 2005). Samples were filtered first with 0.7 µm glass
microfiber filters (Fisher Scientific, Hampton, NH), and then followed by 44 mm, 0.45 µm
nylon filters (GE Water & Process Technologies, Trevose, PA) into 1000 mL Buchner flasks.
The filtrate was then divided into six 250 mL amber bottles using a 250 mL volumetric flask
for standard addition. The remaining sample was then stored in a dark 4°C refrigerator for
backup analysis if necessary. The 250 mL filtrates were spiked with 25 µL of a mixture
containing each of the surrogate standards at a concentration of 0.5 mg/L to obtain an
individual surrogate concentration of 50 ng/L. The filtrates were then capped and the bottle
inverted three times to mix the contents. Four of the six 250 mL bottles were spiked with an
increasing concentration of the working mixture of the 26 antibiotics typically at 20, 100,
500, and 1000 ng/L which captures the range of expected concentrations in the unspiked
samples. The antibiotic and surrogate standard mixtures were spiked into the filtrate using
micropipettes and disposable glass capillaries that ranged from 10 to 250 µL. Two of the 250
mL bottles were left unspiked. All six 250 mL amber bottles were then spiked with a
solution of 25 µL of 1.25 mg/L Na2EDTA in LGW to prevent complexation of target
analytes with any metals in the sample. The filtrate was then pH adjusted to between 5.8 and
6 using 2% formic acid in LGW that is prepared weekly.
The samples were then extracted using 200 mg Strata X polymeric reversed phase
extraction cartridges (Phenomenex, Torrance, CA). First, the cartridges were conditioned
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using 6 mL HPLC-grade MeOH, 3 mL of 0.1% formic acid in MeOH (volume/volume), and
two aliquots each of 6 mL LGW. The samples were then extracted through the cartridges at
a maximum flow rate of 5 mL/min using a 12- or 24-fold vacuum manifold (Fisher
Scientific, Pittsburgh, PA). After extraction but before the cartridges dried out, the cartridges
were rinsed with 5 mL of LGW, and then dried under a vacuum pressure of 15-18” Hg for
approximately 10-15 minutes.
At this point the analytes of interest are retained on the solid phase of the cartridges.
They are eluted into 10 or 13 mL conical vials using 2 x 4 mL of 2% formic acid in MeOH.
The extract was either stored in a freezer for later analysis or blown-down immediately to 50
µL with a gentle stream of nitrogen gas at 99.999% purity. The 50 µL volume was measured
by visually comparing the volume with that to another vial injected with 50 µL of LGW.
The vials were covered with aluminum foil to prevent photodegradation while in the blow-
down apparatus. After concentrating the eluent to 50 µL, it was reconstituted to 250 µL with
9:1 LGW:MeOH (volume/volume) using a 500 µL syringe. 10 µL of a 1.25 mg/L
concentration of simatone was spiked under the surface of the reconstituted extract using a 10
µL syringe. The conical vials are then capped with Teflon-lined screw-on caps, briefly
vortexed (Thermolyine Maxi-Mix, Dubuque, IA), and then allowed to settle for 15 minutes
while covered with aluminum foil.
After settling, the extract is removed from each vial with a 500 µL syringe, the
volume is measured and recorded to later account for any uncertainties about the data, and is
filtered into labeled 2 mL autosampler vials containing 250 µL glass inserts (Laboratory
Supply Distributors, Mt. Laurel, NJ) with 4 mm, 0.45 µL PTFE syringe filters (Laboratory
Supply Distributors, Mt. Laurel, NJ). The autosampler vials were then capped with
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polypropylene screw thread closures containing polytetrafluoroethylene septa (Laboratory
Supply Distributors, Mt. Laurel, NJ). The extracts were stored in a -20°C freezer until
analysis on a Varian 1200L liquid chromatography tandem mass spectrometer (Varian,
Walnut Creek, CA) with a maximum holding time of 7 days.
2.5.2 Sample Preparation for Yeast Estrogen Screen Bioassay
The recombinant yeast estrogen screen (YES) assay is one of many used to measure
the potential estrogenicity of pollutants in surface and wastewaters. The YES assay was
developed by incorporating the human estrogen receptor (hER) gene into the main
chromosome of a yeast strain (Routledge and Sumpter, 1996). The hER gene provides
estrogen receptors that, when activated, cause production of the enzyme β-galactosidase.
The β-galactosidase can then react with chlorophenol-red-β-D-galactopyranoside (CPRG), a
chromogenic substrate added to the growth medium. This causes a color change that is
measured through optical absorbance to determine the amount of enzyme activity and
consequently, the amount of estrogenic activity in wastewater effluent and downstream
surface waters (Routledge and Sumpter, 1996).
500 mL of each sample was filtered through 1.5 m glass filters and placed in a 500
mL amber bottle (Laboratory Supply Distributors, Mt. Laurel, NJ). Strata-X 200 mg RP
cartridges were conditioned with 3 mL MtBE, 3 mL MeOH, and 6 mL LGW. Samples were
run through the cartridges at a flow rate not exceeding 8 mL/min. The cartridges were
washed with 3 mL 40% MeOH in LGW, 3 mL LGW, and 3 mL 10% MeOH and 2%
NH4OH. The cartridges were dried for 1 hour under maximum vacuum pressure (18-20”
Hg), and then eluted with 5 mL MtBE:MeOH (9:1) into 10 mL conical vials (Laboratory
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Supply Distributors). Extracts were blown down to dryness with nitrogen gas and
reconstituted to 200 L with EtOH. Samples were then taken through the YES assay.
The YES assay protocol was modified from Routledge and Sumpter (1996). All
solutions used for the YES assay were prepared in sterilized bottles, stored at 4C, and filter-
sterilized before use with a Uniflow-25 disposable 0.25 m syringe filter. Solutions were
discarded in the event of visible turbidity. The solutions prepared were as follows:
 20% w/v solution of D-(1)-glucose
 4 mg/mL solution of L-aspartic acid
 24 mg/mL L-threonine
 20 mM copper (II) sulfate solution
 10 mg/mL stock solution of chlorophenol red-ß-D-
galactopyranoside (CPRG)
 0.8 mg/mL solution of Fe2(SO4)3
 0.02 mg/mL solution of biotin
 25 mg/mL solution of chloramphenicol
The minimal medium was created by adding the following components into 1 L of LGW.
The medium was autoclaved at 121˚C for at least 15 minutes and stored at room temperature.
 13.61 g KH2PO4
 1.98 g (NH4)2SO4
 4.2 g KOH
 0.2 g MgSO4
 1 mL Fe2(SO4)3 solution (1 g/L)
 50 mg L-leucine
 50 mg L-histidine
 50 mg adenine
 20 mg L-arginine-HCl
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 20 mg L-methionine
 30 mg L-tyrosine
 30 mg L-isoleucine
 30 mg L-lysine-HCl
 25 mg L-phenylalanine
 100 mg L-glutamic acid
 150 mg L-valine
 375 mg L-serine
The vitamin solution was created by adding the following components into 180 mL of filter-
sterilized LGW. The solution was stored at 4˚C.
 8 mg thiamine
 8 mg pyridoxine
 8 mg pantothenic acid
 40 mg insitol
 20 mL of biotin solution
Each time the yeast was inoculated, a new yeast plate was streaked on an agar plate made in
the laboratory. The following components were added to 1 L of LGW, autoclaved at 121˚C
for at least 15 minutes, poured into sterile plates in 15 mL aliquots, and stored in Ziploc bags
at 4˚C.
 60 g Sabourad’s Dextrose Agar (Difco)
 3 mL chloramphenicol solution (available as 25 mg/mL)
2.5.3 YES Assay Protocol
Minimal medium (45 mL aliquots) was added to a sidearm flask and several culture
flasks and capped. The number of culture flasks depends upon the number of samples, but
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generally one culture flask can be used for about 3 96-well plates, and one culture flask was
used as a control. Both aliquots were autoclaved at 121˚C for at least 15 minutes. A growth
medium was also added to the minimal medium on the day of inoculation. The following
components were added to an autoclaved 50-mL beaker and filter-sterilized using a 60-mL
sterile disposable syringe and then added to the autoclaved minimal medium in the sidearm
and culture flasks:
 5 mL glucose solution
 1.25 mL L-aspartic acid solution
 0.5 mL vitamin solution
 0.4 mL L-threonine solution
 125 µl copper (II) sulfate solution
The plates were inoculated using a culture of the yeast strain by selecting a single
colony from the agar plate and transferring into the growth medium using a sterilized metal
microbial loop. The inoculated culture was grown in a 30˚C temperature-controlled room on
a shaker table at 100 rpm until it reached an absorbance of 1.0, read at 640 nanometers in a
Molecular Devices Emax Precision Microplate Reader, Model 383109. Assay plates were
prepared by adding 20-µL aliquots of the extracted samples, a 38 µg/L estradiol standard,
and a negative control (growth medium only) in the first well and then serially diluted in a 96
well plate. 20 µL of ethanol was added to each well in the well plate except for the last
column of wells. 20 µL of sample was transferred from each column and mixed with the
next column to create 50% dilutions along the columns. The solutions in the wells were then
allowed to completely evaporate in a biosafety hood.
1 mL of 10 mg/mL sterile CPRG solution was added to the sidearm flask. A small
volume (250 µL) of this solution was added to each well in the 96-well plate that was
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previously plated with standards and samples. The plate was then covered with Parafilm®
and placed in the 30˚C room. The plate was read after 72 hours of inoculation using a
Molecular Devices Emax Precision Microplate Reader, Model 383109. The standard
operating procedure for the YES assay analysis can be found in Appendix C.
2.6 Liquid Chromatography Tandem Mass Spectrometry Methods (LC/MS-
MS)
The samples prepared for antibiotic analysis were analyzed with a liquid
chromatography triple quad tandem mass spectrometer (LC/MS-MS) (Varian 1200L, Varian
Inc., Walnut Creek, CA) with a dual off-axis electrospray ionization (ESI) interface that was
connected to a solvent delivery module (ProStar 210, Varian Inc., Walnut Creek, CA) and
autosampler (ProStar 430, Varian Inc., Walnut Creek, CA).
Three methods were designed for the chromatographic separation for a subset of the
26 antibiotics in each class (Ye, 2005). 20 µL of the extract was injected three times when
analyzing for all 26 antibiotics. A Varian Pursuit C-18 guard column (3 cm x 2 mm, 3 µm)
attached to a Varian Pursuit C-18 analytical column (15 cm x 2 mm, 3 µm) were used in the
separation of the antibiotics. The mobile phase was A: 0.1% formic acid in LGW and B:
HPLC-grade acetonitrile. The mobile phases were freshly prepared before analysis and
filtered through 0.2 µm nylon fiber filters (Millipore Billerica, MA). The flow rate remained
constant and 0.2 µL/min while the gradient varied throughout the chromatographic run. The
methods were labeled as “SAMA”, “QL”, and “TC”. The “SAMA” method was used to
separate the sulfonamide, macrolides, lincomycin, trimethoprim, surrogate standards 13C6-
sulfamethoxazole and 13C2-erythromycin, and the internal standard simatone. The “QL”
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method separated the quinolones, the surrogate standard 13C3-ciprofloxacin, and simatone,
and the “TC” method separated the tetracyclines, the surrogate standard meclocycline, and
simatone (Table 2.1). The gradient for each method is presented in Table 2.2.
Table 2.1: Antibiotics within each LC-MS/MS method
Antibiotic Class Analyte Group Acronym
Sulfachlorpyridazine
Sulfadimethoxine
Sulfamerazine
Sulfamethazine
Sulfamethizole
Sulfamethoxazole
Sulfonamide
Sulfathiazole
Erythromycin-H2O
RoxithromycinMacrolide
Tylosin
Lincosamide Lincomycin
Diaminopyrimidine Trimethoprim
“SAMA”
Ciprofloxacin
Enrofloxacin
Flumequine
Levofloxacin
Norfloxacin
Fluoroquinolone
Sarafloxacin
Oxolinic AcidQuinolone
Pipemedic Acid
“QL”
Chlortetracycline
Demeclocycline
Doxycycline
Minocycline
Oxytetracycline
Tetracycline
Tetracycline
“TC”
Positive ionization was used to identify ions during mass spectrometry. Electrospray
parameters had been previously optimized and remained constant during antibiotic analyses
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(Ye, 2005). Optimized parameters are shown in Table 2.3. The drying and nebulizer gases
were nitrogen and the collision gas was argon.
Table 2.2: Gradients for “SAMA”, “QL”, and “TC” methods
“TC” Method
Time % A % B
0.00 82 18
5.00 50 50
17.00 50 50
19.00 0 100
21.00 0 100
“QL” Method
Time % A % B
0.00 90 10
20.00 0 100
22.00 0 100
37.00 0 100
“SAMA” Method
Time % A % B
0.00 85 15
15.00 50 50
19.00 50 50
21.00 0 100
34.00 0 100
Table 2.3: Optimized parameters for antibiotic analyses on LC-MS/MS
Nebulizer needle voltage (V) 5000
Detector voltage (V) 1900
Shield voltage (V) 600
Ion-transfer voltage (V) 60
Drying gas flow (L/min) 4
Drying gas temperature (°C) 300
Nebulizer gas flow (L/min) 1
ESI chamber temperature (°C) 50
Collision gas pressure (mTorr) 2.6
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Precursor and product ions were determined during direct infusion of known
standards at a concentration of 10 µg/L in MeOH at a flow rate of 20 µL/min (Ye, 2005).
Two product ions detected at the highest signal strength were identified for each antibiotic
and the internal standard while only one product ion was identified for the surrogate
standards. Precursor and product ions and optimal collision voltages are listed in Table 2.4.
Underlined product ions indicate that they were rarely detected above noise in actual
samples. The analytes listed at the bottom of each section are the surrogate standards.
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Table 2.4: Analyte precursor, product ions, and optimal collision voltages
Product Ions (Collision Voltage, eV)Analyte Precursor Ion
Major Minor
Sulfachlorpyridazine 256.0 156.0 (13) 108.0 (20)
Sulfadimethoxine 311.0 156.0 (15) 108.0 (15)
Sulfamerazine 265.0 156.0 (16) 108.0 (18)
Sulfamethazine 279.0 186.0 (16) 92.0 (18)
Sulfamethizole 271.0 156.0 (12) 108.0 (19)
Sulfamethoxazole 254.0 156.0 (14) 108.0 (20)
Sulfathiazole 256.0 156.0 (13) 108.0 (20)
Erythromycing-H2O 716.4 158.0 (22) 558.0 (22)
Roxithromycin 837.5 158.0 (26) 159.0 (26)
Tylosin 916.6 174.0 (32) 101.0 (38)
Trimethoprim 291.0 230.0 (23) 123.0 (21)
Lincomycin 407.0 126.0 (23) 359.0 (18)
13C2-Erythromycin 718.4 160.0 (22) --
13C6-Sulfamethoxazole 260.0 162.0 (14) --
Ciprofloxacin 332.0 288.0 (17) 245.0 (23)
Enrofloxacin 360.0 316.0 (18) 245.0 (25)
Flumequine 262.0 244.0 (15) 202.0 (30)
Levofloxacin 362.0 318.0 (16) 344.0 (20)
Norfloxacin 320.0 276.0 (17) 233.0 (23)
Oxolinic acid 262.0 244.0 (15) 216.0 (27)
Pipemedic acid 304.0 286.0 (15) 215.0 (29)
Sarafloxacin 386.0 342.0 (17) 299.0 (26)
13C3-Ciprofloxacin 336.0 291.0 (17) --
Chlortetracycline 479.0 444.0 (17) 154.0 (24)
Demeclocycline 465.0 448.0 (17) 430.0 (26)
Doxycycline 445.0 428.0 (17) 154.0 (24)
Minocycline 458.0 441.0 (18) 283.0 (41)
Oxytetracycline 461.0 426.0 (17) 443.0 (11)
Tetracycline 445.0 410.0 (18) 427.0 (12)
Meclocycline 477.0 460.0 (18) --
Simatone (internal standard) 198.0 128.0 (18) 100.0 (22)
Note: Analytes shown in italic font are surrogate standards, values underlined indicates that they are not
consistently seen above a signal to noise ration greater than 10; -- indicates that no minor ions were present for
these analytes.
3. Results
3.1 Antibiotic Analysis by LC-MS/MS
Analyte detection in a sample used three criteria for positive analyte identification: 1)
relative retention time to the internal standard simatone was within 2% of the value obtained
in standard solutions; 2) the target ion for that analyte was found at that retention time; and 3)
at least one product ion (Table 2.4) with a signal-to-noise (S:N) ratio greater than three was
obtained under the predefined breakdown conditions for the parent ion. Chromatographic
peak integration was completed manually or automatically using integration methods
programmed into the Varian Workstation V.6.8 software. Typical retention times for each
analyte are shown in Table 3.1. While retention times varied slightly depending on the
matrix, instrument usage and conditions, a match in relative retention time between a known
analyte and an unknown analyte means that the retention times of a particular peak for an
unspiked and spiked sample varied no more than 2% for a single chromatographic run. The
analytes’ presence is also confirmed when at least one product ion is identified at a matching
retention time.
The internal standard simatone was targeted during each chromatographic run
although it eluted at different times due to differences in the gradient program. Relative area,
which uses the peak area of the internal standard during the same chromatographic run
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designed for the class of the targeted antibiotics, was used to quantify analytes and will be
discussed in Section 3.1.2.
Table 3.1: Typical analyte chromatographic relative retention time
Method Analyte Relative RetentionTime (min)
Sulfathiazole 0.625
Sulfamerazine 0.797
Sulfamethazine 0.895
Sulfamethizole 0.968
Sulfachlorpyridazine 1.19
Sulfamethoxazole 1.32
Sulfadimethoxine 1.59
Tylosin 1.72
Erythromycin-H2O 1.89
Trimethoprim 0.723
"SAMA"
Lincomycin 0.650
Pipemidic acid 0.863
Norfloxacin 0.984
Ciprofloxacin 1.01
Levofloxacin 1.01
Enrofloxacin 1.02
Sarafloxacin 1.11
"QL"
Flumequine 1.74
Minocycline 0.761
Oxytetracycline 0.910
Tetracycline 1.075
Demeclocycline 1.209
Chlortetracycline 1.299
Doxycycline 1.373
"TC"
Meclocycline 1.522
Note: Retention times determined from extract of Stream A wastewater effluent September 22, 2007; relative
retention times were determined using column dimensions and gradients listed in Section 2.6
Example chromatograms showing chromatographic peaks for each analyte in each of
the three methods (SAMA, QL, and TC) are shown in Figures 3.1, 3.2, and 3.3. An extracted
ion chromatogram is created by plotting the intensity of a chosen mass to charge ratio (m/z)
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as a function of retention time. Therefore, any peak shown on these chromatograms was
specifically targeted from both of its known ion breakdowns. Surrogate standards 13C6-
sulfamethoxazole, 13C3-ciprofloxacin, and 13C2-erythromycin were not included in any of
these chromatograms because their retention times match those of their analyte pair and the
chromatographic peaks would not be distinguishable (i.e. 13C6-sulfamethoxazole and 12C6-
sulfamethoxazole have the same retention time). Targeting specific ion breakdowns allows
differentiation between these analytes to be possible. The internal standard simatone was
also not pointed out in these chromatograms as the retention time differed in each method,
but it was targeted in every run.
Figure 3.1: Extracted 12 ion chromatogram for SAMA antibiotics spiked in surface
water at 500 ng/L (Stream A 9/22/07)
(1) Sulfathiazole; (2) Lincomycin; (3) Trimethoprim; (4) Sulfamerazine; (5) Sulfamethazine;
(6) Sulfamethizole; (7) Sulfachlorpyridazine; (8) Sulfamethoxazole; (9) Sulfadimethoxine;
(10) Tylosin; (11) Erythromycin-H2O; (12) Roxithromycin
Retention Time (minutes)
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Figure 3.2: Extracted 8 ion chromatogram for QL antibiotics spiked into surface water
at 500 ng/L (Stream A 9/22/07)
(1) Pipemidic Acid; (2) Norfloxacin; (3) Levofloxacin; (4) Ciprofloxacin; (5) Enrofloxacin;
(6) Sarafloxacin; (7) Oxolinic Acid; (8) Flumequine
Retention Time (minutes)
B
A
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Figure 3.3. Extracted 7 ion chromatogram for TC antibiotics spiked into surface water
at 500 ng/L (Stream A 9/22/07)
(1) Minocycline; (2) Oxytetracycline; (3) Tetracycline; (4) Demeclocycline;
(5) Chlortetracycline; (6) Doxycycline; (7) Meclocycline
Once analytes were identified, each extracted ion chromatographic peak was
integrated, either manually or automatically, to determine the area under the peak, or
instrument response, which is later used to quantify the analytes. Using the Varian
Workstation 6.8 software, each peak is individually targeted from the overall chromatogram
Retention Time (minutes)
72
by identifying the specific ion breakdown for the analyte of interest. Peaks for both the
major and minor product ion for each analyte were targeted, but only one product ion is
required for quantitation.
Figure 3.4 is an example set of ion breakdown chromatograms for extracts from a
spiked and unspiked surface water sample that illustrates the basic concepts in interpreting
LC-MS/MS data. The chromatograms are for extracts of the same surface water;
chromatograms A and B are for extracts of the unspiked water of unknown concentration,
while chromatograms C and D are for extracts of the same water spiked with the 26 antibiotic
mixture listed in Table 3.1 at 1000 ng/L as part of a standard addition calibration curve. The
major ion breakdowns for trimethoprim were targeted: 291 > 230 at -23 eV in Figure 3.4A
and Figure 3.4C; and 291 > 123 at -21 eV in Figure 3.4B and Figure 3.4D. All of these ions
are detected at the same retention time (± 0.1 minutes), indicating a specific match between
trimethoprim in the unspiked and spiked sample. By use of a standard addition calibration
curve, the integrated areas can then be used to quantify the concentration of trimethoprim in
the unspiked sample.
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Figure 3.4: Ion chromatographic peak integration example
(A) Trimethoprim major product ion targeted in extract of unspiked surface water sample;
(B) Trimethoprim minor product ion targeted in the same sample; (C) Trimethoprim major
product ion in extract from same sample spiked at 1000 ng/L; (D) Trimethoprim minor
product ion in extract from (C)
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3.1.2 Data Quantitation by Standard Addition for Antibiotic Analyses
In standard addition, a calibration curve is created which allows the original
concentration of a given analyte in an unspiked sample to be determined by extrapolation.
Calibration curves must be prepared for each analyte in each sample matrix. Environmental
samples from each individual matrix are divided into several equal portions, with unspiked
samples in duplicate and the remaining samples spiked at increasing concentrations with the
analytes. Typical spike concentrations for surface and wastewater are 20, 50, 100, 500, and
1000 ng/L and are selected to cover the range of expected analyte concentrations in the
sample. A calibration curve is then created by plotting the relative area against the spike
concentrations. The relative area is defined in equation 3.1, where the “quantifiying ion” for
each analyte is the major product ion listed in Table 2.4. The response of the internal
standard used in this calculation is that of simatone for the breakdown (m/z = 198 to m/z =
128) that is present in the particular chromatogram of interest.
Relative Area =
Quantifying ion response
Internal standard ion response
(eq. 3.1)
A visual representation of this concept is provided in Figure 3.5 for a surface water sample
from stream B (10/5/07).
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Figure 3.5: Illustration of extrapolation of standard addition calibration curve to
calculate analyte concentration in surface water (Stream B 10/5/07)
A linear regression is conducted in order to find the linear relationship for the calibration.
Typical regression correlation coefficient (R2) values for the calibration curves were greater
than 95%, which was used in this study as acceptable precision across the concentration
range. When R2 values were lower than 95%, outlier data points were removed from the
calibration curve. From the calibration curve, the concentration in the unspiked sample can
be determined by regressing the line back to the x-axis, which is represented by the circle
drawn on Figure 3.5. The concentration can be determined using equation 3.2, viz:
ConcentrationUnspiked =
y  Intercept
Slope
=
0121.0
9682.0 = 80 ng/L (eq. 3.2)
Analyte identity is confirmed by comparing the ratio of the response intensities of the major
and minor product ions (see Table 2.4) in each unspiked sample with that of the spiked
samples.
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Isotopic dilution is another technique used to quantify analytes and is based on using
isotopically labeled compounds that behave physically and chemically like its unlabeled
counterpart as the two compounds only differ by a few mass units. A surrogate standard will
also have the same physical and chemical properties to a compound in the same chemical
class as its unlabeled compound. Twenty-six antibiotics were targeted in this study, but only
four surrogates were available (13C6-sulfamethoxazole, 13C3-ciprofloxacin, 13C2-
erythromycin, and meclocycline). It is not possible for these four surrogates to accurately
represent all twenty-six of the antibiotics, which is why standard addition was solely used for
quantitative analyses.
Standard addition is a time-consuming process since calibrations need to be made for
each matrix for each sampling event. However, for accurate quantitation, standard addition
is necessary to compensate for matrix effects and recovery loss. The degree to which matrix
effects alter signal response is difficult to predict because organic carbon content and
composition vary largely in surface and wastewaters. Compensation for this variation with
calibration curves in each matrix is a valuable contribution of the method of standard
addition.
3.1.3 Linearity, Detection, and Quantitation Limits
The range of linearity of the LC-MS/MS instrument responses were evaluated by
injecting 20 L of standard solutions of the target analytes in 9:1 (volume:volume)
LGW:MeOH (HPLC grade) in the range of 0.5 to 100 g/L representing the range in which
the analytes are expected to be detected in the final concentrated extracts (Ye, 2005). R2
values were typically 0.999. Instrumental detection limits (IDL), previously determined by
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Ye (2005), were calculated as three times the standard deviation of instrument response from
ten consecutive injections of standard solutions in the range of 5 to 100 g/L, depending on
the instrumental sensitivity for a particular analyte.
Ye (2005) previously determined the limits of detection (LOD) and limits of
quantitation (LOQ) in our laboratory using the same instrument and analytical methods in
order to evaluate the lower range of linearity for analytes taken through the whole analytical
procedure. LOD and LOQ are respectively defined as the analyte concentration in a sample
that would give a minimum S:N for the analyte of 3 and 10. Values for IDL, LOD, and LOQ
are all shown in Table 3.2.
The practical quantitation limit (PQL) is defined as the lowest spike level used in the
method of standard addition. This value is relevant to this study because an analyte may still
be detected outside of the range of calibration if the detected value is less than the lowest
spike level. The value can be semi-quantified, but it must be reported as detected below the
PQL. In this study, 20 ng/L was the PQL for surface waters and wastewater effluent because
the targeted breakdown ions could not consistently be distinguished from the noise at spike
levels less than 20 ng/L.
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Table 3.2: Detection and quantitation limits of target analytes in LGW (Ye, 2005)
Analyte IDL (pg) LOD (ng/L) LOQ (ng/L)
Sulfachlorpyridazine 12 1.0 6.7
Sulfadimethoxine 10 1.0 3.5
Sulfamerazine 18 1.0 5.6
Sulfamethazine 14 1.0 2.5
Sulfamethizole 16 1.0 4.7
Sulfamethoxazole 8.0 1.0 5.4
Sulfathiazole 10 1.0 8.2
Erythromycin-H2O 100 0.5 1.4
Roxithromycin 100 0.5 1.0
Tylosin 80 0.5 1.0
Lincomycin 5.0 NA NA
Trimethoprim 8.0 0.5 1.3
Ciprofloxacin 40 1.0 2.7
Enrofloxacin 20 1.0 5.0
Flumequine 2.0 0.5 1.0
Levofloxacin NA NA NA
Norfloxacin 60 2.0 5.6
Sarafloxacin 40 0.5 2.1
Oxolinic acid 2.0 1.0 3.0
Pipemidic acid 80 3.0 10
Chlortetracycline 16 2.0 6.5
Demeclocycline 20 3.0 12
Doxycycline 10 1.0 3.5
Minocycline 40 6.0 32
Oxytetracycline 10 1.0 4.4
Tetracycline 12 0.5 3.2
Note: IDL = Instrument Detection Limit; LOD = Limit of Detection; LOQ = Limit of Quantitation; NA = Not
Applicable. Lincomycin is not extracted in quenched, chlorine samples, and levofloxacin was not a target
analyte at the time of IDL, LOD, and LOQ evaluation. Volume injected to determine IDL was 20 L.
3.1.3 Quality Assurance and Quality Control
The objectives of quality assurance and quality control measures are to achieve
precision, accuracy, and comparability. Components of quality control incorporated into this
study include solvent blanks, method blanks, replicate samples, matrix spikes, and calibration
curves. Solvent blanks were injected along with every sample set analyzed on the LC-
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MS/MS prior to, within, and at the end of each sample run to help ensure column equilibrium
and to prevent any carryover of contamination between methods. The internal standard
simatone, which was targeted during every chromatographic run and used to calculate
relative area for quantitation using the method of standard addition, was also used as an
instrument performance check solution to confirm proper instrument performance. The
retention time and peak area were used, and if these values differed significantly from a
previous instrument performance test or sample run, the instrument was deemed to be not
performing within specifications and measures were taken to fix the problem.
Duplicate samples help to estimate precision, and so one set of duplicates for the
unspiked sample was analyzed with each sample batch in this study. None of the spiked
samples were processed in duplicate due to the more critical need to complete the extraction
of a complete batch of samples in a 24-36 hour period. In order for the analysis of duplicate
samples to be considered acceptable, the relative percent difference (RPD) should be less
than or equal to 20%. In this study, the RPD of the analysis of duplicates of the unspiked
samples was monitored as a measure of quality control. Table 3.3 presents the percentage of
samples that were not considered acceptable. These RPDs were calculated by comparing the
concentrations obtained from the major and minor targeted breakdown ions for all detected
analytes in all of the samples during the entire study period. The data presented in the second
and third columns are the percentage of instances when RPD of the measured concentrations
of the duplicates using the major and minor ions were greater than 20% in either a
wastewater effluent, stream, or reservoir sample.
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Table 3.3: Duplicate quality control and acceptance criteria from all samples sets in all
three streams, WWTP effluent, and reservoir samples (n = 70)
Sampling Location 20% RPD
A 6.0
B 5.7
C 9.1
Reservoir 0.0
Note: RPD for locations A, B, and C include both treated wastewater effluent and surface water samples; 0.0
values for the reservoir sites indicate that no set of unspiked duplicate samples resulted in a relative percent
difference greater than 20%.
The data in this table suggest that duplicate analysis when using the 20% RPD criteria
yields poor precision between 5.7% and 9.1% of the time for all samples, suggesting that the
method or technique occasionally yields poor precision. The values between streams may be
different from each other due to different percentages of natural organic matter or carbon
content that may be affecting extraction processes to varying extents. The RPD for the
streams include treated wastewater and surface water samples whereas the reservoir samples
are just surface water. Fewer samples were also collected in the reservoir (n=10) compared
to the streams (n=60) and the reservoir water was generally clearer than the stream water,
which would explain the differences in RPD between the stream and reservoir samples. One
antibiotic class was not found to generate more precise results than another.
The samples are put through several processing steps such as extraction, blow-down,
reconstitution, etc. where human error may have an impact. Time is a major factor when
processing these samples, and human error could be due to the necessity of processing up to
twelve samples within a few days to ensure integrity in the analysis of samples collected.
Eliminating this error is difficult with manual processing. Matrix effects may also be
contributing to different calculated concentrations between the unspiked duplicates as well.
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Ye (2005) states that co-extracted matrix components in water can compete for
charges during electrospray ionization, resulting in signal suppression or enhancement.
Signal suppression increases with the amount of organic matter in the sample, and this may
have been a factor in the different instrument responses of extracts from surface and
wastewaters. However, quantitation of analytes should not be greatly affected by matrix
interferences because standard addition calibration curves are prepared for every analyte in
each sample batch to help compensate for recovery loss and matrix effects.
3.1.4 Antibiotic Occurrence in the Targeted Watershed
The watershed is located in a rapidly expanding region in the Southeastern United
States that is mainly fed by three smalls streams to the north and a large river to the south
that are all impacted by wastewater inputs. The watershed tributaries flow eastward through
a major basin in the state and eventually into the Atlantic Ocean. This study focuses on the
sections of the three northern streams that are impacted by WWTPs and at two points
downstream of these plants as the streams flow into a drinking water reservoir (Figure 2.1 is
reprinted below for reference). The most frequently sampled point in the reservoir was
located near the intake pipe to a drinking water treatment plant (R5 site). A large portion of
the watershed in which streams A, B, and C are located is urban and home to almost 1.1
million people. The reservoir supplies a source of drinking water to almost 1 million of those
people. The WWTPs that discharge to the streams investigated in this study all use similar
treatment processes (Figure 3.6).
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Figure 2.1 (reprinted): Sampling locations within watershed
Ultraviolet light (UV) irradiation is the main method of disinfection prior to
discharging the effluent to surface waters from all three WWTPs. In the final phase of the
83
treatment process, water flows through a channel with several banks of UV bulbs that emit
light in the ultraviolet range, effectively killing pathogenic organisms. UV light is safer for
the receiving stream since unlike free chlorine, it leaves no chemical residue in the water.
Figure 3.6: Wastewater treatment plant diagram (City of Durham, 2006)
WWTPs A and B each collect waste from similarly sized populations of about 50,000
people, including residential and commercial zones, hospitals, research universities, and
several nursing homes. WWTP C differs in that it only collects waste from a commercial
area that employs about 38,000 people. WWTP A and C are permitted to discharge up to 12
MGD, although WWTP A averages about 10 MGD and WWTP C averages about 4 MGD.
WWTP B is permitted to discharge 20 MGD, and the average daily flow is 16 MGD.
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Effluent flows, as reported by the plant managers at the time of sampling, and stream flows
measured by United States Geological Survey (USGS) monitoring stations located at either
of the downstream sampling points are presented in Table 3.4. In general, peak flows
occurred from 9 AM until about 4 PM and it is during this time that antibiotic concentrations
in the wastewater are likely to be greatest and, therefore, to give rise to the highest
environmental impact.
Table 3.4: Sampling dates, effluent flow rates, USGS stream flow rates, and percent of
stream flow attributed to wastewater effluent
Date Stream Time Effluent InputFlow (ft3/s)
Stream Flow
(ft3/s)
%
Attributed
to Effluent
8/9/07 A 8:15 AM 3.3 7.8 43
8/10/07 B 9:25 AM 14 15 96
8/10/07 C 11:15 AM 6.7 7.5 89
8/24/07 A 10:15 AM 14 17 85
8/29/07 B 11:00 AM 17 17 98
8/29/07 C 12:30 PM 7.2 9.2 78
9/18/07 A 3:00 AM 13 13 99
9/20/07 B 10:15 AM 13 15 87
9/20/07 C 12:20 PM 7.1 9.8 72
10/3/07 A 11:00 AM 14 15 96
10/3/07 B 12:20 PM 7.6 11 69
10/5/07 C 1:50 AM 7.6 9.2 82
12/11/07 A 2:18 AM 15 15 97
12/11/07 B 12:25 PM 16 19 83
12/11/07 C 11:05 AM 6.7 8.8 76
The downstream sampling sites are heretofore referred to as DS the letter for the
appropriate stream and then either a 1 or a 2 to signify how far downstream from the WWTP
it is (for example DS A2 refers to the second downstream sampling location on stream A).
All three receiving streams flow through urban areas before effluents discharge into them,
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while the surrounding areas downstream of the WWTPs are mainly forested and
intermittently swampy with little to no residential impact. A creek that flows through a small
farm flows into stream A in-between the DS 1 and DS 2 sites, but it was not sampled during
this study due to inaccessibility. No other potential nonpoint sources for the targeted
compounds have been identified on any of the streams. Streams B and C both flow through
constructed waterfowl impoundments (DS B2 and DS C2) that are basically dammed up
portions of the streams to serve as a habitat for various waterfowl and aquatic life. It must be
noted that there is a large fish population in these impoundments and that the local residents
do fish for food at these locations.
Streams A, B, and C contribute the majority of the water to the northern half of the
drinking water reservoir. The USGS found that the hydraulic retention time of a plug of
water in the upper reaches is about 418 days, whereas the hydraulic retention time in the
southern half of the reservoir is about 4 days. This suggests that there is sufficient exposure
time for the antibiotics to adsorb to sediments and undergo photodegradation in the northern
half of the reservoir where this study was undertaken.
The study period was from August through December 2007 and a total of 70 samples
were collected within the watershed (see Appendix D for measured data). Real-time stream
data from the USGS can be obtained by going to the USGS Real-time water data website:
http://waterdata.usgs.gov/nwis/rt. From here, a U.S. state can be selected, or a stream name
can be typed into the “select sites by name or number” box. In the “predefined displays”
drop down box, select “Daily Stage and Streamflow”. Depending on the number of USGS
monitoring sites on the specified stream or river, multiple locations may come up. Select the
desired site, and the desired time on the next page. Figure 3.7 displays an example of a graph
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of the daily stream flow of Morgan Creek at the DS A1 site during the period of April 1,
2008 through April 9, 2008. The average flow on April 5, 2008 was approximately 12 cubic
feet per second (cfs). Alternatively, one may choose to view the data in a tabular format,
which is easier to determine stream flow and stream gage. The tabular format is not
presented here due to the length of the table. A USGS monitoring station was located at the
DS A1, DS B2, and DS C2 sites.
Figure 3.7: Example of a USGS Real-time daily stream flow graph
Distances from sampling locations and to the reservoir are presented in Table 3.5
below. The WWTP effluent was sampled at the point where the effluent was being
discharged into each of the streams. The distance listed for the second downstream points to
the reservoir is the distance to the point where each stream flows into the reservoir, and is at
a point where sampling did not occur. The distances from the second downstream sampling
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points to the influent pipe to the drinking water treatment plant (R5) varied between 9 to 12
miles.
Table 3.5: Distances between sampling locations
Location Distance(miles)
WWTP A - DS A1 0.5
DS A1 - DS A2 2
DS A2 - Reservoir 0.9
Reservoir - R5 9
WWTP B - DS B1 0.1
DS B1 - DS B2 1.4
DS B2 - Reservoir 2
Reservoir - R5 12
WWTP C - DS C1 1.2
DS C1 - DS C2 1.9
DS C2 - Reservoir 2.4
Reservoir - R5 11
Samples were collected when the stream was at base flow and rainfall had not
occurred at least three to seven days beforehand. Heavy rainfall was not an issue as the
region was in an extreme drought during the sampling period. However, rainfall did occur
between November and December 2007 and stream flow increased as can be seen in Table
3.4. Effluent flow at the outfall into the stream was obtained from plant charts during the
time of sampling, and varied with each plant depending upon the time of day. During most
of the study, the major component of stream flow was treated wastewater effluent. Stream
flow was less than 50% effluent on only one occasion for Stream A on 8/9/07 (Table 3.4).
General summary tables presenting the maximum and minimum concentrations of the
antibiotics that were detected above the PQL of 20 ng/L are given for each stream and the
reservoir over five sampling events (Tables 3.10 through 3.13). Individual sampling event
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data for stream A are presented in Tables 3.5 through 3.9, but the complete data set for
streams B and C can be found in Appendix D.
In some cases, the sample matrix generated elevated noise in the ion chromatogram,
while in other instances, extended instrument usage and contamination on the electrospray
needle led to an increase in noise. A typical sample run batch usually lasted about 15 hours,
and cleanliness of the electrospray chamber and shield became an issue. This is illustrated in
Table 3.9 where sulfathiazole is detected at 160 ng/L in the wastewater effluent, but is also
detected at 144 ng/L with only one breakdown ion in the DS A2 site. Occasionally
concentrations were found to increase downstream of a particular location (see Table 3.6 for
sulfamethoxazole and trimethoprim). There was a lack of nonpoint sources on each of the
streams so this increase may be attributed to the fact that the antibiotics could have
accumulated from the previous day/night or did not undergo attenuation processes overnight
due to a lack of sunlight at certain locations.
Table 3.6: Antibiotic occurrence data in ng/L for stream A 8/9/07
Antibiotic Upstream Effluent DS A1 DS A2
Sulfamethoxazole < 20 26 124 814
Sulfathiazole < 20 54 97 < 20 (11)
Sulfadimethoxine < 20 359 37 < 20 (7)
Erythromycin < 20 527 316 40
Trimethoprim < 20 < 20 (14) 170 66
Lincomycin < 20 < 20 (4) < 20 < 20
Ciprofloxacin < 20 154 104 43
Levofloxacin < 20 269 148 < 20
Sarafloxacin < 20 < 20 < 20 < 20
Tetracycline < 20 < 20 < 20 < 20 (0.5)
Note: Concentrations are in ng/L; < 20 indicates that analytes were not detected above a S:N ratio above 3 in
chromatograms; < 20 (--) indicates that the analyte was detected above a S:N ratio above 3 in chromatograms,
but concentration was below PQL of 20 ng/L. Underlined values indicate that only one MS/MS product ion
was used to confirm the analyte.
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Table 3.7: Antibiotic occurrence data in ng/L for stream A 8/25/07
Antibiotic Upstream Effluent DS A1 DS A2
Sulfamethoxazole < 20 206 188 94
Sulfathiazole < 20 66 21 81
Sulfadimethoxine < 20 448 26 < 20 (13)
Erythromycin < 20 693 32 209
Trimethoprim < 20 < 20 (19) 36 109
Lincomycin < 20 296 51 < 20
Ciprofloxacin < 20 161 21 < 20 (12)
Levofloxacin < 20 148 122 < 20
Tetracycline < 20 < 20 (3) 121 < 20
See Table 3.6 for legend
Table 3.8: Antibiotic occurrence data in ng/L for stream A 9/22/07
Antibiotic Upstream Effluent DS A1 DS A2
Sulfamethoxazole < 20 2828 2860 1480
Sulfathiazole < 20 217 287 < 20
Trimethoprim < 20 168 195 77
Sulfadimethoxine < 20 35 < 20 (19) 40
Erythromycin < 20 218 181 98
Lincomycin < 20 24 < 20 (1) < 20 (17)
Ciprofloxacin < 20 55 < 20 (14) < 20 (3)
Levofloxacin < 20 338 162 27
Tetracycline < 20 26 < 20 (10) < 20
See Table 3.6 for legend
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Table 3.9: Antibiotic occurrence data in ng/L for stream A 10/5/07
Antibiotic Upstream Effluent DS A1 DS A2
Sulfamethoxazole < 20 1777 1749 1245
Sulfathiazole < 20 160 130 144
Trimethoprim < 20 87 147 60
Sulfadimethoxine < 20 < 20 (16) 53 30
Erythromycin < 20 140 103 85
Lincomycin < 20 < 20 (8) < 20 (15) < 20 (4)
Ciprofloxacin < 20 < 20 (19) 35 < 20
Levofloxacin < 20 253 171 27
Enrofloxacin < 20 < 20 (0.3) < 20 (13) < 20 (1)
Tetracycline < 20 < 20 (13) < 20 < 20
See Table 3.6 for legend
Table 3.10: Antibiotic occurrence data in ng/L for stream A 12/11/07
Antibiotic Upstream Effluent DS A1 DS A2
Sulfamethoxazole < 20 3255 2531 1584
Trimethoprim < 20 106 238 59
Sulfdimethoxine < 20 27 20 459
Sulfathiazole < 20 713 436 335
Erythromycin < 20 224 153 122
Lincomycin < 20 < 20 ( 6) < 20 (1) < 20 (5)
Ciprofloxacin < 20 55 < 20 (18) < 20
Levofloxacin < 20 338 157 33
Enrofloxacin < 20 16 10 49
Tetracycline < 20 20 214 < 20
See Table 3.6 for legend
Of the 26 antibiotics targeted in stream A, 10 were detected during a 5-month
sampling period over five sampling events (Table 3.11). Twelve and eleven of the 26
antibiotics were detected in streams B and C, respectively (Tables 3.12 and 3.123. The
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reservoir 5 site was sampled on four occasions (8/25, 9/22 10/3, and 12/6), whereas the other
six reservoir points were only sampled once (12/6) (Table 3.14).
Table 3.11: Maximum and minimum antibiotic occurrence in Stream A in ng/L (n=20)
See Table 3.6 for legend; Data for period 8/9/07 to 12/7/07
Table 3.12: Maximum and minimum antibiotic occurrence in Stream B in ng/L (n= 20)
See Table 3.6 for legend; Data for period 8/9/07 to 12/7/07
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Table 3.13: Maximum and minimum antibiotic occurrence in Stream C in ng/L (n = 20)
See Table 3.6 for legend; Data for period 8/9/07 to 12/7/07
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Table 3.14: Maximum and minimum antibiotic occurrence in the reservoir (ng/L)
(n=10)
3.2 Estrogenic Activity within Watershed: YES Assay Results
Estrogenic activity in the aqueous samples collected in the watershed was determined
using the YES assay. QA/QC measures included the use of LGW blanks during YES assay
analyses, positive and negative spike controls, and duplicate samples. Stanford (2007)
previously determined the PQLs for the YES assay by analyzing a series of estradiol (E2)
dilutions in LGW. A 38,000 ng/L working solution of E2 was diluted volumetrically eight
times so that the final concentrations ranged from 38,000 ng/L to 148 ng/L. Each dilution
was then plated in duplicate as described in Appendix B, and analyzed as described in
Appendices B and C. Using this method, the PQL used for this study is 15.2 ng/L, assuming
100% recovery (Stanford, 2007).
In order to determine the estrogenicity of the samples, the effective concentration
halfway between the baseline and the maximum of the yeast response (EC50) from the
samples is compared to the EC50 of the yeast response for the estrogen standard (E2). This is
done by creating sigmoidal dose-response plots using the program R (R Foundation for
Statistical Computing, Vienna, Austria) (instructions in Appendix C). An illustrative plot of
an E2 control is presented in Figure 3.8. The maximum color absorbance is 4 because this is
the maximum reading obtained by the Emax plate reader.
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Figure 3.8: Dose-response curve for estradiol (E2) control
Using the EC50 values determined from the dose-response curves, the estradiol
equivalence (EEQ) and estrogenicity for each sample is determined. The EEQ of the E2
control is equivalent to 1 since it is the control. EEQ is calculated using equation 3.3.
EEQ =
EC50 of E2 Control
EC50 of Sample
(eq. 3.3)
The working solution of the E2 control is 38,000 ng/L, and 20 L of that is plated,
evaporated, and then reconstituted to 250 L. Therefore, the in-well concentration is actually
3040 ng/L for the first well and is serially diluted by half for each subsequent well. The EEQ
for each sample is then regressed back to the original concentration plated into the wells.
The original concentration is obtained by dividing the initial E2 concentration (38,000 ng/L)
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by a concentration factor of 2500 (the original 500 mL aqueous sample is concentrated to
200 L) to equal 15.2 ng/L. The EEQ values are multiplied by this value of 15.2 ng/L to
obtain a value of estrogenic activity in the aqueous samples. Table 3.15 presents average
results from YES assay analyses for all of the samples collected at each location. A total of
four YES assays were performed throughout the study period for the dates (8/25/07, 9/22/07,
10/5/07, and 12/7/07). The standard error is a measure of error associated with the regression
curve and is indicative of how well the curve fits the data points. It is automatically
calculated when processing the data with the program R.
Table 3.15: Average results from YES assay analyses
Sample EC50(ng/L) EEQ
Estrogenicity (ng/L)
(= EEQ * 15.2 ng/L)
Standard Error
(ng/L)
Upstream A 12.6 0.012 0.186 5.2
Effluent A 3.15 0.065 0.986 0.5
DS A1 5.47 0.137 2.08 0.8
DS A2 6.56 0.038 0.574 1.0
Upstream B 4.37 0.081 1.23 0.3
Effluent B 12.6 0.016 0.241 3.1
DS B1 5.21 0.045 0.681 0.6
DS B2 6.92 0.031 0.476 1.5
Upstream C 5.50 0.044 0.668 2.9
Effluent C 5.51 0.053 0.808 0.6
DS C1 5.56 0.067 1.01 1.0
DS C2 6.44 0.114 1.74 0.6
Reservoir 5 5.15 0.067 1.03 1.1
Note: EEQ = Estradiol equivalence
Average EC50 values for each sample are within the same order of magnitude, and all
are below 13 ng/L, which is orders of magnitude lower than EC50 values observed where
adverse effects are seen in various trophic levels (see Table 4.1). The calculated
estrogenicity in the upstream surface water samples is lower than that of the wastewater
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effluent as expected, except for stream B where the upstream estrogenic activity is higher
than downstream concentrations. The upstream site on stream B was in a waterfowl
impoundment and the fish and bird waste may have led to an increase in estrogenicity. Also,
the water at this site was murky and more or less stagnant and this may have impacted the
YES assay in some way. All samples were collected using the same method and were treated
similarly after collection.
Estrogenicity decreased downstream of the point of wastewater entry in streams A
and B, but increased slightly between the first and second downstream points in stream C.
The difference in estrogenicity is not consistent between the two downstream points in
streams A and B however. Estrogenicity was measured to be about 3.6 times less between
the two points in stream A, approximately 1.4 times less in stream B, and 0.58 times greater
in stream C. There was still estrogenicity measured in the R5 site (0.689 ng/L), and it is
similar to what is observed in the wastewater and stream water samples so it appears that
compounds exhibiting estrogenic activity were un-attenuated over this distance.
4. INTERPRETATION
4.1 Antibiotic Occurrence
All of the 26 targeted antibiotics were below detection limits upstream of the
wastewater plants, so that detection of these chemicals downstream of wastewater discharge
suggests this point source as a significant contribution of antibiotics in this watershed. The
antibiotics that were detected most frequently in each of the three streams are:
 Sulfamethoxazole
 Trimethoprim
 Erythromycin
 Lincomycin
 Sulfadimethoxine
 Sulfathiazole
 Ciprofloxacin
 Levofloxacin
 Norfloxacin
 Enrofloxacin
Although there generally were not any temporal trends, the highest concentrations of
antibiotics occurred on December 11, 2007. This time period coincides with winter and a
higher likelihood for people to succumb to illness and take these antibiotics.
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In general, antibiotic concentrations were seen to decrease downstream of the input
from the WWTP, as would be expected without additional inputs of non-point source
pollution. However, during the 8/9/07 sampling event for streams A and B, the WWTP
effluent concentrations for sulfamethoxazole, trimethoprim, lincomycin, sulfathiazole, and
sulfadimethoxine were less than the downstream concentrations (see Tables D.1 and D.2 in
Appendix D). This can possibly be explained by the fact that the effluent samples were
collected in the early morning hours (when effluent flow and possibly concentration of these
antibiotics were at their lowest), and the plug of effluent from the previous night hours that
had since moved downstream may have had a higher concentration of antibiotics in the
water. Wastewater effluent is constantly being introduced into the water column and if there
is little to no flow from upstream, as was the case during a large portion of the summer of
2007, the antibiotics could accumulate in a downstream area because the half-lives of these
compounds can be several days (Schmitt-Kopplin et al., 1999; Andreozzi et al., 2003; Verma
et al., 2007). Desorption from sediments could also be another mechanism for increasing
concentrations downstream of the WWTP discharge.
Many of the fluoroquinolones and tetracyclines were either not detected or not found
above detection limits (as defined in QA/QC criterion – see Section 3.1.3) in the effluent and
in surface water samples. This is expected due to their high Koc values (Table 1.5), which
indicate an ability to sorb to solids during wastewater treatment and/or to stream sediments.
Because the sulfonamides have lower sorption coefficients, these antibiotics would be
expected at higher concentrations in the effluent and surface waters. Stream sediments were
not investigated in this study, but sorption coefficients can be useful as a relative predictor of
antibiotics present in sediment as compared to those in the aqueous phase.
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Antibiotics detected in the drinking water reservoir include sulfamethoxazole,
erythromycin, trimethoprim, lincomycin, and enrofloxacin (see Tables D.16 and D.17). The
reservoir site sampled most frequently was Reservoir 5 in which 3 of the 26 targeted
antibiotics were detected above 20 ng/L in all instances except the 8/25/07 sampling event,
which was the first time this site was sampled. As the drought continued, it can be
hypothesized that the antibiotics that did not adsorb to the sediment persisted in the stream
over a distance of 9-12 miles from the second downstream points in each stream to the
Reservoir 5 site, where the influent pipe to the drinking water treatment plant is located. The
treated drinking water at this plant was also analyzed in late May 2007, but none of the
targeted antibiotics were detected above the PQL.
4.3 Estrogenicity in the Targeted Watershed
Estrogenic activity was detected and ranged from 0.19 to 2.1 ng/L in the surface
waters and from 0.24 to 0.99 ng/L in the treated effluent (Table 3.15). Estrogenic activity in
upstream samples was detected, indicating that there were compounds in this water that
induced an estrogenic response. The average activity of the upstream B samples was much
higher than in the downstream samples (1.23 ng/L versus 0.241, 0.681, and 0.476 ng/L in the
effluent and sequential downstream samples). Upstream nonpoint source pollution that may
contain estrogenic compounds, which could degrade before reaching the WWTP, may be
impacting stream B. The upstream A and C samples had a response much lower than
downstream samples indicating that the effluent did contribute estrogenic activity. The raw
wastewater was not sampled in this study, but if estrogenic compounds had been present it
appears that the wastewater treatment processes are effective in removing estrogenic
compounds from the aqueous phase. Peer-reviewed studies have quantified estrogenic
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activity in domestic wastewater treatment effluent in the range of 1.7 to 49 ng/L, and
between 0.04 and 1.5 ng/L in waters downstream from wastewater treatment plants
(Hashimoto et al., 2007; Leusch et al., 2006; Baronti et al., 2000). Results in this current
study are at the lower end of this range.
Although the biosolids at each of these plants were not sampled, there is a concern
that they contain estrogenic activity and that runoff from biosolids may have an impact on
surface waters during rain events (Parks, 2006). It must be noted that the biosolids from
WWTP A are applied to local farmland and have the ability to runoff into surface waters
during rain events, and possibly contaminate the drinking water reservoir. The farmland is
located next to a creek (that was not involved in this study), which flows into a river that
passes through the southern end of the reservoir. The creek and farmland are more than 25
miles upstream from the reservoir 7 sampling point, which is located in the area where this
river entered the watershed. About 32-113 kg/acre/year are applied to 1,044 acres of
farmland adjacent to the creek (Parks, 2006).
4.4 Measured Environmental Hazard
A range of EC50 values taken from published literature (Table 4.1) have been used to
calculate the measured environmental hazards for the surface and wastewaters (Tables 4.2
through 4.6) using equations 1, 2, and 3 as described in Section 1.7.1. Toxicological studies
do not use the same species; hence, there is a range of EC50 values and species presented in
Table 4.1. The European Medicines Agency (EMEA) (2006) states that blue-green algae are
the species of choice to conduct toxicological studies related to antibiotics. It was not
possible to find a set of toxicological studies in the literature that involve the targeted
antibiotics using the same test species let alone studies focused exclusively on blue-green
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algae, but the species presented in Table 4.1 are neither the least, nor the most sensitive, and
can be considered a set of representative species. Cyanobacteria are found to be one of the
most sensitive species to ciprofloxacin. Trimethoprim and sulfathiazole were found to be the
least toxic to different species of green algae. Different species will have different EC50
values for every chemical investigated, so calculated hazard values will change depending on
what EC50 value is used, but the assessment factor or 1000 is supposed to account for these
intra- and interspecies differences. It is important to note that these hazard values are just
estimates and are not meant to be absolute values of a hazard or risk.
Table 4.1: EC50 values used for hazard quotient calculations
Antibiotic EC50 (µg/L) Species Reference
Sulfamethoxazole 81 L. gibba (aquatic plant) a
Trimethoprim 16 mg/L R. salina (green algae) b
Sulfamethoxazole/
Trimethoprim 275 S. capricornutum (green algae) c
Norfloxacin 22 V. fischeri (luminescent marinebacteria) d
Ciprofloxacin 5 M.aeruginosa (cyanobacteria) e
Erythromycin 36.6 S. capricornutum (green algae) c
Sulfadimethoxine 230 S. capricornutum (green algae) c
Lincomycin 23.8 D. magna (crustacean cladocera) f
Levofloxacin 81 L. gibba (aquatic plant) a
Enrofloxacin 840 V. fischeri (luminescent marinebacteria) g
Sarafloxacin 150 S. capricornutum (green algae) b
Sulfathaizole 17.2 mg/L C. vulgaris (green algae) h
Tetracycline 400 L. gibba (aquatic plant) a
a. Brain et al. (2004); b. Holten Lützhøft et al. (1999); c. Eguchi et al. (2004); d. Backhaus et al. (2000);
e. Halling-Sørensen (2000); f. Isodori et al. (2005); g. Hernando et al. (2006); h. Baran et al. (2006).
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Tables 4.2 through 4.6 present calculated hazard values using the maximum measured
concentrations for each stream and reservoir sampling point during the entire study period.
There are no specific units for the hazard value, and as explained in Section 1.7.1, a “low
hazard” ranges from 0.5 to 2, a “medium hazard” from 2 to 10, and a “high hazard” from 10
+. Values shown in red represent a “high hazard”, those in orange represent a “medium
hazard” and those in blue represent a “low hazard”. Only those antibiotics that were detected
are presented in each of the tables, and the environmental hazard for the combined effect of
sulfamethoxazole and trimethoprim has also been calculated. Eguchi et al. (2004) found an
enhanced growth inhibitory effect when S. capricornutum (green algae) were exposed to a
mixture of these two antibiotics (EC50 = 0.275 mg/L) when compared to the adverse effect of
sulfamethoxazole and trimethoprim alone (1.53 mg/L and 80.3 mg/L, respectively).
Synergistic effects of antibiotics and other PhACs are largely unknown, but the possibility is
there.
Sulfamethoxazole poses the largest calculated environmental hazard in all three
streams and both downstream locations because it was detected at the highest concentrations.
Calculated hazards are found to decrease downstream, but erythromycin, ciprofloxacin, and
the combined effects of sulfamethoxazole and trimethoprim in stream A have a calculated
“medium hazard” in DS A2, just 0.9 miles from the reservoir. All other compounds are
found to have a “low hazard” in the DS A2 site (Table 4.2).
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Table 4.2: Maximum calculated hazard quotients for Stream A
Note: SMX + TMP = sulfamethoxazole + trimethoprim; MEC = measure environmental concentration; red =
high hazard (10+), orange = medium hazard (2-10), and blue = low hazard (0.5-2); na = not applicable.
In stream B, ciprofloxacin and sulfamethoxazole pose the greatest hazard at the DS
B1 site, with ciprofloxacin having a much larger calculated hazard value (Table 4.3).
Interestingly, the maximum detected concentration for sulfamethoxazole was found to be
higher at the DS B2 site than at the DS B1 site. Because the concentration is higher, the risk
is correspondingly higher; the same occurs for erythromycin. The combined effect of SMX
+ TMP is found to have a “medium hazard” in the DS B2 site; a greater hazard than at the DS
B1 site due to the increase in concentration of sulfamethoxazole. Lincomycin and
levofloxacin also pose a “medium hazard” at the DS B1 site, but the hazard decreases
downstream to a “low hazard” for lincomycin. Despite the decrease in concentration of
ciprofloxacin (84 ng/L to 18 ng/L), it still poses a “medium hazard” to the environment at the
DS B2 site. The DS B2 site is a waterfowl impoundment that supports a large fish
population that is caught by some of the local population. Although very few toxicological
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studies have investigated plants and animals at higher trophic levels, adverse effects seen in
algae, bacteria and plants may be seen in fish as well. DS B2 is about 2 miles from the
entrance to the reservoir, so there is still a considerable distance during which the compounds
could adsorb to sediments or undergo photodegradation, therefore decreasing the
concentration and consequently, the hazard.
Table 4.3: Maximum calculated hazard quotients for Stream B
Note: SMX + TMP = sulfamethoxazole + trimethoprim; MEC = measure environmental concentration; red =
high hazard (10+), orange = medium hazard (2-10), and blue = low hazard (0.5-2); na = not applicable.
The hazard for sulfamethoxazole in stream C (Table 4.4) is lower than in the
downstream sites of stream A and B, but there is still a “high hazard” at a much lower
effluent flow rate (~4 MGD vs. ~10 MGD and ~16 MGD for streams A and B, respectively).
Erythromycin, lincomycin and ciprofloxacin pose a “medium hazard” at DS C1, and the
hazard remains the same for all three antibiotics except for lincomycin at the DS C2 site.
The DS C2 site is also a waterfowl impoundment that many locals fish at, and is
approximately 2.4 miles from the reservoir.
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Table 4.4: Maximum calculated hazard quotients for Stream C
Note: SMX + TMP = sulfamethoxazole + trimethoprim; MEC = measure environmental concentration; NA =
not applicable; red = high hazard (10+), orange = medium hazard (2-10), and blue = low hazard (0.5-2).
Calculated hazard values for the antibiotics present above quantitation limits at the
reservoir 5 site (Table 4.5) are low. The same is true for the rest of the sites sampled in the
reservoir except for those at locations reservoir 6 and 7 (Table 4.6), where sulfamethoxazole
presents a “medium hazard”. Erythromycin, lincomycin, and ciprofloxacin all pose a
“medium hazard” at the reservoir 7 site. Reservoir 6 is just downstream from the drinking
water treatment plant influent pipe and reservoir 7 is at the very southern end of the reservoir
where a major river flows in. About three WWTPs discharge treated effluent into this river
and several antibiotics are still present at high levels as the river flows into the reservoir.
Because the hydraulic retention time at this area of the reservoir is about 4 days, the
pollutants are most likely carried through the reservoir and downstream.
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Table 4.5: Maximum calculated hazard quotients for Reservoir 5
8/25/07 9/22/07 10/5/07 12/6/07
Antibiotic EC50(µg/L) MEC(µg/L) Hazard
MEC
(µg/L) Hazard
MEC
(µg/L) Hazard
MEC
(µg/L) Hazard
Sulfamethoxazole 81 0.013 0.16 51 0.63 64 0.79 38 0.47
Trimethoprim 16000 0.37 0.02 16 0.001 < 20 NA 7 0.00
SMX + TMP 275 0.383 1.4 67 0.244 64 0.23 45 0.16
Sulfadimethoxine 230 < 20 NA < 20 NA < 20 NA 4 0.02
Erythromycin 36.6 0.015 0.41 37 1.01 44 1.2 6 0.16
Lincomycin 23.8 < 20 NA 24 1.01 44 1.8 21 0.88
Ciprofloxacin 5 < 20 NA 11 2.20 4 0.80 3 0.60
Levofloxacin 81 0.010 0.12 1 0.012 7 0.09 3 0.04
Enrofloxacin 840 < 20 NA 0.3 0.0004 2 0.002 1 0.001
Table 4.6: Maximum calculated hazard quotients for reservoir sites on 12/7/07
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Antibiotics have been detected in the aqueous phase in this watershed at the ng/L
level but not at the acute level (mg/L) likely to induce lethal toxicity to aquatic organisms or
to have a significant impact on the growth of plants and bacteria. Antibiotic residues in the
ng/L range may contribute to the widespread resistance of bacterial pathogens and post-
therapeutic effects, especially from exposure to antibiotics in stream sediments. The toxicity
studies cited in this section involve single high-dose exposures over a short time period, and
it is difficult to extrapolate the effects resulting from continuous, sub-therapeutic exposure,
which is the case in this watershed. More toxicological studies are needed to investigate
synergistic and antagonistic effects as well as continuous low-level exposure of PhACs and
the vast array of other chemicals in treated wastewater effluent before risk can be thoroughly
categorized.
4.5 Rates of Antibiotic Removal from Watershed
Antibiotics were found to decrease as a plug of effluent moved downstream during
most sampling events. Removal rates using a first order decay rate are calculated here for
sulfamethoxazole and erythromycin, the two most frequently detected antibiotics, using
measured concentrations in each stream and for each sampling event to determine
approximately how long either of these pollutants remains in the aqueous phase. These
removal rates were only calculated from their point of entry to the second downstream point
on each stream because there were no additional inflows of water in these areas.
A mass balance is a mathematical accounting of the sources (wastewater effluent) and
sinks (adsorption to sediments, photodegradation) of a substance within a system, such as a
water body. A mass balance model for a water body is useful to help understand the
relationship between the loadings of a pollutant and the levels in the water and sediments.
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The law of conservation of matter states that matter is conserved, and if the amount of
material that enters a chain of processes is known and the amounts that are added or
subtracted are also known, then the decay rate can be estimated. The mass balance can be
written as:
t
Mass

 = (flux in - flux out of SMX) - first order reaction rate (eq 4.1)
Often the reaction rate is due to adsorption of an antibiotic to sediments, biological or photo-
degradation, and is also known as a decay rate. The term “decay rate” is commonly used in
this situation, but for clarification, the antibiotics are not truly decaying, but are instead being
removed from the aqueous phase by attenuation processes such as adsorption to stream
sediment, photodegradation, and/or biodegradation. Hence, the term “decay” is being
replaced with “removal”.
The removal rate is often modeled as a first order reaction, which means that the
amount removed is proportional to the amount present at any time (equation 4.2).
C = C0 e-kx (eq. 4.2)
where the first order reaction rate, k, describes the rate of antibiotic removal in surface
waters, and is what will eventually be solved for.
Equating the mass balance equation 4.1 for a certain volume V gives:
VC
t
QCQ'C' kVC  QC kVC (eq. 4.3)
where V is the volume of a stream at a specific sampling point, Q is the effluent flow, C is
the concentration of SMX entering the stream, and Q’ and C’ are the flow and concentration
of SMX downstream of the WWTP. Dividing equation 4.3 by the volume of the stream at
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the sampling point (V=A*dx, where A is the wet cross sectional area of the stream reach and
dx is its length), and taking the limit for Dt0 and Dx0, equation 4.4 is obtained. The
purpose of this equation is to identify C
x
.
C
t
 
1
A
QC
x
 kC = Q
A
C
x

C
A
Q
x
 kC (eq. 4.4)
It was assumed during this study that the stream flows were at a steady state, or 0


t
C , due
to a lack of additional flow from rainfall. When substituting 0


t
C into equation 4.4 and
solving for C
x
, equation 4.5 is obtained.
C
x
 
kCA
Q

CC
Qx





  
k
u

1
Q
Q
x





C (eq. 4.5)
where u  Q
A
is the velocity of water passing by USGS monitoring stations, which were
located at a downstream location on each stream where samples were collected for antibiotic
analysis. The term 1
Q
Q
x
accounts for the dilution of the upstream flow where the antibiotics
were below the PQL. On several sampling dates, the upstream flow was near 0 cubic feet per
second (cfs or ft3/s). When this occurred, the upstream flow was assumed to be equivalent to
the downstream flow in order to fit the model.
Since the distances between the sampling points were relatively short and there was
no rainfall during the study period, it is reasonable to assume that 1
Q
Q
x
is constant.
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Therefore, integrating equation 4.5 and solving for C leads to equation 4.6, which is
equivalent to equation 4.2 presented earlier.
C  Co exp 
k
u

1
Q
Q
x





x  Co exp(Kx) (eq. 4.6)
where K  k
u

1
Q
Q
x





. Prior to solving for K, the concentration of the antibiotic in the
effluent, Co, must be converted into a stream concentration that takes into account the
dilution effect from the stream that the effluent is flowing into. The stream flow must be
greater than the effluent flow (i.e. Q0 > Qoutlet). This is done using equation 4.7.
Co 
Coutlet * Qoutlet
Q0
(eq. 4.7)
In order to determine K in equation 4.6, the natural logarithm of the concentration of
the antibiotic at the sampling locations (x0 or the point of effluent discharge, x1, and x2) is
divided by the initial concentration of the antibiotic in the effluent, C0, and plotted against the
distance (x) from the WWTP to each of the downstream sampling locations is plotted (Figure
4.1). The slope is equivalent to K in units of ft-1.
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Figure 4.1: Illustrative plot to determine K for Stream A on 10/5/07
Crude cross-sectional areas of the streams at each of their respective sampling points
were determined using a measuring tape and yardstick. The dilution flow contribution per
unit distance along the creek
x
Q

 and the average velocity (u) of the water for each stream
and day of sampling was then calculated. This value is then plugged into equation 4.8, where
k is the first order removal rate. This equation is obtained by solving for k in equation 4.6.
u
x
Q
Q
Kk 








1 (eq. 4.8)
The half-life of the antibiotics is then determined using equation 4.9.
t1/ 2 
ln(2)
k
(eq. 4.9)
Removal rates and half-lives (t1/2) have been calculated for sulfamethoxazole and
erythromycin in all three streams for each sampling date because these were the only two
antibiotics detected at every sampling point on every sampling day. As mentioned earlier,
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there were some instances where concentrations increased downstream of the WWTP.
Decay rates and half-lives were not presented on days where this effect occurred. Table 4.7
presents sulfamethoxazole decay rates (k) in units of s-1, and Table 4.8 presents the
corresponding t1/2 values.
Sulfamethoxazole is observed to undergo removal from the aqueous phase at a slower
rate in stream C than in streams A and B (an average of 3.9 x 10-6 s-1 versus 1.7 x 10-5 s-1 and
1.1 x 10-4 s-1). Stream characteristics play a large part in the fate of pollutants. Stream B
flows through a swampy area where there is a greater chance for adsorption to stream
sediments. Stream C is deeper and wider than the other two streams, and pollutants would be
expected to undergo less photodegradation and adsorption to stream sediments. The size and
shape of stream A falls in-between the other two.
Table 4.7: Removal rates (k) for sulfamethoxazole (SMX)
Stream A SMX Stream B SMX Stream C SMXDate
k (s-1) k (s-1) k (s-1)
8/9/07 na 7.15E-05 3.85E-06
8/25/07 3.38E-05 5.49E-05 2.13E-06
9/22/07 1.41E-05 1.16E-04 1.65E-06
10/3/07 8.78E-06 1.95E-04 5.65E-06
12/11/07 1.23E-05 1.29E-04 6.15E-06
Mean 1.72E-05 1.13E-04 3.88E-06
STDEV 1.12E-05 5.51E-05 2.02E-06
Variance 1.26E-10 3.03E-09 4.08E-12
95% CI 1.10E-05 5.40E-05 1.98E-06
Note: na = not applicable; STDEV = standard deviation; CI = confidence interval
Data is not presented for the stream A 8/9/07 sampling event because SMX was not
found to decrease downstream and, therefore, a removal rate was not calculated. The half-
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lives increase slightly in stream A as the study progresses (0.24 days on 8/25 vs. 0.65 days on
12/11). The half-lives do not vary greatly between streams, but stream C was shown to have
the greatest half-lives. It seems as if seasonal differences may have an influence on the half-
lives of SMX because they are not consistent throughout the period of the study.
Rate of removal and half-lives for erythromycin are presented in Tables 4.9 and 4.10.
Erythromycin was found to increase downstream of the WWTP on 10/3/07 but the removal
rate was not calculated because it was not found to decrease downstream. The decay rates of
erythromycin are within the same order of magnitude as those for sulfamethoxazole and the
same pattern is seen with respect to the order of removal by stream (i.e k for stream C < A <
B).
Table 4.8: Half-life (t½) values for sulfamethoxazole in days
Stream A Stream B Stream CDate
t 1/2 (day) t 1/2 (day) t 1/2 (day)
8/9/07 na 0.11 2.1
8/25/07 0.24 0.15 3.8
9/22/07 0.57 0.07 4.9
10/3/07 0.91 0.04 1.4
12/11/07 0.65 0.06 1.3
Mean 0.59 0.09 2.7
STDEV 0.28 0.04 1.6
Variance 0.08 0.002 2.4
95% CI 0.27 0.041 1.5
Note: na = not applicable; STDEV = standard deviation; CI = confidence interval
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Table 4.9: Removal rates (k) for erythromycin
Stream A Stream B Stream CDate
k (s-1) k (s-1) k (s-1)
8/9/07 5.13E-05 1.82E-05 9.64E-07
8/25/07 2.33E-05 3.26E-05 2.98E-06
9/22/07 1.62E-05 9.59E-05 6.23E-06
10/3/07 1.02E-05 1.63E-04 na
12/11/07 6.21E-06 2.68E-04 4.45E-06
Mean 1.40E-05 1.16E-04 3.66E-06
STDEV 7.44E-06 1.03E-04 2.23E-06
Variance 5.54E-11 1.05E-08 4.99E-12
95% CI 7.29E-06 1.01E-04 2.19E-06
Note: na = not applicable; STDEV = standard deviation; CI = confidence interval
The erythromycin half-life values (Table 4.10) calculated for stream A are found to
increase with time, while those for stream B decrease slightly. The half-life calculated using
the stream C 8/25/07 data shows a much larger value than for the other sampling events, and
this skews the average half-life so that it is much higher than those obtained from the three
other sampling events, and also contributes to the very large variance for this data set. This
is most likely due to the large decrease in concentration from DS C1 to DS C2 (316 ng/L to
40 ng/L).
Table 4.10: Half-live (t½) values for erythromycin
Stream A Stream B Stream CDate
t 1/2 (day) t 1/2 (day) t 1/2 (day)
8/9/07 0.16 0.44 8
8/25/07 0.34 0.25 2.7
9/22/07 0.50 0.08 1.3
10/3/07 0.78 0.05 na
12/11/07 1.3 0.03 1.8
Mean 0.61 0.17 3.5
STDEV 0.44 0.17 3.2
Variance 0.20 0.03 11
95% CI 0.39 0.15 2.8
Note: na = not applicable; STDEV = standard deviation; CI = confidence interval
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The half-lives for both sulfamethoxazole and erythromycin seem to be the most
consistent from month to month in stream B, whereas those for streams A and C vary quite a
bit. Published half-life values for sulfamethoxazole and erythromycin in a natural, aqueous
setting are scarce. In a lab-controlled study, Andreozzi et al. (2003) calculated the half-life
of SMX in salt and organic-free bi-distilled water (buffered to 5.5 with NaH2PO4 and
KH2PO4 salts) caused by photodegradation to be 2.4 days in the presence of nitrates, and 3.3
days in the presence of humic acids. Humic acids are thought to act as a photosensitizer
towards sulfamethoxazole, and there may be a higher proportion of humic acids in stream C
that may be causing the increased persistence of both antibiotics (Andreozzi, et al. 2003).
This same study found other pharmaceutically active compounds to have degradation rates of
5.0, 10.6, and 16.8 days for diclofenac, ofloxacin, and propranolol, indicating that
sulfamethoxazole more readily degraded in the presence of UV light. In relation to this
current study, these literature findings suggest that even though sulfamethoxazole was
detected at the highest concentrations among all antibiotics studied, it undergoes photo-
degradation relatively quickly and will therefore be less likely to adsorb to stream sediments.
Compounds that are less likely to undergo photo and biodegradation and that also have high
sorption coefficients are expected to be found in the stream sediment. Published studies
investigating removal rates and half-life values for erythromycin in terms of a natural setting
were not found and so it is difficult to compare the values calculated here.
4.6 BMEGUI Maps
As described in Section 1.8, the BME framework is a validated model that can be
used to estimate concentrations of environmental pollutants in different matrices (Christakos
and Serre, 2000a and b; Serre et al., 2003; Serre et al., 2004). In this current study, the
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space/time random field (S/TRF) of sulfmethoxazole, SMX(p), is used to represent the
uncertainties and natural variability associated with sulfamethoxazole at any space/time point
p = (s, t) of interest, where s is the geographical coordinate, and t is the time. The BME
space/time mapping analysis provides a rigorous mathematical framework used to process
the physical data for SMX in this watershed.
The mean function mx(p) = )( pX of the S/TRF characterizes trends and systematic
structures in space and time, while the covariance function in equation 4.1 expresses relevant
correlations;
cx (p, p’) = [ X (p)X (p)][X(p')X (p')] (eq. 4.1)
where: cx denotes the covariance
p and p’ are spatial points
X(p) denotes random fields
a subscripted x represents random variables
The BME space/time analysis framework can be used to predict concentrations of SMX at
unmeasured points, pK, given the total knowledge base available. The total knowledge base
available, K, is broken down into two subsequent knowledge bases: the general knowledge
base, G, and the site-specific knowledge base, S, so that K = G  S. Knowledge base G is
general in that it is based on watershed characteristics such as its space/time moments,
relevant flow and transport laws, and any other assumptions that may apply. The site-
specific knowledge base, S, represents measured data obtained at certain locations within the
watershed. S can be further broken down into hard and soft data, but only hard data were
included in the model used here (see concentrations for SMX in Appendix D). Hard data are
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accurate measurements, whereas soft data are probabilistic descriptions of the possible values
for SMX at certain points.
The BME model consists of three main approaches, and more detailed information on
the theory and equations behind the BME model is provided in Christakos et al. (2002).
1) Structural stage: G, which refers to values of the pollutant in the watershed at all
mapping points is considered, where pmap = (phard, psoft, pk).
2) Specificatory stage: The S knowledge base is then expressed in terms of exact
measurements hard and a variety of soft data soft. Then, map = (hard, soft, k).
3) Integration stage: The total knowledge base, K = G  S, is assimilated by means
of an operation Bayesian conditionalization rule that produces a posterior density
function (PDF), K, providing a full stochastic description of SMX at any
estimation point pk of interest within the watershed.
The dataset used in this model includes all measured SMX data (n = 54) in treated
wastewater effluent and surface water samples during the entire study period from August 9,
2007 through December 11, 2007 at a total of 16 monitoring locations (see Figure 2.1 for
sampling locations within the watershed). Data measured upstream of the WWTPs were not
included in the model because SMX was below quantitation at these locations, and including
these points would have temporally skewed the dataset.
An exploratory data analysis was conducted to determine how the data are distributed
in the raw and log form (Figure 4.2). Relevant statistics for the dataset in both raw and log
form can be found in Table 4.11. The natural log (ln) of the data is a more normal shape
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when compared to the raw data, and was chosen for further analysis within the model; all
concentrations are herein reported as ln-ng/L.
Table 4.11: Statistics for SMX raw and natural log distribution
Statistics Raw (ng/L) Natural Log
Mean 1001 6.29
Std. Deviation 892 1.36
Skewness 0.861 -0.739
Kurtosis -0.092 -0.395
Figure 4.2: Histogram of SMX (ng/L) measurements in raw and natural log form
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Temporal trends for SMX in the final effluent of each of the three WWTPs during the
study period are presented in Figures 4.3. The points on the graph correspond to actual
sampling events. Day 1 is equivalent to August 1, 2007. Sampling began on August 9, 2007
and ended December 11, 2007. The concentration of SMX in the effluent mostly increases
over time during the study period at all three WWTPs, but there is a significant drop in
concentration at WWTP B and C during late August and September.
Figure 4.3: Temporal trend of SMX in ln-ng/L in effluent for WWTP A (Station 01),
WWTP B (Station 11) and WWTP C (Station 13)
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Table 4.3 (cont.): Temporal trend of SMX in ln-ng/L in effluent for WWTP A (Station
01), WWTP B (Station 11) and WWTP C (Station 13)
The temporal trend for all of the stream and reservoir measurements remains steady
during August to October, but then decreases by half the concentration just before the final
sampling event in early December when the concentration spikes up again (Figure 4.4). The
mean trend is shown as the dashed line, and it essentially smoothes the spatiotemporal
fluctuations of the data. Overall, the concentration of sulfamethoxazole fluctuates, but there
do not appear to be any definite trends during the study period.
Figure 4.4: Temporal mean trend at all locations for SMX in ln-ng/L
----- = smoothed
temporal mean
trend of data
= mean trend of
data
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A space/time covariance analysis has been used to calculate the spatial and temporal
components of the covariance of the residual of the data since its mean trend was removed.
The residual data are assumed to be homogeneous and stationary, which implies that the
covariance between two space/time points p=(s,t) and p’=(s’,t’) is only a function of the
spatial lag (i.e. the spatial distance) r=||s-s’|| and time lag (i.e. the time difference) =|t-t’|
between these two space/time points. The covariance c(p,p’) between points p and p’ can be
written as:
c(p,p’) = c(r=||s-s’||,=|t-t’|),
where r is the spatial lag and  is the temporal lag
There are two steps in modeling the covariance. First the covariance values for different
spatial and temporal lags were estimated and are referred to as experimental covariance
values. Then a covariance model was fitted to the experimental covariance values using
three space/time separable components as shown below:
More detailed information on what each of these terms represents can be found in Christakos
et al. (2002).
The spatial and temporal components of the data are presented in Figure 4.5. The y-
axis in both plots represents the covariance of the data set. The x-axis in the first plot
represents the spatial lag in degrees, and represents the temporal lag in days in the second
plot. The spatial lag is more or less the distance that the data correspond to each other and
c(r,)  c0i cri(r)cti()i1
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the temporal lag is equivalent to how well the data correspond to each other over time. For
reference, 1 degree is approximately 111 km, so 0.01 degrees is approximately 1.1 km.
The data correlate spatially very well within about 0.03 degrees, or about 3 km. This
indicates that the model can estimate concentrations accurately within this distance around
actual sampled points assuming that the measured data is similar to days that were not
sampled during the study period, but estimated concentrations outside this range may not be
as reliable. There appears to be a slight temporal trend as concentrations are seen to fluctuate
up and down about every ten days.
Figure 4.5: Spatial and temporal covariance of the mean trend removed ln-transformed
SMX data
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Using the BME method, the general knowledge base consisting of the mean trend and
covariance model is combined with the site-specific knowledge base consisting of all of the
SMX data to obtain a BME posterior PDF which estimates the concentration of SMX at any
point within the whole watershed at various days throughout the study period. Maps have
been produced for various days during the study showing the targeted area and estimated
concentrations in the form of color shading, where a dark red is equivalent to the highest
concentrations and a dark green is equivalent to the lowest concentrations (Figure 4.6). The
upper and lower bounds of the color shades are provided in the map legend in units of ln-
ng/L.
The area of greatest concentration is at the point of origin, the WWTP. From there
the concentration of SMX is estimated to decrease downstream until the reservoir 6 point,
and then increase again in the southern portion of the reservoir due to the additional input
coming from the river flowing through the reservoir (R7). This trend is generally observed
over the duration of the study as can be seen in all four maps for days 9, 23, 49, and 64,
which correspond to August 9, August 23, September 18, and October 3, 2007.
It is interesting to note how differently the model predicts concentrations in the
stream locations upstream of the WWTPs. On day 9, the model predicts upstream areas in
streams A and B to be significantly higher than they should be considering SMX was below
detection limits at this point. This is because upstream data was not included in the model,
but it does not explain why estimated concentrations for stream C are so low. As time
progresses, the estimated concentrations in the stream portions generally increase.
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Figure 4.6: BMEGUI mean estimation maps for SMX in ln-ng/L on various days after
August 1, 2007
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The majority of the drinking water reservoir is estimated to have low concentrations
of SMX over the study period, which agrees with the measured data. From a public health
perspective, this is good because the green areas are where most of the boating and fishing
occurs, and this is also the area where the drinking water treatment plant influent pipe is (R5
site).
Estimated concentrations fluctuate greatly over the study period. This point was
sampled in a large river that is impacted by three upstream WWTPs and was found to have
the highest concentration of SMX in the reservoir during the 12/11/07 sampling event. But,
estimated concentrations are only high around August 23 (Mean estimate day 23 map). In
order for the model to more accurately represent the observed concentrations, upstream data
needs to be included in the model, as well as “soft” data points that estimate concentrations
based on removal rates calculated for the specific sampling events.
Overall, the BMEGUI framework allows one to rigorously process the space/time
variability of a pollutant in a watershed, the uncertainty in the site-specific data, and the
relevant flow and transport governing laws. The model estimates pollutant concentrations at
any point within the targeted watershed where a low number of samples were collected due
to site accessibility and budgetary constraints, and can be more accurate than those obtained
by classical modeling methods lacking the flexibility of BME. These estimation maps can
visually portray spatial and temporal trends of a pollutant as well as areas of concern within
the watershed, which may help to assess the uncertainty and risks associated with water
quality in the targeted watershed, and can also be used to improve future sampling plans.
5. Conclusions
The original purpose of this research project was to investigate the occurrence and
persistence of twenty-six antibiotics in a watershed that supplies a drinking water and
recreational reservoir in a rapidly expanding area in the Southeastern United States. The
research objectives are restated to frame this discussion within the context of the original
purpose of this study:
 Determine the aqueous concentration and persistence of antibiotics in
wastewater and receiving waters in a watershed that includes a drinking water
source and recreational area.
 To complete an environmental hazard assessment of detected antibiotics and
in the watershed.
 Estimate the concentration of a frequently detected antibiotic in surface waters
at locations where samples were not taken using the BMEGUI geostatistical
software, and to also determine any spatial and/or temporal trends during the
study period.
 To investigate possible policy implications in order to reduce the presence of
pharmaceuticals in surface waters.
The results of this study will be used to discuss how these objectives have been met.
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5.1 Antibiotic Occurrence in the Targeted Watershed
Throughout this study, anywhere from 10 to 12 of the targeted antibiotics were
detected in at least one aqueous sample collected from at least one of the three streams. At
least one and up to eight antibiotics were detected in the reservoir samples during a specific
sampling event. Detection criteria for an analyte’s presence assessed with LC-MS/MS
analysis were three-fold: 1) matching chromatographic retention time (within 2%) of
unspiked and spiked calibration samples; 2) confirmation by at least one of the two targeted
product ions from the analyte’s parent ion (as listed in Table 2.4); and 3) matching relative
ion abundance between standards and sample extracts. Quality assurance measures included
the use of solvent blanks, method blanks, method blanks with standards, replicate samples,
matrix spikes, and standard addition calibration curves for quantitation with typical linear R2
values of 95% and above. Precision was relatively good, with only 5.2% of the total number
of samples generating a RPD greater than 20% (Section 3.1.3).
Watershed and wastewater treatment plant information along with occurrence
summary tables presenting the maximum and minimum concentrations of antibiotics detected
within each stream during the entire study period are presented in Section 3.1.4. The
sulfonamides were the most frequently detected class of targeted antibiotics with
concentrations ranging from 1 ng/L to 3.3 g/L, followed by the fluoroquinolones with
concentrations from 1 to 338 ng/L. The tetracyclines were rarely detected in the treated
effluent or surface water samples, most likely due to their high sorption coefficients when
compared to those of sulfonamides and fluoroquinolones (Table 1.5). Sulfamethoxazole,
trimethoprim, and erythromycin were present in each stream and were detected at the highest
concentrations in every sampling event. The detected antibiotics and their concentrations are
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similar to those found in other studies (Vanderford et al., 2003; Kolpin et al., 2002;
Lissemore et al., 2006; Nakata et al., 2005) as discussed in Section 1.5. Sulfamethoxazole
was detected at relatively high concentrations in this watershed, but this may be due to the
fact that the area was under strict water conservation measures and a “normal” usage of
antibiotics may have been concentrated by measures such as not flushing the toilet as often.
This would concentrate any PhACs passing through the body in the toilet water before being
flushed. Dilution as a primary attenuation process should affect all analytes in the same
manner regardless of antibiotic class or chemical properties, and since the whole area was
practicing strict conservation measures and there was minimal rainfall during the study, the
concentration of sulfamethoxazole was similar in each of the three streams.
Table 5.1 presents a summary of detected antibiotics during the study period, where
an x represents detection during at least one of the sampling events and a red star indicates
that the antibiotic was detected during every sampling event. Areas where neither an x nor a
red star is present indicate that the antibiotic was not detected at all. In general, the variety of
antibiotics present and their concentration in the three streams were similar despite the fact
that the daily volume of effluent discharged into each of the streams differed. Wastewater
treatment processes are comparable, as are the population sizes and absence of nonpoint
sources of pollution.
There were two antibiotics that were not consistently measured in each of the three
streams, sarafloxacin and norfloxacin. These two antibiotics were only occasionally detected
in the wastewater effluents at all three treatment plants, and only found in the waterways
after the 9/22/07 sampling event. These results seem to indicate a seasonal usage pattern, but
since norfloxacin is commonly prescribed to treat gonorrhea, prostrate, and urinary tract
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infections and sarafloxacin is both a human and veterinary antibacterial drug, this does not
seem to be the case. Sarafloxacin is commonly used as an antibacterial for aquarium fish,
and this is the most likely source for this antibiotic in the treated wastewater effluent.
Table 5.1: Summary of overall antibiotic occurrence
Note: x = analyte was detected during at least 1 sampling event; red star = analyte was detected during every
sampling event.
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Figure 5.1 presents a graphical summary, in a logarithmic scale, of the average sum
of detected antibiotics by stream over the entire study period. This figure is intended purely
for comparison purposes to illustrate that there was not a specific class of antibiotics that was
detected in one stream compared to another.
Figure 5.1: Average antibiotic occurrence by stream for comparison purposes (log-
ng/L)
Each stream has slightly different characteristics; stream A is slow-moving and its size falls
in-between the other two streams, stream B branches off and flows through a very swampy
area, and stream C is wider and deeper than both streams A and B. Implications of stream
characteristics are discussed in further detail in Section 5.4.
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Several antibiotics were detected in the reservoir 1 through 6 locations (see Table
3.13) at much lower concentrations than found in the streams, and the overall decrease in
antibiotic concentrations is thought to be caused by photodegradation and adsorption to
stream sediment. Several more antibiotics were found in the aqueous phase at the reservoir 7
location, which is where a major river impacted by three wastewater treatment plants enters
the reservoir (Table 3.13).
The BMEGUI framework with modern spatiotemporal geostatistics was used to
process information about the space/time variability of sulfamethoxazole in this watershed
and governing flow and transport laws in order to obtain statistically estimated
concentrations of sulfamethoxazole at locations within the watershed that were not sampled.
Estimation maps created by the model generally agree with the measured data that the areas
of greatest concern coincide with streams A and B (see Figure 4.6). The BMEGUI maps
illustrate how the concentration of SMX is greatest at its point of entry into the watershed
(i.e. the wastewater treatment plant discharge), and then decreases as a plug of water from
each of the three streams flows into the reservoir. The model estimates that the area of the
reservoir in the vicinity of the drinking water treatment plant influent pipe has a low
predicted aqueous concentration of SMX. SMX is found to increase in the southern portion
of the reservoir due to the impact of another river flowing into it at that point only around the
end of August. There are some discrepancies for estimated concentrations in the southern
portion of the watershed, but this may be remedied by including upstream hard data and soft
data points for the reservoir locations.
The model is useful in that it can predict analyte concentrations in areas and on days
when samples were not taken, which is beneficial to this study due to a prevalence of site
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inaccessibility and budgetary constraints. However, some weaknesses should be noted.
First, the model predicts concentrations over a specified area and it does not distinguish
between land, air, or water so the reader must consider this when interpreting the data.
Second, there can be a large amount of variance associated with the expected concentrations
due to a lack of sampling points in the study area or a lack of sampling events, etc. Third,
weather events are not taken into account when predicting concentrations, so if sampling data
were all collected during a period of heavy rainfall, the estimations would probably differ
from estimations of a dry spell, etc. Fourth, the estimations are subject to how the modeler
manipulated the model to generate the estimations, and may differ from person to person.
Suggestions to overcome these limitations are generating more data by sampling
more frequently over a larger temporal and spatial period so that the model can more
accurately predict concentrations throughout the watershed; “soft” data can also be generated
by estimating concentrations using fate and transport laws at specific locations. Despite
these limitations, it is a useful tool that shows general trends over a whole study area during a
specific time and can be valuable in watershed management practices.
5.2 Estrogenic Activity in the Targeted Watershed
The aquatic environment is the ultimate sink for most chemicals, whether natural or
man-made. However chemicals and products are disposed of, whether in landfill sites or via
drains to WWTPs, they, or their degradation products, will enter the aquatic environment and
some will cause estrogenic responses in aquatic life. Estrogenic activity was detected in the
surface and treated wastewater samples at concentrations up to 2 ng/L, which is equivalent to
an EEQ to estradiol of 0.14 (Table 3.15). Samples taken upstream of the WWTPs on streams
A and C were found to have estrogenicity, but the input of treated wastewater effluent
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increased the estrogenic activity at the point where the effluent and stream water mix in
streams A and C. The opposite occurred in stream B, where the estrogenic activity at the
upstream sampling point was higher than the effluent itself (1.23 ng/L vs. 0.241 ng/L). Other
pollutants that were in the upstream surface water that are estrogenically active may have
caused this increased response at the upstream location. These pollutants may also have been
removed from the aqueous phase between the upstream and WWTP sites. The estrogenicity
then decreased downstream, most likely due to attenuation processes of the estrogenic
compounds, and was measured at an average 0.7 ng/L at the reservoir 5 site (location of
drinking water influent pipe).
The YES assay is easy to use, but there are major reservations due to a lack of
standardization, strain differences between yeast, and the unique physiology of yeast as
compared to mammalian cells. Another major limitation of the YES assay is that it cannot
determine the exact pollutant(s) which is/are causing an estrogenic response, and cannot
distinguish between agonists and antagonists. Wastewater effluent is composed of a wide
variety of chemicals and this is a major limitation to using the YES assay for this matrix.
Major advantages of the YES assay include ease of use (because cells do not have to be
continuously transformed), short-term duration, the ability to quantify results without using
toxic materials, and the ability to use results as a comparative tool in a watershed setting.
5.3 Calculated Environmental Hazard in Targeted Watershed
The environmental hazard was calculated using measured concentrations and various
EC50 values taken from the published literature for a wide variety of species. An assessment
factor of 1000 was applied to the EC50 value in order to account for inter- and intra-species
variability.
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Sulfamethoxazole, ciprofloxacin, and erythromycin were consistently shown to have
the greatest environmental hazard in all three streams and reservoir locations. Calculated
environmental hazard values were found to decrease with increasing distance from the point
of entry due to lower concentrations of the antibiotics, but there is still a hazard associated
with the antibiotics in the drinking water reservoir.
It is difficult to assess what this means in terms of the aquatic life in the watershed.
Present knowledge indicates that pharmaceutical residues in the aquatic environment are
unlikely to pose a hazard for acute toxicity within the environment and the public.
Environmental concentrations of the antibiotics detected in this watershed are at least 48
times less than known EC50 values (smallest difference between measured antibiotics and
listed EC50 values in Table 4.1), but environmental concentrations are continuous whereas
most toxicological studies are single dose exposures. When looking at all investigated
antibiotic classes, the sulfonamides were the most frequently detected and therefore may
present the greatest environmental threat.
There is a general lack of chronic toxicity data on PhACs, particularly for higher
trophic levels, such as fish. More research about potential long-term ecotoxicological
effects, particularly with respect to endocrine disruption, immunological status, or gene
activation and silencing during long-term exposure is in order as well as the potential for
additive and antagonistic effects within chemical mixtures. Due to the low concentrations of
antibiotics seen in treated drinking water and source waters, public health effect are thought
to be minimal, but subtle changes and disturbances may have negative consequences for
aquatic life, and until more studies are completed it is difficult to assess what occurrence
studies mean in terms of environmental hazard.
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5.4 Impact of Watershed Characteristics on Occurrence and Persistence of
Antibiotics
Watershed characteristics greatly affect the occurrence, fate, and transport of PhACs
in the environment. Watersheds, receiving wastewater discharge and non-point sources of
pollution from agricultural run-off are more susceptible to PhAC intrusion, and those areas
closer to the source are expected to have higher concentrations relative to those areas farther
away from the source due to attenuation processes such as sorption, dilution,
photodegradation, and biodegradation. Land use surrounding the watershed is also closely
related to the type of PhACs that can enter the watershed (i.e. urban, rural, agricultural, etc.).
For example, an area that is home to several CAFOs and rainfall may have higher antibiotic
concentrations in the surrounding watershed due to non-point source pollution than a semi-
arid, urban area.
The size and average daily stream or river flow can also affect PhAC attenuation.
PhACs found in a large, shallow, slow-moving stream would be more likely to adsorb to
stream sediment and undergo photo- or biodegradation. Sediment transport is more likely in
a high flow stream as high flow will agitate and move sediment to a greater extent than a low
flow stream. Also, PhACs found in rivers that are narrow and deep would be less likely to
adsorb to stream sediment or undergo photodegradation because there would be less contact
with stream sediment, and sunlight may not be able to penetrate at certain depths.
As much information as possible was obtained about the watershed, such as potential
point and non-point sources, land use practices, flow and stream characteristics, and
wastewater treatment processes in order to assist with data interpretation. The streams
investigated in this study are located in the same watershed and have relatively similar
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characteristics. All three flow through a semi-urban area, are impacted by wastewater
discharge, and are not impacted by non-point sources of pollution downstream of the
WWTP. After wastewater effluent is discharged into these streams, they flow through a
heavily forested/intermittently swampy area before entering a recreational reservoir that also
serves as a drinking water source.
There are, however, differences in stream size. Stream A is shallower and narrower
than streams B and C. Stream B branches off and then flows through a very swampy area
before entering the reservoir, and stream C is deeper and wider in most locations when
compared to streams A and B. These differences may have a significant impact on
attenuation processes. For example, because stream C is wider in comparison to the other
two streams, PhACs in the aqueous phase may be less prone to undergo photodegradation or
adsorb to stream sediment, whereas the characteristics of stream B would most likely result
in a greater percentage of PhACs in the aqueous phase more readily adsorbing to the stream
sediment. This is, in fact, observed when comparing the rate of removal (k) values calculated
using measured data for sulfamethoxazole and erythromycin (see Tables 4.7 and 4.9).
Stream C has k values that are lower than streams A and C, which indicates that both of these
antibiotics are found to undergo slower rates of removal from the aqueous phase. This is
also clear when looking at the half-lives (T½) of both sulfamethoxazole and erythromycin
(Tables 4.8 and 4.10). During the study period, sulfamethoxazole was found to have average
T½ values of 1.58, 0.09, and 2.5 days in streams A, B, and C, respectively. Erythromycin
was found to have average T½ of 0.61, 0.17, and 3.5 days in streams A, B, and C,
respectively. These values indicate that aqueous concentrations of antibiotics in stream B
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undergo the fastest rate of removal from the aqueous phase, followed by stream A, and
finally stream C.
5.5 Reduction of Antibiotics Through Wastewater Treatment Technologies
WWTPs are a major potential PhAC point source to the aquatic environment, while
also providing a major opportunity for centralized removal processes. Conventional WWTPs
effectively remove solids, nutrients, and biodegradable organic matter but are not typically
designed to remove PhACs during normal operation.
Individual PhACs have distinct chemical and physical properties that suggest
potentially different mechanisms and locations in the WWTP treatment train for removal or
reduction. Biological transformations, the effects of mixtures, hydraulic and temperature
variations, analytical limitations, and the combination of treatment processes in a WWTP can
contribute to uncertainties in PhAC removal. Advanced treatment such as ozonation,
activated carbon, and membrane filtration are receiving considerable attention, while
research into a better understanding of removal in conventional treatment (primary,
secondary and tertiary) remains active. It is difficult to justify upgrading conventional
wastewater treatment systems when the effects of PhACs in the environment are largely
unknown. If, and when adverse toxicological effects evidence is sufficient to warrant
additional treatment, it is practicable that abatement design will not be tailored to an
individual compound but based rather on overall capacity to remove trace contaminants.
Until then, research in this area remains of fundamental importance.
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5.6 Public Health Significance
Antibiotics can be considered an indicator of anthropogenic contamination in surface and
drinking water. In this case study, several antibiotics, most notably sulfamethoxazole,
ciprofloxacin, and erythromycin, have been found to have an environmental hazard as
described in Section 4.4. The environmental and human risk associated with PhACs in
watersheds and drinking water reservoirs are largely unspecified. Little is known about long-
term exposure to sub-therapeutic doses of antibiotics and other compounds, either
individually or as a mixture through drinking water. Drug resistant pathogens are an
increasing threat to the health care industry, and the presence of PhACs in surface waters
may be a cause of this phenomenon. Little is also known about transformation products of
PhACs that may also pose a public health threat. Exposure through recreation in the
reservoir, or consuming fish from the waterfowl impoundments along these streams is also of
concern. If antibiotics are present in the waterways, it can be assumed that other pollutants
are present as well, and the results from this study indicate that environmental concentrations
of antibiotics in the aqueous phase validate public health and antibiotic resistance concerns.
5.7 Policy Implications
Policy implications were discussed in Section 1.10. There are several regulatory
agencies involved in the development and dispersion of pharmaceuticals, as well as their fate.
It is important to coordinate research between government, pharmaceutical companies,
academia, and the public in order to formulate a plan to decrease the presence of
anthropogenic compounds in the environment.
Controlling pollution at its source is a better option than spending large amounts to
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upgrade current wastewater and water treatment plant infrastructures. Effective source
control reduces the consumed quantities as well as the ecological exposure of selected
compounds by educating the public and medical professionals on the consequences of PhACs
in the environment. It is of paramount concern to decrease the prevalence of these
compounds in the environment because of the unknown effects of long-term, sub-therapeutic
exposure of these compounds.
Several suggestions to help decrease this waste in the environment are:
 modify current regulations that impose stricter testing by pharmaceutical
companies and encourage the development of more readily biodegradable
drugs,
 develop plain language educational programs to inform medical professionals and
the public of the fate and potential environmental/health hazards of these
compounds,
 promote alternative or “natural” medicines, as well as discourage over-
prescription and overuse to decrease reliance on these anthropogenic sources of
pollution,
 educate pharmacies, medical professionals, and the public on how to properly
dispose of prescription and non-prescription drugs,
 better coordination between the FDA and EPA when conducting environmental
assessments in order to establish maximum contaminant levels,
 create worst-case scenario model ecosystems or watersheds to determine
maximum contaminant levels, and to create predictive models to investigate
fate and transport of PhACs, and
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 create a comprehensive monitoring program that includes compounds that are
indicators of each major source of PhACs to the environment (for example,
antibiotics or caffeine as a tracer for WWTP effluents) and frequently used
compounds in high use.
Sharing information and opening up the discussion to the public without pushing false
assumptions and scare tactics will result in consumer and corporate responsibility and
hopefully a decrease in the environmental presence of these pollutants.
5.8 Recommendations for Future Study
This study has shown that antibiotic occurrence in the aqueous phase is prevalent in
an impacted watershed that supplies a drinking water reservoir. Investigating sediment
samples in impacted watersheds is also helpful to understand the sorption mechanisms for
PhACs, to further understand their fate and transport and provide a more complete mass
balance that in turn will assist in predictions of environmental hazard. Investigating WWTPs
that utilize different treatment processes would help to determine which processes are more
effective in PhAC removal at the full-scale plant level. The impact of PhACs in the
environment is still largely unknown, and more in-depth toxicological studies are warranted
in order to understand the effects of long-term, continuous exposure of the aquatic
environment to a range of compounds. Improvements in analytical methods, as well as
developing standard methods in all matrices should be considered to ensure more comparable
research results.
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5.9 Parting Thoughts
Knowledge of the presence of antibiotics and other pharmaceutically active
compounds in the environment has increased due to improved analytical methods for their
detection, and an increase in peer-reviewed publications on the subject matter. This study
was conducted to investigate the occurrence of 26 antibiotics using validated analytical
methods and LC-MS/MS identification, and corresponding estrogenic activity within a
drought-ridden watershed impacted by wastewater effluent in the Southeastern United States.
It is unique in that the study period investigated three streams that flowed over a short
distance directly into a drinking water reservoir and coincided with an extreme drought,
which resulted in treated wastewater effluent feeding the northern half of a drinking water
reservoir. The study is not entirely representative with respect to the long-term temporal
evolution of this watershed. No other case study known to the author has previously
investigated the occurrence of antibiotics in a watershed during a period of extreme drought.
This also allowed the removal rates of two of the most prevalently detected antibiotics,
sulfamethoxazole and erythromycin, to be determined because there was no additional stream
flow other than the wastewater effluent during the study period. The use of the BMEGUI
framework also allowed the author to reliably estimate concentrations of sulfamethoxazole
within the whole watershed despite a limited number of sampling sites. Other studies of this
nature have only relied on measured data to create a picture of what was occurring in
investigated areas. BMEGUI concentration estimations can be used in future watershed
management issues concerning emerging contaminants and possibly other water quality
criteria.
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Case studies such as this are beneficial as they can give us insight into the occurrence
and fate of anthropogenic pollution originating from a point source in a “worst-case”
scenario. They also provide a basis for toxicological and health impact studies on
environmental levels of PhACs that are critical to the development of a regulatory
framework.
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Appendix A: Standard Operating Procedure for Antibiotic Analysis using LC/MS-
MS
Purpose: This standard operating procedure (SOP) describes the analysis of 26
antibiotics including 7 tetracyclines, 7 sulfonamides, 7 (fluoro)quinolones, 3 macrolides,
trimethoprim, and lincomycin in wastewater effluent and surface water samples at ng/L
levels using solid phase extraction and liquid chromatography electrospray tandem mass
spectrometry.
1. Preparation of solutions
Supplies:
- balance
- 10 and 25 mL volumetric flasks
- 100 mL beakers
- glass funnel
- 10 and 40 mL amber vials and Teflon-lined caps
- spatula
- weighing dishes – whatever size available
- 5 ¾ inch pasteur pipettes
- 250 mL and 1 L amber bottles with Teflon-lined caps
- 10 mL conical vials with Teflon-lined caps
Parts from Laboratory Supply Distributors (Mt. Laurel, NJ):
- amber glass autosampler vials, graduated spot (LSD Part #20211AS-1232)
- autosampler vial 10mm/425 black closure with hole (LSD Part #41360-10)
- 0.45 m syringe filters (LSD Part #NN8012-100)
- 250 L Glass LVI with prospering inserts (LSD Part #21100-11)
Reagents:
Antibiotic standards purchased from Sigma-Aldrich (St. Louis, MO) include:
sulfathiazole, sulfamerazine, sulfamethazine, sulfamethizole, sulfachlorpyridazine,
sulfamethoxazole, sulfadimethoxine, erythromycin, tylosin, roxithromycin, trimethoprim,
lincomycin, norfloxacin, sarafloxain, flumequine, levofloxacin, pipemidic acid, oxolinic
acid, minocycline, oxytetracycline, tetracycline, demeclocycline, chlortetracycline,
doxycycline; all are 99% pure.
Isotopically labeled standards (13C6-sulfamethoxazole, 13C3-ciprofloxacin, and 13C2-
erythromycin) were purchased from Cambridge Isotope Laboratories (Andover, MA).
The internal standard, simatone, was purchased from Accustandards (New Haven, CT).
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Erythromycin-H2O was prepared at the University of North Carolina laboratory with the
erythromycin standard and the method described by McArdell et al. (2003) and Ye,
2005).
Na2EDTA and sodium azide were purchased from Aldrich (Milwaukee, WI).
Location of Reagents:
The antibiotic, internal standard simatone, and surrogate standard stock and working
solutions are stored in Freezer D. Neat standards of minocycline, meclocycline,
ciprofloxacin, pipemidic acid, flumequine, erythromycin, and levofloxacin standards are
stored in Fridge A. Neat standards of sulfamethazine, sulfamethoxazole, and EDTA are
stored in the Organics cabinet by hoods. All other neat standards are stored in Freezer D.
Formic acid is also stored in Fridge A.
Solvents:
- HPLC-grade methanol (Fisher Scientific)
- LGW/methanol (1:1, 0.2% HCl, v/v)
- HPLC-grade acetonitrile (Fisher Scientific)
- HPLC-grade formic acid (Fisher Scientific)
1.1 Preparation of antibiotic stock solutions (see Table 1)
1. For an EASILY soluble antibiotic (listed on Table 1 without an “*”):
 Tare the scale on the weighing balance (Fisher Scientific Accu-124D Dual Range,
Serial #15806759) after placing the weighing dish
 Close the glass door of the balance before weighing
 Use the spatula to transfer a predetermined amount (Table 1) of antibiotic neat
standard to the weighing dish (record exact weight to 4 decimal places)
 Use 5 ¾” pasteur pipette to transfer appropriate solvent into the weighing dish
(start with 2 pipettes of solvent)
 Use a different pipette and gently stir in dish to dissolve antibiotic
 Transfer the antibiotic solution into a volumetric flask of appropriate volume
 Transfer all remaining antibiotic in the dish to the volumetric flask by adding
solvent and transferring a few times
 Fill up the volumetric flask up to the line with the solvent
 Cap the volumetric flask and invert 3 times
 Calculate the actual concentration of the prepared stock solution
 Transfer the solution into an amber vial of separate volume and cap with Teflon-
lined cap
 Label the vial with antibiotic name, concentration, initials, and date of preparation
and store in Freezer D
 Clean the spatula thoroughly (with LGW and then methanol) and dry thoroughly
with Kimwipes
 Brush off scale gently between use
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2. For an antibiotic that is DIFFICULT to dissolve (listed on Figure 1 with a “*”):
 Tare the balance and then weigh the volumetric flask without stopper; tare the
balance
 Add antibiotic neat standard directly into the volumetric flask through a filter
funnel using a spatula
 Add appropriate solvent directly into the flask with a 5 ¾” Pasteur pipette
 Cap the flask and invert until the antibiotic dissolves
 If the antibiotic still does not dissolve, cover the flask in aluminum foil (to
prevent photodegradation) and let the flask sit on bench for a while, or put a small
stir bar into the flask and use magnetic stir until it dissolves
 Once the antibiotic fully dissolves, transfer the solution into an amber vial (10
mL, or use a 40 mL vial for 25 mL of stock solution) and cap with Teflon-lined
cap
 Calculate the actual concentration
 Label the vial with antibiotic name, concentration, initials, and date and store in
Freezer D
Note:
 For ciprofloxacin ONLY, take 5 mL of the prepared 1000 mg/L stock solution to
another volumetric flask and fill to 10 mL with methanol. This prevents the
solution from being frozen because the solvent is LGW.
 Store all solutions in Freezer D at about 10F, except for aqueous solutions, which
should be kept in Fridge A at about 45F. The stock solutions are stable for at
least 3 months (tetracyclines, quinolones, macrolides, lincomycin, and surrogate
standards) and 1 year (sulfonamides, trimethoprim, simatone) when stored in
freezer.
 Usually takes ~ 1-2 days to prepare stock solutions for all 26 antibiotics
 Antibiotic standards are stored in the little blue box in Freezer D
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Table 1. Preparation of Stock Solutions of Antibiotics
Analyte MolecularWeight
HCl
or
salt
form
Stock
Conc.
(mg/L)
Amount
of Neat
Std. (g)
Solvent Volume(mL)
Minocycline 457.5 494 1000 0.0108 MeOH 10
Oxytetracycline 460.4 496.9 1000 0.0108 MeOH 10
Tetracycline 444.4 480.9 1000 0.0108 MeOH 10
Demeclocycline 464.9 501.4 1000 0.0108 MeOH 10
Chlortetracycline* 478.9 515.4 400 0.0135 MeOH 25
Doxycycline 444.4 480.9 1000 0.0108 MeOH 10
Meclocycline 476.9 695 1000 0.0146 MeOH 10
Sulfamerazine* 264.3 287.3 400 0.0109 MeOH 25
Sulfathiazole 255.3 278.3 1000 0.0109 MeOH 10
Sulfamethazine* 278.3 - 400 0.01 MeOH 25
Sulfamethizole 270.3 - 1000 0.01 MeOH 10
Sulfachlorpyridazine 284.7 - 1000 0.01 MeOH 10
Sulfamethoxazole 253.3 - 1000 0.01 MeOH 10
Sulfadimethoxine 310.3 - 1000 0.01 MeOH 10
Trimethoprim* 290.3 - 400 0.01 MeOH 25
Ciprofloxacin 331.3 367.8 1000 0.0111 LGW 10
Norfloxacin* 319.3 - 400 0.01
LGW/MeOH
1:1, 0.2%
HCl, v/v
25
Enrofloxacin* 359.4 395.9 400 0.011
LGW/MeOH
1:1, 0.2%
HCl, v/v
25
Sarafloxacin* 385.4 - 80 0.008 90% LGW :10% MeOH 100
Pipemidic acid* 303.3 - 400 0.01
LGW/MeOH
1:1, 0.2%
HCl, v/v
25
Oxolinic acid* 261.2 - 400 0.01 ACN (2%NH4OH, v/v)
25
Flumequine 261.2 - 1000 0.01 ACN (2%NH4OH, v/v) 10
Tylosin 916.1 1066 1000 0.0116 MeOH 10
Erythromycin 733.9 - 1000 0.01 MeOH 10
Roxithromycin 837.1 - 1000 0.01 MeOH 10
Lincomycin 406.5 443.5 1000 0.0109 MeOH 10
Note: * = not easily soluble.
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1.2 Mixture of each antibiotic group (usually prepared at 20 mg/L)
Group 1: six tetracyclines (TCs) — minocycline, meclocycline, oxytetracycline,
tetracycline, demeclocycline, chlortetracycline, doxycycline
Group 2: seven sulfonamides (SAs) and trimethoprim (TMP) — sulfamerazine,
sulfathiazole, sulfamethazine, sulfamethizole, sulfachlorpyridazine, sulfamethoxazole,
sulfadimethoxine, trimethoprim
Group 3: seven (fluoro)quinolones (QLs) — ciprofloxacin, norfloxacin, enrofloxacin,
sarafloxacin, pipemidic acid, oxolinic acid, flumequine
Group 4: three macrolides (MAs) and lincomycin (LIN) — tylosin, erythromycin,
roxithromycin, lincomycin
Procedure
1. Calculate the volume of antibiotic stock solution to be added to 10 mL of methanol.
Cstock *Vstock Vmixture *Cmixture
2. Obtain the antibiotic stock solutions from freezer, 10 mL volumetric flask, 50-250 μL
micropipette, capillary tubes, HPLC-grade MeOH, waste bucket, and wash MeOH.
3. Fill the flask with some MeOH (estimate total volume of solution that will be added
and make sure there is more than enough room for it)
4. Pipette the stock solution (Vstock) and inject below liquid in the volumetric flask (begin
with ones that need the largest Vstock)
- Adjust the micropipette volume setting to the desired value
- Clean the micropipette tip with MeOH and dry with Kimwipe
- Insert capillary tube, tighten, and check
- Withdraw antibiotic solution (Vstock)
- Wipe off solvent outside of capillary with Kimwipe
- Inject under liquid level and shake the pipette gently
- Remove glass capillary
- Rinse tip with wash MeOH and dry with Kimwipe
- Repeat process for each injection
5. Fill the volumetric flask up to the mark with methanol, cap and invert
6. Repeat for all antibiotic groups
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7. Store the solutions in labeled amber glass vials capped with Teflon-lined caps in
Freezer D
1.3 Mixture of 26 antibiotics at 0.5 mg/L in MeOH
1. Calculate volume to be taken from each mixture to a certain volume of methanol
(usually 10 mL)
Cmixture: concentration of antibiotic in the mixture of each group (see 1.1.2)
For example, to prepare a mixture of antibiotics at 0.5 mg/L in 10 mL methanol from
each 20 mg/L mixture:
20 mg/L * Vtaken = 0.5 mg/L * 10 mL
Vtaken = 0.25 mL
2. Prepare the mixture of 25 antibiotics using the same technique as described in Section
1.1.2
1.4 Preparation of Surrogate and Internal Standard Solutions
1.4.1 Mixture of surrogate standards at 0.5 mg/L
1. Calculate the volumes of stock solutions of surrogate standards (13C6-
sulfamethoxazole, 13C3-ciprofloxacin, 13C2-erythromycin, and meclocycline) to be taken
to prepare a mixture of the surrogates at an individual concentration of 0.5 mg/L in 5 or
10 mL of methanol.
For example, to prepare a 5 mL solution:
Cstock * Vtaken = 0.5 mg/L * 5 mL
2. Prepare the mixture in HPLC-grade MeOH using the same technique as described
Section 1.1.2.
1.4.2. Internal standard (I.S.) solution
- The concentration of the internal standard simatone reagent solution is 100 μg/mL
(i.e.100 mg/L)
- Make dilution of the simatone stock solution to a desired I.S. concentration of 1.25
mg/L by adding 125 μL of stock solution to 10 mL MeOH
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- Pour working solution into an amber vial, cap with Teflon-lined cap, label the vial, and
store in Freezer D
1.5 Preparation of other solutions
1.5.1 0.1% Formic acid in methanol (also referred to as acidified methanol; used to
condition and, later, to elute compounds from SPE cartridges)
Measure 200 mL HPLC-grade MeOH into a 250 mL amber bottle and add 200 μL formic
acid with micropipette. Cap the bottle with a Teflon-lined cap and invert 3 times.
*** Prepare fresh solution within one week of analysis***
1.5.2 0.25 g/L Na2EDTA stock solution in LGW (added to samples to prevent metal
complexation before SPE)
Weigh 0.025g Na2EDTA, transfer to a 100 mL volumetric flask, and dissolve in LGW.
(Na2EDTA is stored in Organics cabinet; use most recently opened bottle).
1.5.3 Solvent mixture of LGW and methanol (10% MeOH: 90% LGW) (for
reconstitution of samples after blow-down)
Measure 180 mL LGW and 20 mL methanol, respectively, and mix in a 250 mL amber
bottle. Cap with Teflon-lined cap.
1.5.4 2% Formic acid in LGW (for pH adjustment of water samples)
Measure 200 mL LGW and pour into 250 mL amber bottle. Inject 4 mL formic acid with
5 mL glass pipette and bulb below the surface. Cap bottle with Teflon-lined cap and
invert 3 times.
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2. Sample processing
2.1 Sample Collection
1. Samples should be collected in 1 L amber bottles
2. Rinse bottle with sample 3 times before collecting the appropriate volume
3. When collecting actual sample, wear latex gloves, put bottle below surface and
fill to the top, cap with Teflon-lined cap
4. Bottle should be labeled with sample name, collector name, date, and time
2.2 Sample Filtration
1. The 1st bench left side in MHRC 1210 is designated for filtration
2. Use filtration glassware designated for the appropriate type of water sample,
usually a 1 L Buchner flask
3. The surface/raw water samples are filtered through glass fiber filters (0.7 μm pore
size) and then nylon filters (0.45 μm). For drinking water or LGW, only use
nylon filter (0.45 μm)
4. Connect the vacuum and place the filter into the system using forceps
5. Wet the filter with a small amount of LGW
6. Switch on vacuum
7. Pour about 100 mL of water sample into the sample reservoir and let it filter
through under vacuum. Stop vacuum before the filter dries, swirl the 100 mL
around in flask, then dump out (this serves to condition the glassware and further
remove any residue). Pour water sample into the reservoir and filter the rest of
the sample; make sure water in flask does not exceed 1000 mL to prevent it from
being sucked into the vacuum (this will damage the vacuum!)
8. Rinse the sample bottle (1 L amber) with a small amount of the filtered sample
and pour the filtered water back into the bottle
9. Replace the filter with a 0.45 μm pore size filter (get from drawer, blue paper is
waste, the white is the actual filter)
10. Re-run the sample through the 0.45 μm filter (this will take a longer time due to
its smaller pore size)
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2.3 Solid phase extraction (SPE)
2.3.1 Sample Preparation
After filtration, each 1 L sample is divided into six aliquots of 250 mL each: two for the
unspiked samples and four for spiked samples. (Note: at least 2 spike levels are needed
for standard addition).
1. Label 250 mL amber bottles:
For example:
0-1  non-spiked sample 1
0-2  non-spiked sample 2
S-50  spiked sample with 50 ng/L
S-100  spiked sample with 100 ng/L
2. Divide 1 L sample evenly into four 250 mL amber bottles. To prevent contamination
of sample from glassware, this volume is sometimes estimated. To be more precise, use a
250 mL volumetric flask to measure volume and then pour into bottles.
3. Addition of surrogate standards
The surrogate standard mixture is a mixture of 4 surrogates including 13C6-
sulfamethoxazole, 13C3-ciprofloxacin, and 13C2-erythromycin, and meclocycline at a
concentration 0.5 mg/L.
Spike the surrogate standard mixture prior to antibiotic mixture to avoid contamination
and because surrogates monitor the entire sample processing procedure.
a) Calculate the volume of surrogate mixture to add to 250 mL. The desired
concentration is 50 ng/L so, for a 250 mL sample, the volume of the mixture required is
calculated as follows:
b) Use a micropipette with an appropriate volume range (ie 10 – 50 μL) and adjust to the
desired volume
c) Inject surrogate mixture (from nonspiked to spiked samples with increasing
concentrations) using the same technique as described in section 1.1.2. The same volume
of the surrogate standard mixture is added to each bottle.
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4. Spike of antibiotics
a) Prepare the 26-analyte mixture (see section 1.1.3) on the day of extraction
b) 0.5 mg/L is usually a good concentration for the analyte mixture, depending on how
much volume you want to spike
c) The spike levels for raw water are usually 20, 50, 100, and 500 ng/L
d) The spike levels for finished drinking water are usually 2, 5, and 10 or 20 ng/L
e) The spike levels for treated wastewater effluent are usually 20, 100, 500, and 1000
ng/L
f) Calculate the amount of antibiotic mixture to spike for each increasing spike level. For
example, if a spike concentration in a 250 mL sample of 50 ng/L is desired, then the
volume of a 0.5 mg/L mixture required would be:
g) Inject the antibiotic mixture below the surface using the same techniques as discussed
earlier.
5. Addition of Na2EDTA at 1 mg/L
Na2EDTA is added to prevent complexation between the analytes and the metals in
water. The surrogates and analytes are spiked into the sample before EDTA addition so
that they will undergo the same procedure as the analytes present in the original sample).
a) Prepare 0.25 g/L Na2EDTA stock solution (section 1.3.2)
b) Calculate the amount of Na2EDTA stock solution to add. For a 250 mL sample, the
volume of the 0.25 g/L working solution required is calculated as follows:
c) Addition of Na2EDTA to samples:
- Fill a 10 mL graduated pipette with the EDTA solution and dispense 1 mL of this
solution to each sample in its 250 mL amber bottle on top of the liquid level of the
sample
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- Cap and invert the amber bottle once
- Repeat for every sample
6. pH adjustment
Notes:
- The pH meter (Fisher Scientific) is located on the first bench
- When not in use, store the electrode in buffer storage solution and put the meter in
standby mode
1) Calibration of pH meter
a. Remove the electrode from the buffer storage solution and rinse thoroughly
with LGW
b. Dab electrode dry gently using Kimwipe
c. Set “slope” on meter to 100 and “temperature” at room temperature in the lab
(usually ~22 deg C)
d. Insert the electrode into a pH 7 buffer
e. Switch mode from “standby” to “pH”
f. Shake the buffer gently to equilibrate the electrode
g. Adjust the “standardize” knob until the reading reaches 7.00 (wait a while for
pH to stabilize)
h. Switch mode back to “standby”
i. Rinse electrode with LGW and dry again with Kimwipe
j. Place electrode in pH 4 buffer, switch from “standby” to “pH” and adjust the “slope”
knob only to pH 4.00 (get as close as possible)
k. Switch back to “standby”, remove electrode from pH 4 buffer, rinse and replace in pH
7 buffer. Place in “pH” mode and read. If measurement is within 0.1 pH units, the meter
is ready to use. If not, the buffer solution should be replaced, and if same problem
occurs, then the electrode needs to be replaced.
l. Switch back to “standby” mode and insert the electrode in pH 4 buffer
2) Measure pH of samples starting with the unspiked samples
3) Adjust to pH 6.0 (range from 5.8 – 6.0 is acceptable) as described below:
- To lower the pH, use ~ 2% formic acid; to increase pH, use diluted NaOH solution (but
this is rare with surface and wastewater samples)
- Due to buffer capacity of environmental water samples, it is impossible to calculate the
exact amount of acid to add, so slowly add drops of 2% formic acid until the sample pH
reaches the desired value
- It is important to adjust all samples to approximately the same pH so that the co-
extracted matrix from solid phase extraction is the same for each sample
a. Add ~ 5 drops of ~ 2% formic acid using Fisher 5 ¾” pipettes
b. Cap, invert, and measure pH
c. Continue adding acid until the pH reaches 6.0
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- If the pH of the unspiked sample goes below 5.8, mix it with the other portion of
the unspiked samples and readjust pH
d. RECORD the total number of drops added into one sample to reach the desired
pH and add the same drops to each of the other samples
e. It is best to then check pH on each subsequent sample
f. After pH measurement, rinse the electrode and store in the pH 4 buffer solution
4) Repeats steps 2) and 3) above for each of the samples in order from lowest to highest
spiked sample in each sample set.
2.3.2 Solid phase extraction
Preparation
1. Equipment Needed:
a. vacuum manifold (Supelco Visiprep 24)
b. solid phase cartridges cartridges (Strata-X 6 mL or equivalent cartridge per sample)
2. Place cartridges on the manifold (open valves where cartridges are)
3. Close all other valves on top of the manifold
Procedure
1. Preconditioning of SPE columns
Notes:
- Start preconditioning before sample pH adjustment because it takes ~10 minutes
- Precondition using MeOH, which cleans and activates HLB or Strata-X sorbent, and
acidified MeOH, which is later used as the eluting solvent
- LGW is used to wash the MeOH out of the cartridge
1) Add ~ 6mL MeOH into each cartridge and let it run through by gravity
2) Connect the SPE manifold to the waste container which is connected to the vacuum
3) When MeOH has almost completely passed through the cartridge, add ~ 1 mL of
acidified MeOH (0.1% formic acid in MeOH) (one squeeze of 5 ¾” pasteur pipette; or
use 1 mL or larger pipette)
4) If the sample drips through cartridge really slowly, use a 10 mL syringe filled with air
to push solvent through gently
5) Apply 6 mL of LGW to each cartridge twice and try not to introduce any air bubbles
(air bubbles can fill pores of stationary phase and reduce effectiveness). When about 3
mL of LGW is remaining in cartridge, proceed to extraction.
7) Label each cartridge according to the sample I.D.
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2. Extraction
1) Insert a T adapter between each cartridge and the valve on the manifold
2) Open each sample amber bottle, insert one small, precleaned tubing into each bottle
(try to get tubings that have equal length if possible), and connect the tubing fittings to
the SPE cartridge with a piece of tape (with ~ 3 mL LGW remaining in the cartridge)
3) Apply vacuum pressure to initiate the sample extraction
5) Record start time (it takes approximately 1 hour for extraction of a 250 mL sample)
6) Adjust flow rate to be at approximately 5 mL/min
- Estimate flow rate by extraction for 10 minutes and watch the water level in
amber bottles (it should be down by ~50 mL) and the level should be the same in
each bottle
7) Complete checks
a. make sure tubing is at very bottom of amber bottles
b. no leak around cartridge and t-adaptor
c. each cartridge is labeled and labels match with bottles
d. equal flow through each cartridge
8) Continue to monitor and adjust flow rate using the T-connectors.
9) After all samples have passed completely through the cartridges, rinse each cartridge
with 6 mL LGW at least twice to remove salts remaining in cartridge.
10) Let the cartridge dry for 5 minutes with a vacuum pressure of 15 - 18 mm Hg, or push
3 syringe volumes of air through each cartridge.
11) Turn off vacuum and remove each cartridge from the manifold.
12) Tap cartridges on bench surface to get rid of any extra water.
13) Clean SPE tubing: use tubes designated for cleaning tubing (in a labeled plastic bag
in drawer). Put them on each of the valves used, connect tubing to the top. Get two
beakers, one for LGW and another for wash MeOH. Apply a vacuum and suck LGW
through tubing, followed by methanol. Keep the vacuum on until tubing is dry. Place
tubing back in SPE drawer.
14) Rinse MeOH through each orange valve on the manifold that was used (where each
cartridge was connected).
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15) Wipe off water on the underside of the manifold cover.
16) Dry inside of manifold by first applying vacuum and tilting manifold, and then
wiping off remaining water with paper towels.
17) Pour extraction waste into sink.
3. Elution
(~ 15 minutes)
Note:
- Use acidified MeOH (0.1% formic acid in MeOH) prepared no more than 1 week prior
to extraction because formic acid may evaporate over time
1) Locate ~10 mL conical vials (1 per sample) and one Teflon-lined cap for each tube
******* Make sure that filter syringe can fit into the test tubes first ********
2) Label test tubes to match sample I.D.
3) Place white plastic rack inside the manifold
4) Place cartridges on the manifold without T-adaptors (try to put them in the same
position as for extraction)
5) Place conical test tubes into the rack according to the corresponding labels
6) Add 2 mL of acidified MeOH to each cartridge using a 10 mL pipette, allow to pass
through the cartridge by gravity, and refill (do this 4 times for a total of 8 mL elution
volume for each sample)
7) If necessary, apply some pressure with air-filled syringe or apply some low vacuum
pressure to initiate the elution process (for the first 2 mL ONLY)
8) At the end of elution, apply vacuum pressure to pull through the last drops of the
eluting solvent out of the cartridge
9) Place used cartridges in labeled and sealed bag in Freezer D. Do NOT throw away
cartridges until all analyses are complete.
2.4 Solvent reduction
Notes:
- This process takes ~ 2 hours
- Can begin to set up blow down during elution
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2.4.1 Blow down procedure
1. Place all test tubes with SPE eluent into a beaker and bring it to the blow down setup.
2. Get small plastic blow-down tubes from the drawer under the blow-down apparatus.
3. Check the nitrogen tank in advance (to make sure there is enough nitrogen head to use
for blow down) by opening valve on top of the tank and checking to see if the pressure is
> 500 psi. Stop using the nitrogen tank after its pressure drops below 500 psi.
4. Set the heating block at “low temperature” at 4 ~ 5 (closer to 5), which means the
temperature will be between 40 and 50 deg C. Fill holes at least half-way with LGW.
5. Wait ~ 5 minutes for the block to heat up.
6. Connect tubes to the top (number of tubes = number of samples, close the unused ones
with metal cap).
7. Place conical vials in the heating block. Place
8. Lower and secure the top.
9. Put the plastic tubes into the conical vials and make sure that the plastic tubes are
above the liquid surface of the SPE eluent.
10. Open the nitrogen tank and adjust the flow rate so that the nitrogen blows gently with
minimum disturbance to the eluent.
- More samples necessitate higher flow rates because the pressure is distributed
over open valves – for example, for 4 samples the pressure was ~ 10 – 15 psi.
- Pressure is measured by left gauge and is regulated by adjusting the two valves
on the left of the tank.
11. Pull the moveable snorkel above the blow-down apparatus down as low as possible.
12. Wrap aluminum foil around sample test tubes to prevent photolysis.
13. Check the liquid level in the conical vials approximately every 15 minutes, and lower
the top if necessary as the liquid evaporates.
14. Add 50 μL of LGW/ methanol (9:1) mixture to an empty conical test tube using the
designated syringe located in the drawer to the left of the LC-MS/MS. Cap with Teflon-
lined cap. This vial will is labeled as the solvent blank + internal standard (internal
standard is added later).
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15. Blow down SPE eluents to ~ 50 μL in the conical vial. Visually compare to the
solvent blank prepared in previous step. NEVER blow down to dryness!
16. After the desired volume is achieved, turn off heating block and close the nitrogen
tank.
17. Clean tubing with wash MeOH and place on a Kimwipe to dry. After they dry, place
them back in the designated drawer.
2.4.2 Reconstitution
1. Estimate the residual volume of SPE eluent by visually comparing to solvent blank +
I.S. conical vial:
a) If the estimated sample volume is > 50 μL, make another solvent blank in a separate
conical vial with 70 μL of LGW/methanol solvent mixture, and try to estimate the level
of the sample (it might be ~ 60 μL).
b) Record estimated volume on the label of each conical vial.
(Note: the sample extract after blow down often looks slightly yellow due to the presence
of natural organic matter in water).
2. Rinse the 500 μL syringe that is located in the drawer to the left of the LC-MS/MS
with HPLC-grade MeOH three times.
3. Fill a 10 mL beaker with LGW/MeOH solvent mixture (9:1).
4. Reconstitute each sample to a final volume of 250 μL with the LGW/MeOH solvent
mixture (9:1) using the 500 μL syringe starting with the unspiked samples and then
moving on to increasing spike levels. Add reconstituting solvent above the liquid level of
the sample and avoiding touching the sides of the conical vial. If syringe does not touch
sides of conical vials, then it does not have to be rinsed in-between reconstituting each
sample.
5. Rinse syringe with wash MeOH after reconstitution of all samples.
2.4.3 Addition of internal standard simatone
1. Clean the designated 10 μL syringe (located in the drawer to the left of the LC/MS-
MS) with HPLC-grade MeOH three times, and then pull up 10 μL of internal standard
(I.S.) solution at 1.25 mg/L (see Section 1.2.2) and discard to waste at least three times.
2. Add I.S. solution to each sample and into solvent + internal standard blank conical
vials.
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1) Add 10 μL of 1.25 mg/L I.S. solution to each conical vial (if the volume in each
conical vial is not 250 μL, then the volume to add needs to be recalculated).
Technique:
a. Draw I.S. solution slowly into the 10 μL syringe making sure that no air bubbles are
drawn up (if air bubbles are present, put the solution in the syringe to waste and try
again).
b. Inject I.S. under the eluent surface in each conical vial. Add I.S. solution from
unspiked sample to spiked samples with increasing concentration.
c. Re-cap vials after I.S. injection and place back in test tube rack.
d. Rinse syringe needle with wash MeOH and dry with a Kimwipe between every
injection.
3. Vortex each sample using the vortexor (Thermolyne Maxi Mix Plus, model #M63215).
4. After vortexing each sample, slowly turn conical vial around to cover the surface area
of the conical vial with the extract liquid that was not reached by vortexing (sometimes
there are solids stuck to the vial).
5. Let each sample sit for 10-15 minutes covered with aluminum foil in a vial rack to
allow liquid settle to the bottom of the vial.
2.4.4 Syringe filtration of sample extracts
1．Preparation:
a) Gather a vial rack and autosampler rack, 250 μL glass inserts, 2 mL amber autosampler
vials, and Teflon-lined plastic screw caps
b) Label each autosampler vial with sample ID, name, and date.
c) Place a glass insert into each vial.
2. Syringe filtration of extracts:
a) Locate 0.45 μm pore size syringe filters from the LC-MS drawer
b) Use the 500 μL syringe to slowly draw sample from conical vial starting with samples
of increasing concentration.
c) Measure the total volume to verify that it is ~ 250 μL and record in lab book.
d) With sample still in syringe, unscrew the needle and attach a syringe filter.
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e) Slowly push sample through the syringe filter directly into the glass insert in the
labeled autosampler vial.
****Be careful when pushing sample through syringe filter. If pressure increases too
much, the filter may pop and the sample extract may be lost.****
The syringe filter can be changed for a new one by pulling up air with syringe to pull out
any liquid in the actual filter. Then replace the old filter with a new one and continue to
push the sample through.
f) After sample is filtered, take filter off the syringe, draw in air, re-attach the filter, and
push the remaining sample into the vial.
g) Close the vial with appropriate cap.
h) Tap the vial to get rid of bubbles in the insert.
i) Rinse syringe twice in-between each sample using the LGW/MeOH solvent.
j) Repeat steps 1 – 10 for each sample.
Cleaning: rinse syringe 3 times with LGW/MeOH solvent, then rinse syringe with HPLC-
grade MeOH. Remove the plunger and unscrew the syringe and rinse each with wash
MeOH and place on a KimWipe to dry.
Autosampler vials with extracts can be stored in Freezer D until LC-MS/MS analysis.
2.5 Overall clean-up:
1. Collect all dishes/parts/tubes/etc. in a plastic bucket and fill with tap water and
soap mixture (by the sink) if dishes are not to be immediately washed.
2. Pipettes:
a) Rinse with tap water and then with LGW, inside and outside
b) Rinse tips and the whole pipette with wash MeOH over a waste bucket
c) Place a large KimWipe or paper towel inside a clean, plastic bucket and then
place the pipettes in the bucket to dry overnight.
d) Place a label on the bucket with your name and date.
4. T-adaptors: rinse with LGW and then wash MeOH and put back in beaker in the SPE
drawer
5. Amber bottles (don’t need to be acid-washed if it is cleaned right after use):
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a) Wash bottles in dishwasher in MHRC Room 1206 on setting 3. (If not trained in use
of the dishwashers, then seek out someone who knows).
b) After the dishwashing cycle is complete, submerge amber bottles in 10% nitric acid
bath in the teaching lab (MHRC Room 1204) for about 6 hours. (Must know how to use
acid bath before using).
c) After soaking in the acid bath, carefully remove the bottles following the proper
protocol and place in a clean plastic bucket. Take the bucket back to MHRC Room 1210
and rinse each bottle 3 times with LGW.
d) Place amber bottles in oven overnight to dry. After completely dry, cover openings
with aluminum foil and put back in proper storage cabinet.
6. Caps: soak in 500 mL beaker with a mixture of LGW and soap for a few hours. Rinse
with LGW three times, and then rinse with wash MeOH, then place on a KimWipe to
dry.
3. LC-MS/MS analysis
3.1 Equilibration of LC system
1. Check mobile phase levels (make sure there is at least 3 inches of liquid in bottle, and
if not enough prepare more).
-mobile phase A: 0.1% formic acid in LGW (2 mL formic acid into 2 L LGW, filtered to
0.2 µm nylon filter)
-mobile phase B: Acetonitrile (filter with 0.2 µm nylon filter)
2. If the mobile phase bottles are changed, the user needs to remove the air bubble as
described below and then prime the system.
1) Connect a 10 mL plastic syringe to the mobile phase A fitting under the degasser
(tubing is labeled as A or B).
2) Switch T valve so it is facing to the left to open it.
3) Slowly pull out mobile phase to get all of the bubbles out. Close the T-valve before
removing syringe, and then discard any mobile phase solution in syringe to a waste
bucket.
5) Repeat for mobile phase B.
Priming:
This needs to be done when the pumps have not been used within ~ 24 hours.
1) Open black B valve at the bottom of the pump station to divert the mobile phase to
waste
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2) Prime pump A first.
3) Push “Stop” on the pump screen
4) Push “Prime”, and then set the flow rate (do not exceed a flow of 5 mL/min; 1 mL/min
is a good flow rate). Pressure should be around 330 – 400 psi. If pressure is much
higher, stop priming and check that black B valve is open. If pressure continues to
increase, there may be a blockage in the tubing.
5) Prime for ~ 2 minutes
6) Push “Stop” again
7) Repeat process for mobile phase B (pressure should be around 220 psi)
8) Retighten the black B valve to return mobile phase to column (also important!)
3. If the instrument has been used within 24 hours: before starting the pumps check the
mobile phase lines to make sure there are no air bubbles. If there are air bubbles, prime
the system until they are removed.
4. Flush the system as described below if there has been user change or the LC-MS has
not been used for more than one week:
Flushing:
1) Unscrew tubing from the column and cap column ends with end caps found in LC-MS
drawer
2) Connect red tubes directly using a union (found in LC-MS drawer)
3) On the main window, open file  activate method  go to methods directory
under Varian WS  methods folder  select “flushing” method  open
4) Maximize the Prostar/Dynamax window to monitor the flow rate and mobile
phase composition (leave in inject position to prevent corrosion to interface)
5) Flush for about 5 - 10 minutes
6) Maximize Prostar/Dynamax window again
7) Click “Stop Pumps” to stop flushing
5. Wash autosampler needle – do this every time before injecting samples
1) Open auto sampler window 430.25
2) Click “Wash” and do this twice
3) Minimize window
6. Attach LC guard and analytical column: Pursuit C18 (15 cm, 2.0 mm, 3 μm)
1) Make sure the guard column is tightly connected to the analytical column
2) Attach in the direction of flow (guard column on left)
3) Tape column down to secure
4) Put the caps in a plastic bag in the drawer
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7. Check to see if shield inside electrospray chamber is clean, if not:
1) Moisten Kimwipe with LGW and wipe shield, ensuring that no water enters the MS
2) Repeat with methanol
3) Clean needle tip with methanol
3.2 LC-MS/MS analysis
Method Activation
-The 26 antibiotic analytes are separated by three different LC runs, which means that
each sample extract is injected at least 3 times
-The three different LC runs are based on combining analytes of similar structure and
must be independently run
-The order of analysis is sulfanomides/macrolides (SAMA)  fluoroquinolones (QL) 
tetracyclines (TC)
Note: The windows control the instrument components as follows:
- Prostar/Dynamax.24  LC
- 430.25  Autosampler
- 1200.42  Mass Spec ESI
- Prostar 430  Sequence
1. Click the view/edit method button on the top of the screen
- Open an existing method
2. Make configuration adjustments to the method (should not be necessary if nothing has
changed).
- For the SAMA method:
- Click on configuration tab on the left
- Adjust needle height to avoid breaking the needle:
- For 250 μL inserts, set the needle height at 6 mm
- For 50 μL inserts, set the needle height at 10 mm
- Needle height measures the distance from the bottom of the vial
up to the tip of the needle (ie a needle height of 10 mm will not
go as far into the vial as a needle height of 6 mm)
- Save the method every time you make any change
- May also need to change the needle tubing volume (ntv)
- Check ntv value listed on configuration tab
- Check ntv value on 430.25 (subwindow of system control)  hardware  ntv
- If the values are not equal, adjust the hardware value to be
consistent with the value on the configuration tab in the method
3. Check MS settings:
- On the “Scan method” window (under Method Window) select:
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- ion source: ESI
- mode: centroid
- CID gas: on
- polarity: positive
- Save method and close
4. Activate method
- System Control Window  Mass Spec subwindow  File  Activate method  open
method
- Note: if unable to activate, go to Automation  Stop Automation and try again
- Minimize the main screen
- Open the LC Prostar screen
- Watch the pressure increase until it reaches and stabilizes at ~ 1800 -2000 psi
5. Set up a sequence
- File  new sample list  Varian WS  data  Your Name  create new folder and
label using whichever labeling method is best for you
- Enter sequence parameters:
- Sample name: solvent blank, etc
- Injection mode: μL pickup
- Injection volume: 20 μL
- Well vial: begin with A1 (wherever the vials are placed in the rack)
- Click on Data File (bottom right) and save data under the user’s directory
Note: the first sample should always be solvent blank. Make 2 or 3 injections of solvent
blank to equilibrate the LC column and to check for contamination. If there are any
peaks on the chromatogram at the retention times of the analytes (indicating
contamination), continue running solvent blank samples until there is no more
contamination.
Every few months, make a 10 µg/L test solution of the antibiotic mixture and analyze
using the three methods to determine if the retention times have shifted.
6. Set up instrument parameters and turn on the ESI-MS (before you start the sequence)
- Open N2 dewar all the way
- Select API auto on main screen
- drying gas temp at 300ºC
- API house temp at 50ºC
- Click OK
- Click icon with green arrow in the upper left to turn on electrospray
- Wait until drying gas temperature gets to 160ºC, then click “turn on the
instrument” icon to turn on the detector (when the light is green, it is on). Wait
until the temperature stabilizes before starting the sequence
- Make sure the MS valve is in the “Load” mode
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7. Last minute checks (before you start the sequence)
- Make sure samples are in the autosampler tray with the correct vial number on
the sequence
- Make sure samples have come to room temperature after being removed from the
freezer
- Check that the clear glass solvent vial (called transport vial) behind the rack is
full of the reconstituting solvent (90% LGW 10% MeOH)
8. Start sequence
- Return to Prostar 430 sequence window  click begin on bottom left  click
Ok
- Each run takes ~ 30 minutes
9. Check the chromatograms of the solvent blank to see if there is contamination
10. If there is NO contamination, add all samples to the sequence following the same
scheme in step 5 above
11. After putting all samples in the sequence, activate the second method by browsing the
method in the method files
Sample type: Activate method
Auto link: select method
12. Repeat the sample sequence for the second method
13. At the end of the whole sequence, put in one line saying:
Sample type: Activate method
Auto link: methods  ZY  stop run (use only if the run stops at night or when no one
is around to turn instrument off)
4. Data Analysis
4.1 Integration of analyte peaks
4.1.1 Manual integration
Software: Varian WS Work station 6.8.
Notes: targeted analyte ions must be integrated separately
1. Click on the Review/Process MS Data button
- Find data file
- Open chromatogram on the screen; an ion list will show up on left and the
chromatogram for each ion breakdown will appear by clicking on it
Note: the second product ion column is used for confirmation of detection of the analyte
(if the ratio of the areas of the two product ions listed in the 1st and 2nd column,
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respectively, is within a certain range, it confirms the detection of the analyte – the ratio
varies depending on individual analyte)
3. Adjust chromatograph
- Right click on chromatogram  select local chromatograph plot preferences 
chromatogram plot  under filtrating  smooth data (points 5 or 7) AND remove spikes
 OK
4. Zoom in to enlarge peak
- Adjust x axis by dragging mouse along axis
- Adjust on y axis by just clicking
5. Integrate peak
- Select “set click and drag action”  integrate area
- Draw a straight line along the base of the peak
- Enter area and retention time into Excel
4.1.2 Automated integration
Create a quantitation method
1. Create a new method (create new method  next  finish)
2. Select the file that you want to analyze (on left MS Data handling compound table)
3. Click “add” to add the number of ions you want to integrate (two ions for one analyte),
so 20 ions need to be integrated for 10 analytes
4. Double click retention time column header to get total ion chromatogram
5. Zoom out a specific peak to make it larger
6. Name the ion (eg. Sulfamethoxazle-156)
7. On quantum ions tab select scan channels (under merged) and select the target ion
8. Under integration tab, set integration window at 3.0 min, under “filter peaks” smooth
the chromatogram with a factor of either 7 or 5 and set the “remove spikes” at a factor of
5.
9. If the integration peak looks weird, adjust the peak width and slope sensitivity to
improve
10. Under identification tab, select retention time with search time +/- 0.5 min
11. Select close
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12. For confirmation, peak areas of both fragment ions for each analyte are needed
13. Continue for each ion, adjusting peak width and slope sensitivity if necessary
14. Save method in methods subfolder
Data processing using the quantitation method
Advantage: this method is more accurate than the manual integration method and the data
files can be copied to Excel and saved
1. Open the chromatograms folder
2. Double click to open the chromatograms
3. Select one file  quantitation  process active folder
4. Under methods folder, select a representative method to process the data with
5. Click “process” to analyze data file with the method
6. Click “view results”
- For EACH peak draw a line from beginning to the end of the peak and click
“integrate”
- If the integration is not correct, need to edit method to adjust parameters. Save
the method each time it is updated
- Click “done” after adjusting each
7. Save method changes if you want (usually a good idea)
8. Save the integrated data file: Print  sample report (ASCII)  folder data file, name
as sample ID and save it so it can be opened and saved by Excel
4.2 The method of standard addition
1. Integrate the peaks of a specific analyte and the major targeted breakdown ion of I.S.
(m/z = 198 > 128) (either by manual or automatic integration)
2. Set up an Excel Spreadsheet with rows or columns for spike amount (ng/L), simatone
(I.S.) Area, and analyte Area
3. Calculate relative area = Area of analyte/area of I.S.
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4. Build two calibrations (one with 0-1 sample and the spiked samples, the other with the
duplicate nonspiked sample (0-2) and the spiked samples) – Area (y) versus
concentration (x)
5. Extrapolate to get the absolute value of x when y = 0
6. These two values are the concentrations in the original sample from duplicate
measurements – average the two values and calculate the relative percent of difference
(RPD) using the formula below. Use two significant figures.
 
 
100
221
21(%) 



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xxRPD
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Appendix B: Yeast Estrogen Screen (YES) Assay Protocols
This protocol is modified from Routledge and Sumpter 1996 Environmental Toxicology
and Chemistry 15 (3): 241-248. Modifications include the use of plate-grown cultures to
inoculate liquid media, less dilution of the growth culture into the assay medium and
increased CPRG concentration. They yeast strain used for this YES-assay are the human
estrogen receptor (hER) transfected Saccharomyces cerevisiae provided under agreement
with Prof. J.P. Sumpter at Brunel University, UK. The modified SOP was written by
Chad Roper and Ben Stanford.
Materials
Spectrophotometer (Visible Range)
96-well Plate Reader (Molecular Devices, EMax)
Shaker table
125 mL sidearm flask with metal cap
125 mL culture flask with metal cap
100 mL beaker
1 L or more screw top glass bottle
4 x 250 mL or more screw top bottles
Disposable sterile syringes with luer lock tip (60 mL)
Sterile syringe filters (0.2 m for filter sterilization), disposable
Disposable filter sterilization flasks
Disposable sterile petri plates
Disposable sterile 96 well plates
Disposable sterile 96 well plate covers
Parafilm
10 mL sterile pipets (with pipet bulb)
V shaped wells for multichannel pipetting (autoclavable) with cover
8 Channel Pipettor (250 L) and tips
Pipettor (20 L) and tips
Aluminum foil
Autoclave tape
Ethanol (EtOH), high purity (denatured is ok)
Solutions:
 500 mL solution of D-(1)-glucose 20% w/v solution
 100 mL solution of L-aspartic acid 4 mg/mL solution
 100 mL of L-threonine 24 mg/mL
 25 mL 20 mM copper (II) sulfate solution
 10 mg/mL stock solution of chlorophenol red-ß-D-galactopyranoside (CPRG) in
LGW
 100 mL solution 0.8 mg/mL solution of Fe2(SO4)3
 100 mL solution of 0.02 mg/mL solution of biotin
 25 mL solution of chloramphenicol at 25 mg/mL (dissolve in ~2-3 mL EtOH first,
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then add sterile water to 25 mL)
 10 mg/L estradiol (E2) in ACN (for positive control row in assay)
o 38 L of 10 mg/L E2 working solution diluted to 10 mL EtOH
Minimal Media
Amounts are per liter LGW. The solution should be autoclaved at 121C for a minimum
of 15 minutes, and then stored at room temperature. In the event of precipitation during
autoclaving, filter sterilize the solution into 500 mL sterile flasks.
• 13.61 g KH2PO4
• 1.98 g (NH4)2SO4
• 4.2 g KOH
• 0.2 g MgSO4
• 1 mL Fe2(SO4)3 solution (1 g/L)
• 50 mg L-leucine
• 50 mg L-histidine
• 50 mg adenine
• 20 mg L-arginine-HCl
• 20 mg L-methionine
• 30 mg L-tyrosine
• 30 mg L-isoleucine
• 30 mg L-lysine-HCl
• 25 mg L-phenylalanine
• 100 mg L-glutamic acid
• 150 mg L-valine
• 375 mg L-serine
Vitamin Solution
Amounts below should be added to 180 mL LGW, then the solution should be filter
sterilized into a sterilized screw top bottle and stored at 4C.
• 8 mg thiamine
• 8 mg pyridoxine
• 8 mg pantothenic acid
• 40 mg insitol
• 20 mL of biotin solution
Sabauroud’s Dextrose Agar with Chloramphenicol
Amounts given are per liter LGW. The solution should be autoclaved at 121C for a
minimum of 15 minutes, allowed to cool to 60C, and then be poured into sterile plates in
aliquots of 15 to 20 mL. Once the agar has set and cooled completely, the plates should
be stored at 4C in plastic Ziploc bags for up to one year.
• 60 g Sabourad’s Dextrose Agar (Difco)
• 3 mL chloramphenicol solution (available as 25 mg/mL)
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Propagation and Storage of Yeast Strain
Every two weeks (4 weeks maximum), a single colony should be selected from the
current agar plate with the YES-human estrogen receptor (hER) culture and that colony
should be streaked out on a new agar plate using proper technique. Agar plates should be
wrapped in Parafilm after the colony has been streaked.
The new agar plate should be grown for 48 to 72 hours at 30C and then stored in a
refrigerator at 4C. This then becomes the current agar plate for use.
In the event that the assay ceases to work due to the selection of a revertant colony of
yeast incapable of responding to estrogenic compounds, the previous plate can be used
for an inoculum and new streak plate. Dispose of old plates after 3 generations of
colonies have been streaked onto new plates.
Assay Protocol (Day 1)
Preparation:
 Light Bunsen burner and work within a 1 foot radius to ensure sterility of minimal
medium.
 Add 45 mL minimal medium to sidearm culture flask using a graduated cylinder,
and put cap on. Label with autoclave tape. This will be the flask that grows the
stock colony culture. Create one of these for every 8 flasks that will be inoculated
(see chart below).
 Add 45 mL minimal medium to culture flask and put cap on. Label with
autoclave tape (use the chart below to determine the number of these flasks that
will be needed).
# of 96-well plates
needed
# of culture flasks needed # of stock colony side-arm
culture flasks needed
2 1 1
4 2 1
6 3 1
8 4 1
10 4 2
12 5 2
14 6 2
16 7 2
18 8 3
20 8 3
22 9 3
24 10 3
 Wrap 100 mL beaker in aluminum foil.
 If pipette tips are not sterile, place pipette tips in box/rack, and label with
autoclave tape.
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 Wrap V-shaped well for multichannel pipetting and cover in foil (if not already
sterile)
 Autoclave all of the above items at 121C for 15 minutes on the liquids cycle.
 While hot, move all autoclaved items into biosafety cabinet and allow to cool.
 Light Bunsen burner and work within 1 foot radius to ensure sterility of solutions.
Mix the following in the sterile 50 mL beaker using sterile pipettes. If sterile
pipettes are not available, briefly wave the pipette through the flame of Bunsen
burner to sterilize. *Note: amounts are per 45 mL minimal medium to be
inoculated!
 5 mL glucose solution
 1.25 mL L-aspartic acid solution
 0.5 mL vitamin solution
 0.4 mL L-threonine solution
 125 µl copper (II) sulfate solution
 Draw this mixture into the 60 mL sterile disposable syringe and attach the syringe
filter. Note the volume. Dispense the appropriate portion of the solution into one
of the sterile minimal medium sidearm flasks aseptically (flame both the tip of the
filter and lip of the flask). Add the remaining volume to each of the remaining
flasks. The volume will be approximately 7 mL added per flask. Remember
to flame lips of glassware and lids before putting caps back on.
Inoculation of Growth Medium
 Remove current streak plate of hER culture from refrigerator.
 In biosafety cabinet, remove Parafilm from plate.
 Flame loop the full length that will extend into the culture flask. If no loop is
available, melt the end of a glass Pasteur pipette (when end closes, it’s sterile).
 Select a single colony from the plate.
 Remove the lid.
 Touch loop to blank agar surface to cool it. Remove single colony from plate
with loop. Immediately replace the plate lid.
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 Open sidearm flask, flame the lip of the flask, and insert the loop with the colony
into the media. Try not to touch the sides of the flask. Stir media with loop to
remove colony. Remove loop from flask, flame the lip of the flask and cap the
flask. Flame loop again.
 Put inoculated culture sidearm flask and other culture flasks into 30C warm
room on shaker table (approximately 100-130 rpm on continuous mode) until its
optical density reaches ~1.0 (approximately 18-24 hours). The OD640 is often at
about 0.6 to 0.8 after 24 hours, depending on the size of the colony used to
inoculate the stock culture. The lower O.D. solutions still work just fine in the
assay with no impact on sensitivity. Just add a bit more of this culture in the step
below (e.g. 8 mL is fine for 0.6 O.D.). If, however, an OD640 of 0.6 has not been
reached within 24 hours, discard the solution and start over.
o The UV spectrophotometer is in Dr. Aitken’s laboratory in MHRC. Turn
on UV spec, open UV Spec Software. Select ‘Spectrophotometer’ on
upper tabs, then ‘Set Wavelength’, select 650 nm. Hold cap onto sidearm
flask and carefully insert arm into cuvette holder; be very careful not to
spill any of the growth medium.
Preparation of Assay Plates (Day 2)
 Prepare fresh E2 working solution in EtOH in (38 L in 10 mL EtOH from 10
mg/L E2 solution in ACN) volumetric flask from stock solution stored in freezer.
This will be used for the positive control, row 1 on 96-well plates.
 In biosafety cabinet, cut open 96 well-plate and cover with sterile lid, label both
plates and lids with a number and place lids on plates and set aside.
 For EtOH-based samples:
o Pour some HPLC-grade EtOH into a small beaker. Draw up 3 volumes of
EtOH with syringe and discard to waste.
o Add 20 L of E2 standard with syringe to the first two wells of row 1.
o Clean syringe with HPLC-grade EtOH.
o Add 20 L of EtOH to first two wells in row B.
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o Samples will be plated in duplicate (i.e. two rows for 1 sample). Add 20
L of sample 1 to first two wells starting with row C. Add 20 L of
sample 1 to first two wells to row D.
o Repeat for subsequent samples, plating each sample in duplicate and
cleaning syringe with EtOH in-between samples.
 Each row can be sequentially diluted with EtOH across the plate such that the
effective volume of starting solution is decreased by half in each well. Pour some
EtOH into a V-shaped well, set micropipettor to 20 L, and put on sterile pipette
tips. Pull up 20 L of EtOH. Start at column 10 and inject 20 L of EtOH into
the left corners of each well in each previous column, stopping at column 2. The
volume in the wells in column 2 will now be 40 L.
 Pick up 20 L in column 2 and mix 3-4 times by pulling the volume up and
blowing it out. After mixing, pick up 20 L and inject it into column 3. Mix up
column 3, pick up 20 L, and blow out into column 4. Repeat the process until
20 L is in the wells of column 11. Leave column 12 empty!
 One row of negative controls (EtOH) and blanks should be included on each
plate. Leave the last column (column 12) on the plate completely empty as a
“blank” calibration for the plate reader. Allow solvents to evaporate completely
by placing the plate (uncovered) in the laminar flow cabinet for 30 to 60 minutes.
Once dry, cover with lid until ready to inoculate with yeast.
 For aqueous samples:
o The same dilution scheme as the EtOH-based samples should be used
without the added evaporation step. In the steps below where the assay
medium is added, adjust volume to 230 L instead of 250 L used with
the evaporated EtOH samples.
Dilution for Assay (after EtOH is evaporated)
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 Into each flask to be used for the assay, add 0.5 mL of the 10 mg/mL sterile
CPRG solution (10 mg of CPRG into 10 mL LGW). Solution in the culture flasks
will turn yellow.
 Using a disposable, sterile 10 mL pipette, collect 5 mL (or the appropriate volume
given the actual OD – a greater volume if OD is < 1.0) of the OD 1.0 culture in
the sidearm flask and aseptically (flame the exterior of the pipette containing the
culture briefly and flame the lip of the culture flask containing the assay medium)
transfer that volume to a culture flask.
o If using more than 1 culture flask, pour all of the solutions in the culture
flasks into one culture flask to create a homogeneous mixture.
 Flame the lip of the culture flask again and cap the flask.
 Mix the culture in the flask gently for approximately 1 minute.
 Open the foil on the V-shaped well for multichannel pipetting.
 Open the cap on the culture flask and flame the lip.
 Pour the dilute culture into the V-shaped well.
Assay
 Change volume on micropipettor to 250 L. Dispense inoculated assay solution
250 L per well in the 96 well plate from V-shaped reservoir using the 8-channel
pipettor and sterile pipette tips. (Use only 230 L if working with aqueous
samples!).
 Completely cover plate with Parafilm (about 2.5 lengths). If plate is not
completely covered, the liquid in wells will evaporate and the evaporated wells
cannot be used in the dose-response curve.
 Cover plate with lid and press down. 96 well plate wells should be sealed by
Parafilm.
 Tap side of plate to mix well contents.
 Put plate(s) in 30C warm room on counter.
Reading the Assay
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72 hours after inoculation, the plate(s) can be read (though an additional 24 hours may be
needed for full color development). The plate reader is in Dr. Nylander-French’s
laboratory on the 3rd floor of MHRC. Turn on plate reader, the password to the computer
is leena123$!, open Shortcut to SPF. Select ‘Experiment’, then ‘New Experiment’.
Open the template and select which wells contain the standard, which contain samples,
and which are blanks.
The lid and Parafilm should be removed and the plate inserted into the plate reader.
Select ‘Setup’ and ‘Set Wavelength’ to measure absorbances at 562 nm (have to select
570 nm though) for chlorophenol red and 650 nm for turbidity should be recorded. Blank
wells must be included in each plate as the software automatically corrects the remaining
wells based on the absorbance of the empty ones. Data should be saved by date and plate
number and then exported as a text file using the software export tool (File > Export . . .
). Remember to bring a usb key to take data off computer. Remember to close
software and turn off instrument when finished.
Data imported in Microsoft Excel should be manipulated as follows:
To obtain the plate reading that corrects for turbidity caused by the assay, subtract A650
from A570. If multiple experiments are compared and the data need to be normalized, the
relative absorbance (R) could also be converted into logistic form: R = [(A562 – A650)-
min(A562-A650) / [Max(A562 – A650) – min(A562-A650)], where “Max” is the maximum
response for a given row of samples and “min” is the minimum response for a given row
of samples. Simple sigmoidal dose-response plots can be created by placing the
concentration on the x-axis with the absorbance (or relative abasorbance) on the y-axis.
In order to compare the results, the concentration which elicits 50% of the maximum
response (EC50, also known as ED50) needs to be estimated for each compound and/or
sample tested. This can be done by regression of the data according to the dose-response
equation:
!Syntax Error, + y = min + [(max – min) / (1 + 10 (log EC50 – x)Hillslope]
where min = minimum corrected response plateau
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max = maximum corrected response plateau for E2
y = response
x = log concentration
hill slope = slope of the sigmoidal dose-response curve at its midpoint
When the percent relative response is used, note that min = 0% and max = 100% for 17-
estradiol (E2). E2 is used as the standard reference compound for this assay and the
maximum absorbance value is taken from the E2 control samples (Huber, Ternes et al.,
2004). Each plate should theoretically have its own E2 “calibration curve” for proper
reference.
The EC50 is used to compare relative estrogenicity for each compound/sample tested. For
samples with unknown concentrations of estrogens, concentration is replaced with the
concentration factor (relative to extraction from original sample). The hill slope taken
from the E2 curve is used as a constant hill slope for the unknowns. E2 equivalents
(EEQs) are expressed as EC50 for E2 / EC50 for the unknown.
For information on data manipulation using R-software, see Appendix C.
A note about data analysis: The original Routledge and Sumpter (1996) paper as well as
several current papers use a simple 50% of maximum response estimation (e.g. draw a
line at the 50% response and find where this intersects on the graph, then determine the
corresponding x-axis concentration). Though this method has been accepted in peer-
reviewed literature, it does not allow for calculation of statistical variation and confidence
limits within data sets. By using the dose response equation, 90% (or higher) confidence
intervals can be calculated for the EC50 and subsequent EEQs.
Clean Up
 All plates that have been inoculated (or that came in contact with yeast) should be
autoclaved prior to disposal.
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 All culture media that has been inoculated should be autoclaved prior to putting
them down the drain.
 All glassware should be soap and water washed. Any glassware that has been
acid washed should be rinsed with lab grade water and dried prior to use in this
protocol.
 All disposable items that have had contact with media containing inoculated
culture media should be autoclaved prior to diposal.
Routledge, E.J. and J.P. Sumpter (1996). Estrogenic activity of surfactants and some of
their degradation products assessed using a recombinant yeast screen. Environmental
Toxicology and Chemistry 15 (3) pp. 241 – 248.
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Appendix C: Instructions for Working with YES Data in R
2.4.0
In order to minimize the difficulty of working with a programming language like R 2.4.0
the following set of instructions have been prepared for the specific analysis of data
generated by the yeast estrogen screen (YES) assay. Sections of these instructions were
generated by Prof. Nina Cedergreen of Aarhus Unviersity, Denmark and were presented
in the workshop “Statistical Assessment of Dose-Response Curves with Free Software”
presented at the SETAC Montreal Conference, November 2006. The original
instructions were for general dose-response curve and have since been modified in this
research project to be specific to dealing with the YES assay. The original instructions
were provided by Dr. Cedergreen with permission to use and modify as needed. As such,
they are being included as an appendix to this dissertation with acknowledgement to Dr.
Cedergreen and her colleague, Christian Ritz, who co-designed and led the workshop.
1. Software Installation
Assuming that the necessary software has been provided, double-click on the file R-
2.4.0-win32.exe and install on the local computer. Follow all screen prompts.
Once installed, two packages must be installed to add functionality to the program for
working with dose-response curves. On the upper tool bar click Packages > Install
package(s) from local zip file… From there navigate to the folder from where R was
installed and select plotrix_2.1-1.zip and drc_1.0-5.zip. Install each of those packages
and follow screen prompts.
If the R software is not available it can be downloaded from http://www.r-project.org/ .
Once it has been installed, the “drc” and “plotrix” packages can be downloaded under the
Packages menu. Once downloaded, the installation instructions above can be followed.
2. Preparing Data in Excel for Export to R
There are two ways to import data into R from Excel: copy and paste from the clipboard
or directly import from a comma separated format (.csv) file. In general, data in Excel
need to be stored in .csv format, one worksheet only. Data also need to be in column
format: Column 1 heading = “concentration”; 2 = “curve”; 3 = “Response”; 4 = “Type”.
“Type” is another label for “curve”. The “curve” column should always have an
associated number with a given group of data within the sample set (e.g. 1, 2, 3, etc.)
while the “Type” column will be given names for each group of data within the sample
set (e.g. E2 Control, Sample Extract 1, Negative Ctrl, etc.). Note that everything in R is
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case sensitive. The column headings may be changed, just make sure to note the changes
and place the correct text into the program.
The easiest way to prepare data is to have an Excel document where the first tab or
“worksheet” is set up with the proper column headings. Once the data are in place and
the summary worksheet is active, select save as… from within Excel, choose the “.csv”
format, and give the file a new name (e.g. Data for Export to R.csv). The file is now
ready for manipulation in R.
Another way to move small bits of data into R is to use the clipboard. Here, the user does
not have to change anything to .csv format, but it is important to capture the column
headings. Without the column headings, R uses the default headings and will not
recognize the dose-response commands. Simply highlight the data with column
headings, and press ctrl-C to copy. The data is now on the clipboard for importing into
R.
3. R Start-up Commands and Data Import
From this point forward, all text in italicised, bold, Courier font can be directly copied
and pasted into R as a command line. The black text must be used as is. Any text
written in red can be changed to suit the name and/or functionality required by the user.
The red text could be broadly called “Dataname”. Use a period instead of a space to
separate words in the dataname.
The first step to using R for the analysis of dose-response curves is to load the DRC
package. This must be done every time the program is started. To load the DRC package
type:
> library(drc)
Once the DRC library is active, then data can be imported from Excel. For import of an
entire .csv file, type:
> YeastE2<- read.csv(file.choose(), dec=”.”, sep=”,”, header=T)
In the case of importing data from the clipboard, type:
YeastE2.Clipboard<- read.delim(file="clipboard", row.names=NULL)
The exact table or selection can be shown on screen by typing the dataname alone:
>YeastE2
The row.names=NULL gets around the error stating that each row must have unique
name. The
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command basically puts in a unique value for each row. For more information type,
>help(read.delim)
or type
>help(read.table)
To see a list data files associated with the workspace type:
>ls()
To clear the screen, press ctrl-L
4. Data Analysis and Generation of Results
There are many different models included in the DRC curve which can be used to
describe a dose-response curve. The user may access these through any of the help
commands or by referencing the “Statistical assessment of dose-response curves with free
software: Collection of examples” packet created by Christian Ritz and Jens C. Streibig.
The main model used for the YES assay is a four-parameter logistic model described by:
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where b = hill slope
c = lower limit
d = upper limit
e = EC50
In R, the four-parameter logistic function is named l4(). In the case where the user’s data
contains only one dose response curve, the program will fit a best-fit curve by typing
>model <- multdrc(Response ~ concentration, curve, fct=l4(), data = YeastE2)
The above command will work for multiple curves, but the error associated with the
curves is much higher than if they are treated singly. In the case where the data file
contains multiple curves, simply break the analysis into subsets for each curve:
>model.curve1 <- multdrc(Response ~ concentration, fct=l4(), data = subset(YeastE2,
curve == 1))
To view the numeric output of the results type
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>summary(model)
To view the results graphically type
>plot(model)
The “plot” command alone does not generally provide enough detail to adequately
interpret the data. For example, in the default “plot” settings data points below 0.01 are
shown as x=0 and subsequently are masked or do not show up on the graph. The line of
text input shown below will provide parameters for the most common changes necessary
for each plot. Note that the order of text within the parentheses does not matter. As such,
items may be moved out or added in to the parentheses as needed for each plot.
>plot(model, ylim=c(0,5), xlim=c(0,1000), conLevel=(0.0001), xlab=“Dose”, ylab
=“Response”, main= “Main Title”)
Explanation:
ylim sets the min to 0 and the max to 5 (or whatever values are entered); same for
xlim.
conLevel forces all values above the number entered will be shown as their true
value, not zero as in the default settings.
xlab, ylab, and main provide labels/titles for the plot
Other functions which can be added to the plot() command include:
Type = “points” shows all points instead of the average of points as in the default
legendPos=c(100,1)) fixes the legend at the desired x, y coordinates
add=TRUE allows the user to add multiple plots to the currently displayed plot
col=c(1,3,5,9) or col=TRUE adds colors to the plots. To get help on the
numerical values for color names, type help(plot) or help(col) or help(color).
ldw=c(1) changes the line width. Larger numbers make bolder lines; the number
defines the number of pixels used to create the line width.
lty=0 makes the model line disappear while still plotting the points (lty = line
type). The lty command can also be used to modify dash/dot and color
settings.
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pch=19 can be used to modify the point characteristics (e.g. change dots to open
triangles, filled triangles, squares, etc.). A full string of values can be
accessed in help(plot)
There are numerous lines of text towards the end of this document that describe different
things the user can do with the program and how to examine and manipulate the data. At
this point the instructions will focus on what to type in order to process a YES data set
with multiple curves and describe how to interpret the data.
The section of the model fit command line that is fct=l4() invokes the program to solve
for each parameter b, c, d, and e. In many cases it is desirable to force upper limits, lower
limits, and/or slope values based upon the behavior of the estradiol positive control
standard or samples of similar matrix and concentration. The command line needed to
change the fct=l4() model from the default settings to the user settings looks like this:
model.modified <- multdrc(Response ~ concentration, Type, fct=l4(fixed=c(NA, 0.1,
3.6, NA)), data = YeastE2)
OR,
model.modified.curve1 <- multdrc(Response ~ concentration, fct=l4(fixed=c(NA, 0.1,
3.6, NA)), data = subset(YeastE2, curve == 1))
The l4(fixed=c(NA, 0.1, 3.6, NA)) portion of the command line can be set to
l4(fixed=c(NA, NA, NA, NA)) in order to return to all default settings. “NA” specifies
default settings while numerical values specify user input. Each of the input parameters
within the parentheses refer to b, c, d, and e in order. Of course, “e” should never be
specified (since “e” corresponds with the EC50 value for which the program is trying to
solve). The lower limit (c) will rarely be zero since the lowest corrected response is
typically around 0.11 absorbance units. Similarly, the upper response (d) cannot exceed
4 (the maximum absorbance possible on from the plate reader) and is typically between
3.1 and 3.8. The hillslope (b) should be modified to reduce the standard error associated
with each line. Visually (using the plot() command) this corresponds to the fitted line
evenly splitting the data and passing through as many points as possible. Numerically
this corresponds with a decrease in standard error shown in the summary(model)
command. Both numerical and graphical data should be visually inspected to ensure a
proper line fit. The user may compare two model results using an ANOVA test to
determine statistical significance as follows:
>anova(model, model.modified)
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Please note that during the data analysis phase, if the user does not change/modify the
model name each time then the data from the previous model will be overwritten. This is
important when wanting to compare models and compare samples.
As data are processed, plots should be copied and pasted into a Microsoft Word
document. R does not have the option of uniquely naming each plot and then recalling
the plot later. Therefore, the plots should be saved as soon as they are generated. Plots
may be copied and pasted using the copy and paste commands in the edit menu. The user
may specify whether to export/copy as a windows metafile or as a bitmap image.
Similarly, numerical data should be copied and pasted into Microsoft Word. The
simplest way to do this is at the end of processing all data, invoke the program to produce
summaries of all the models obtained. e.g.:
>summary(model.1)
>summary(model.2)
>summary(model.3)
>summary(model.4)
…etc.
Copy the whole lot into Word and/or into a blank Microsoft Excel spreadsheet. In
Microsoft Excel, the data can be force into column format by selecting from the toolbar
Data>Text to Columns… after selecting all of the data in the first column.
5. Convergence Errors
In the case of hormesis where yeast die off in high concentration extracts, the program
will give a convergence error like the following:
Error in mdrcOpt(opfct, startVec, optMethod, derFlag, constrained, warnVal, :
Convergence failed
This is due to the programs inability to determine where in the data set the maximum
value and minimum values can be found. The user has two options: The easiest option is
to go back into the data set (in Excel) and delete the upper hormesis/die-off data points.
From here, copy the data back into R and then use the data available to fit the slope and
expected upper limit for the assay. The other option involves use of the five-parameter
logistic equation (fct=l5()) to account for hormesis. The former approach has been
validated in Chapter 3 of this dissertation while the latter approach has not been tested
here.
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6. Programming Information from Original Workshop
The commands listed below are those originally provided by Nina Cedergreen at the
“Satistical Assessment of Dose-Response Curves with Free Software” workshop. Note
that the # sign is used to signify a new line. This was done to allow the user to copy and
paste entire sections of programming and instruction into R. Lines with the # sign at the
beginning are not recognized as commands by R, so they are simply ignored.
One curve only in the data set
#For fitting one dose-response curve to a model (model name is given in the manual) you
write:
model<-multdrc(Response~dose, fct=l3(), data = Dataname)
# To see a graph of your model and data averages write:
plot (model)
# To get the parameters of your function, write:
summary(model)
#The t-value tests whether the parameter is significantly different from zero. If c is not (p
> 0.05), a # model without a lower limit is recommended.
# To check for homogeneity of variance in your data, you can inspect a plot of the
residuals versus # the model predicted values:
plot(fitted(model), residuals(model))
# If the variance is not homogeneous, data should be transformed. We use a box-cox
# transformation. This is done by adding the following term (boxcox=TRUE). If you
have missing
# value in your dataset, you can use (na.action=na.omit):
tmodel<-multdrc(response~dose, fct=l4(), data = Dataname, boxcox = TRUE,
na.action=na.omit)
# Remember. If your data-set contains zero or negative values, they cannot be
transformed using
# boxcox.
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# If you want to know for example the ED10 or the ED90 you write:
ED(tmodel, c(10,90))
Multiple curves
# To get a view over your multiple curves, write:
plotraw(response~dose, curve, data = Dataname, trellis=TRUE)
# To fit a model to the data, write:
mult<-multdrc(response~dose, curve, fct=l4(), data = Dataname, boxcox = T)
#To fit multiple data with one common parameter (here the upper limit. Parameter names
are #arranged alphabetically)
multa<-multdrc(response~dose, curve, fct=ml3a(), data = Dataname,
collapse=data.frame(curve, 1,curve, curve))
#To do F-test between models, do this:
anova(mult, multa)
#If no significant difference between these two models, then use the simpler of the two
# summary, plots, residuals, ED-values ect. are as for one curve.
Binomial endpoint
# Binominal data is distributed differently from gradual data, and therefore need to be
described
# with a different model. Note that also the data has to be set up differently with a column
for both
# the response (for example “immobile”) and the total number of individuals. An l2
model fits a
# curve which is defined with an upper limit of one and a lower limit of zero. Apart from
l2, the
# same models can be used for binominal data as for gradual data.
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bin <- multdrc(no/total~dose, weights =total, fct = l2(), type = “binomial”, data =
Dataname)
# To fit more than one curve, to receive a summary, plots, residuals, ED-values ect. The
same
# commands are used as for gradual data.
Fixing a parameter at a certain value
# A parameter can be fixed using the five parameter logistic model, where the parameters
are listed #alphabetically: b, c, d, e, f, with f being a parameter describing hormesis.
Setting f to one reduces #the model to a four parameter logistic model (l4) model. The
example fixes c at 0.5 while #estimating b, d and e:
model<-multdrc(response~dose, fct=logistic(fixed=c(NA, NA, 4, NA, 1), data =
Dataname))
Graphs
# There are several commands to use, to modify your graphs. Some of the most used
follow here:
# The value you want your controls to be situated at (conLevel= 0.1), the name you will
put instead
# of the control value (conName= “control”), the labels of your axes (xlab = dose, ylab=
response),
# the limits of your axes (ylim= c(0,10)), if you want to see all your data (type=
“points”), or if you # want to hide the data (obs = “none”). Colours can be added on the
graph (col = TRUE). The
# command are just added to the plot-command line as in the example:
plot( model, conlevel = 0.1, xlab = “Concentration (mM)”, ylab = “Freshweight (g)”)
If you want to know more about the use of R as a programme to solve statistical
problems you could consult the http://www.r-project.org/ and browse through the
manuals. A good way to start is to go to the contributed documentation.
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7. DRC Help File for “Plot” Copied and Pasted From R.2.4.0
DRC Plot Instructions
plot.drc(drc)
Plotting fitted curves for a drc object
Description
'plot' displays fitted curves and observations in the same plot window, distinguishing
between curves by different plot symbols and line types.
Usage
## S3 method for class 'drc':
plot(x, ..., level = NULL, broken = FALSE, col = FALSE,
conLevel, conName, grid = 100, legend, legendText, legendPos,
type = "average", obs, lty, log = "x", pch, xlab, ylab, xlim, ylim,
bcontrol = NULL, xt = NULL, xtlab = NULL, yt = NULL, ytlab = NULL,
add = FALSE)
Arguments
x an object of class 'drc'. For instance, 'lwd=2' or 'lwd=3' increase the width of
plot symbols.
... additional arguments.
level vector of character strings. To plot only the curves specified by their names.
broken logical. If TRUE the x axis is broken provided this axis is logarithmic
(requires the CRAN package 'plotrix').
col either logical or a vector of colours. If TRUE default colours are used. If
FALSE (default) no colours are used.
conLevel numeric. Dose level below which the dose is zero (the amount of stretching
on the x-axis above zero). Default is 1e-2.
conName character string. Name on x axis for dose zero. Default is '"0"'.
grid numeric. Number of points in the grid used for plotting the fitted curves.
legend logical. If TRUE a legend is displayed.
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legendText a character string or vector of character strings specifying the legend text.
legendPos numeric vector of length 2 giving the position of the legend.
type a character string specifying how the originals observations should be
plotted. There are 4 options: "average" (default), "none" (only the fitted
curve(s)), "obs" (only the data points), "all" or "points" (all data points).
obs Outdated argument. Use type.
lty a numeric vector specifying the line types.
log a character string which contains '"x"' if the x axis is to be logarithmic, '"y"'
if the y axis is to be logarithmic and '"xy"' or '"yx"' if both axes are to be
logarithmic. The default is "x". The empty string "" yields the original axes.
pch a vector of plotting characters or symbols (see points).
xlab an optional label for the x axis.
ylab an optional label for the y axis.
xlim a numeric vector of length two, containing the lower and upper limit for the
x axis.
ylim a numeric vector of length two, containing the lower and upper limit for the
y axis.
bcontrol a list. Controlling the appearance of the break (if 'broken' is TRUE).
xt a numeric vector containing the positions of the tick marks on the x axis.
xtlab a vector containing the tick marks on the x axis.
yt a numeric vector, containing the positions of the tick marks on the y axis.
ytlab a vector containing the tick marks on the y axis.
add logical. If TRUE then add to already existing plot.
Details
Suitable labels are automatically provided.
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The use of xlim allows changing the x-axis, extrapolating the fitted dose-response
curves.
See colors for the available colours.
Value
An invisible data frame with the values used for plotting the fitted curves. The first
column contains the dose values, and the following columns (one for each curve) contain
the fitted response values.
Author(s)
Christian Ritz and Jens C. Streibig Contributions from: Xiaoyan Wang
See Also
plotraw plots the observations only.
Examples
## Fitting models to be plotted below
model1 <- multdrc(MEANLR~MM, data=FA)
model2 <- multdrc(MEANLR~MM, data=FA, fct=l3()) # lower limit fixed at 0
## Plotting observations and fitted curve for 'model1'
plot(model1)
## Adding fitted curve for 'model2'
plot(model2, add = TRUE, type = "none",
col = 2, lty = 2)
## Fitting model to be plotted below
model3 <- multdrc(SLOPE~DOSE, CURVE, data=PestSci)
## Plot with no colours
plot(model3, main="Different line types (default)")
## Plot with default colours
plot(model3, col=TRUE, main="Default colours")
## Plot with specified colours
plot(model3, col=c(2,6,3,23,56), main="User-specified colours")
## Plot of curves 1 and 2 only
plot(model3, level=c(1,2), main="User-specified curves")
## Fitting another model to be plotted below
model4 <- multdrc(weight~conc, data=hormesis)
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## Using the argument 'conLevel'. Compare the plots!
par(mfrow=c(2, 2))
plot(model4, main="conLevel=1e-2 (default)") # using the default
plot(model4, conLevel=1e-4, main="conLevel=1e-4")
plot(model4, conLevel=1e-6, main="conLevel=1e-6")
plot(model4, conLevel=1e-8, main="conLevel=1e-8")
par(mfrow=c(1,1))
## Using the argument 'broken'
plot(model1, conLevel = 0.1, broken = TRUE)
plot(model1, conLevel = 0.1, broken = TRUE,
bcontrol=list(style="zigzag"))
## Removing models from work space
rm(model1, model2, model3, model4)
193
Appendix D: Antibiotic Occurrence in Streams and Reservoir
Concentrations are in ng/L; < 20 indicates that analytes were not detected above a S:N
ratio above 3 in chromatograms; < 20 (--) indicates that the analyte was detected above a
S:N ratio above 3 in chromatograms, but concentration was below PQL of 20 ng/L.
Underlined values indicate that only one MS/MS product ion was used to confirm the
analyte.
Table D.1: Stream A 8/9/07 Sampling Event
Antibiotic Upstream Effluent DS A1 DS A2
Sulfamethoxazole < 20 26 124 814
Sulfathiazole < 20 54 97 < 20 (11)
Sulfadimethoxine < 20 359 37 < 20 (7)
Erythromycin < 20 527 316 40
Trimethoprim < 20 < 20 (14) 170 66
Lincomycin < 20 < 20 (4) < 20 < 20
Ciprofloxacin < 20 154 104 43
Levofloxacin < 20 269 148 < 20
Sarafloxacin < 20 < 20 < 20 < 20
Tetracycline < 20 < 20 < 20 < 20 (0.5)
Table D.2: Stream B 8/9/07 Sampling Event
Antibiotic Upstream Effluent DS B1 DS B2
Sulfamethoxazole < 20 1419 1153 240
Sulfathiazole < 20 < 20 (17) 195 97
Sulfadimethoxine < 20 < 20 (14) 56 < 20 (12)
Trimethoprim < 20 42 651 98
Sulfamerazine < 20 189 43 80
Erythromycin < 20 86 155 73
Lincomycin < 20 < 20 (6) < 20 (5) 25
Ciprofloxacin < 20 77 no data < 20 (12)
Levofloxacin < 20 261 no data < 20 (7)
Sarafloxacin < 20 67 no data 82
Norfloxacin < 20 < 20 (19) < 20 < 20
Tetracycline < 20 < 20 (11) < 20 < 20 (16)
Note : nd = no data, measurements were not collected at this site on this day
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Table D.3: Stream C 8/9/07 Sampling Event
Antibiotic Upstream Effluent DS C1 DS C2
Sulfamethoxazole < 20 556 198 302
Sulfadimethoxine < 20 165 75 < 20 (12)
Trimethoprim < 20 < 20 (19) 55 28
Erythromycin < 20 58 36 55
Lincomycin < 20 < 20 (0.5) < 20 (13) 24
Ciprofloxacin < 20 35 < 20 < 20
Levofloxacin < 20 47 < 20 92
Sarafloxacin < 20 127 < 20 < 20
Enrofloxacin < 20 < 20 (18) < 20 < 20
Tetracycline < 20 34 < 20 < 20
Table D.4: Stream A 8/25/07 Sampling Event
Antibiotic Upstream Effluent DS A1 DS A2
Sulfamethoxazole < 20 206 188 94
Sulfathiazole < 20 66 21 81
Sulfadimethoxine < 20 448 26 < 20 (13)
Erythromycin < 20 693 32 209
Trimethoprim < 20 < 20 (19) 36 109
Lincomycin < 20 296 51 < 20
Ciprofloxacin < 20 161 21 < 20 (12)
Levofloxacin < 20 148 122 < 20
Tetracycline < 20 < 20 (3) 121 < 20
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Table D.5: Stream B 8/25/07 Sampling Event
Antibiotic Upstream Effluent DS B1 DS B2
Sulfamethoxazole < 20 1292 237 237
Sulfathiazole < 20 238 < 20 (7) 127
Trimethoprim < 20 437 190 208
Sulfadimethoxine < 20 < 20 (16) < 20 < 20 (10)
Sulfamerazine < 20 134 108 < 20 (11)
Erythromycin < 20 75 58 41
Lincomycin < 20 < 20 (3) < 20 (14) < 20 (8)
Ciprofloxacin < 20 35 < 20 (2) < 20
Levofloxacin < 20 < 20 (19) < 20 (9) < 20 (12)
Sarafloxacin < 20 121 36 < 20 (13)
Norfloxacin < 20 < 20 (5) < 20 < 20
Enrofloxacin < 20 < 20 < 20 < 20
Tetracycline < 20 < 20 (9) < 20 < 20
Table D.6: Stream C 8/25/07 Sampling Event
Antibiotic Upstream Effluent DS C1 DS C2
Sulfamethoxazole < 20 651 443 651
Sulfathiazole < 20 113 < 20 < 20
Sulfadimethoxine < 20 208 128 111
Trimethoprim < 20 < 20 (11) < 20 (2) < 20 (5)
Erythromycin < 20 53 45 46
Lincomycin < 20 < 20 (1) 161 < 20 (2)
Ciprofloxacin < 20 62 < 20 (6) < 20 (9)
Levofloxacin < 20 241 < 20 (12) < 20 (10)
Sarafloxacin < 20 65 < 20 (4) < 20 (9)
Enrofloxacin < 20 274 21 235
Tetracycline < 20 < 20 < 20 < 20
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Table D.7: Stream A 9/22/07 Sampling Event
Antibiotic Upstream Effluent DS A1 DS A2
Sulfamethoxazole < 20 2828 2860 1480
Sulfathiazole < 20 217 287 < 20
Trimethoprim < 20 168 195 77
Sulfadimethoxine < 20 35 < 20 (19) 40
Erythromycin < 20 218 181 98
Lincomycin < 20 24 < 20 (1) < 20 (17)
Ciprofloxacin < 20 55 < 20 (14) < 20 (3)
Levofloxacin < 20 338 162 27
Tetracycline < 20 26 < 20 (10) < 20
Table D.8: Stream B 9/22/07 Sampling Event
Antibiotic Upstream Effluent DS B1 DS B2
Sulfamethoxazole < 20 1809 1337 806
Sulfadimethoxine < 20 184 198 91
Trimethoprim < 20 696 672 240
Sulfathiazole < 20 173 27 26
Erythromycin < 20 173 152 97
Lincomycin < 20 28 < 20 (3) 24
Ciprofloxacin < 20 35 60 < 20 (11)
Levofloxacin < 20 40 251 23
Sarafloxacin < 20 130 56 131
Norfloxacin < 20 < 20 (17) < 20 (12) < 20
Enrofloxacin < 20 < 20 (18) 302 < 20 (10)
Tetracycline < 20 < 20 < 20 < 20
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Table D.9: Stream C 9/22/07 Sampling Event
Antibiotic Upstream Effluent DS C1 DS C2
Sulfamethoxazole < 20 689 1106 1019
Sulfathiazole < 20 185 110 < 20
Trimethoprim < 20 < 20 (13) < 20 (5) < 20 (4)
Erythromycin < 20 65 56 38
Lincomycin < 20 < 20 (1) < 20 (2) < 20 (3)
Ciprofloxacin < 20 67 < 20 (0.13) < 20 (13)
Levofloxacin < 20 282 < 20 (14) < 20 (5)
Sarafloxacin < 20 80 < 20 (12) < 20 (18)
Enrofloxacin < 20 311 29 215
Tetracycline < 20 < 20 < 20 < 20
Table D.10: Stream A 10/5/07 Sampling Event
Antibiotic Upstream Effluent DS A1 DS A2
Sulfamethoxazole < 20 1777 1749 1245
Sulfathiazole < 20 160 130 144
Trimethoprim < 20 87 147 60
Sulfadimethoxine < 20 < 20 (16) 53 30
Erythromycin < 20 140 103 85
Lincomycin < 20 < 20 (8) < 20 (15) < 20 (4)
Ciprofloxacin < 20 < 20 (19) 35 < 20
Levofloxacin < 20 253 171 27
Enrofloxacin < 20 < 20 (0.3) < 20 (13) < 20 (1)
Tetracycline < 20 < 20 (13) < 20 < 20
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Table D.11: Stream B 10/5/07 Sampling Event
Antibiotic Upstream Effluent DS B1 DS B2
Sulfamethoxazole < 20 1894 nd 155
Trimethoprim < 20 1396 nd 98
Sulfadimethoxine < 20 500 nd 49
Sulfathiazole < 20 43 nd < 20
Erythromycin < 20 153 nd 37
Lincomycin 20 20 nd < 20 (18)
Ciprofloxacin < 20 86 nd < 20 (18)
Levofloxacin < 20 (10) 114 nd 168
Sarafloxacin < 20 198 nd 58
Norfloxacin < 20 51 nd < 20
Enrofloxacin < 20 42 nd < 20
Tetracycline < 20 42 nd < 20 (16)
Note : nd = no data, measurements were not collected at this site on this day
Table D.12: Stream C 10/5/07 Sampling Event
Antibiotic Upstream Effluent DS C1 DS C2
Sulfamethoxazole < 20 1118 1379 1051
Trimethoprim < 20 14 43 < 20 (3)
Sulfathiazole < 20 242 < 20 (0.04) < 20 (17)
Erythromycin < 20 60 155 81
Lincomycin < 20 55 60 < 20 (9)
Sulfadimethoxine < 20 214 296 91
Ciprofloxacin < 20 18 <20 (1) < 20 (17)
Levofloxacin < 20 109 < 20 (8) < 20 (2)
Sarafloxacin < 20 < 20 < 20 < 20 (7)
Enrofloxacin < 20 < 20 (10) < 20 (1) < 20 (1)
Tetracycline < 20 < 20 < 20 < 20
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Table D.13: Stream A 12/11/07 Sampling Event
Antibiotic Upstream Effluent DS A1 DS A2
Sulfamethoxazole < 20 3255 2531 1584
Trimethoprim < 20 106 238 59
Sulfdimethoxine < 20 27 20 459
Sulfathiazole < 20 713 436 335
Erythromycin < 20 224 153 122
Lincomycin < 20 < 20 ( 6) < 20 (1) < 20 (5)
Ciprofloxacin < 20 55 < 20 (18) < 20
Levofloxacin < 20 338 157 33
Enrofloxacin < 20 16 10 49
Tetracycline < 20 20 214 < 20
Table D.14: Stream B 12/11/07 Sampling Event
Antibiotic Upstream Effluent DS B1 DS B2
Sulfamethoxazole < 20 3006 1210 1936
Trimethoprim < 20 1270 432 181
Sulfadimethoxine < 20 293 155 < 20 (17)
Sulfathiazole < 20 < 20 41 < 20
Erythromycin < 20 139 108 50
Lincomycin < 20 25 < 20 (4) < 20 (5)
Ciprofloxacin < 20 59 84 < 20 (6)
Levofloxacin < 20 76 23 < 20 (1)
Sarafloxacin < 20 < 20 88 97
Tetracycline < 20 34 < 20 (10) < 20
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Table D.15: Stream C 12/11/07 Sampling Event
Antibiotic Upstream Effluent DS C1 DS C2
Sulfamethoxazole < 20 1304 791 1199
Trimethoprim < 20 < 20 (12) < 20 (6) < 20 (2)
Sulfathiazole < 20 337 63 < 20
Erythromycin < 20 59 57 87
Lincomycin < 20 61 < 20 (13) < 20 (2)
Sulfadimethoxine < 20 25 < 20 (4) < 20 (11)
Ciprofloxacin < 20 < 20 (13) < 20 (10) < 20 (2)
Levofloxacin < 20 101 < 20 (17) < 20
Sarafloxacin < 20 < 20 < 20 (5) < 20
Enrofloxacin < 20 < 20 (13) < 20 (6) 242
Tetracycline < 20 < 20 < 20 < 20
Table D.16: Reservoir 5 Sampling Event
8/25/07 9/22/07 10/5/07 12/6/07Antibiotic
R5 R5 R5 R5
Sulfamethoxazole < 20 (13) 51 64 38
Erythromycin < 20 (15) 37 44 < 20 (6)
Trimethoprim 37 < 20 (16) < 20 < 20 (7)
Lincomycin < 20 24 44 21
Sulfadimethoxine < 20 < 20 < 20 < 20 (4)
Ciprofloxacin < 20 < 20 (1) < 20 (4) < 20 (3)
Levofloxacin < 20 (10) < 20 (1) < 20 (7) < 20 (3)
Norfloxacin < 20 < 20 (11) < 20 (16) < 20 (4)
Enrofloxacin < 20 < 20 (0.3) < 20 (2) < 20 (1)
Tetracycline < 20 < 20 < 20 < 20
201
Table D.17: Antibiotic Occurrence in Drinking Water Reservoir 12/11/07 Sampling
Event
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